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Abstract 
Deficiencies in the mismatch repair (MMR) pathway are associated with several 
types of cancers, as well as resistance to commonly used chemotherapeutics. Rhodium 
metalloinsertors have been found to bind DNA mismatches with high affinity and 
specificity in vitro, and also exhibit cell-selective cytotoxicity, targeting MMR-deficient 
cells over MMR-proficient cells.  
Here we examine the biological fate of rhodium metalloinsertors bearing 
dipyridylamine ancillary ligands. These complexes are shown to exhibit accelerated 
cellular uptake which permits the observation of various cellular responses, including 
disruption of the cell cycle and induction of necrosis, which occur preferentially in the 
MMR-deficient cell line. These cellular responses provide insight into the mechanisms 
underlying the selective activity of this novel class of targeted anti-cancer agents. 
In addition, ten distinct metalloinsertors with varying lipophilicities are 
synthesized and their mismatch binding affinities and biological activities studied. While 
they are found to have similar binding affinities, their cell-selective antiproliferative and 
cytotoxic activities vary significantly. Inductively coupled plasma mass spectrometry 
(ICP-MS) experiments show that all of these metalloinsertors localize in the nucleus at 
sufficient concentrations for binding to DNA mismatches. Furthermore, metalloinsertors 
with high rhodium localization in the mitochondria show toxicity that is not selective for 
MMR-deficient cells. This work supports the notion that specific targeting of the 
metalloinsertors to nuclear DNA gives rise to their cytotoxic and antiproliferative 
activities that are selective for cells deficient in MMR. 
viii 
 
To explore further the basis of the unique selectivity of the metlloinsertors in 
targeting MMR-deficient cells, experiments were conducted using engineered NCI-H23 
lung adenocarcinoma cells that contain a doxycycline-inducible shRNA which suppresses 
the expression of the MMR gene MLH1. Here we use this new cell line to further 
validate rhodium metalloinsertors as compounds capable of differentially inhibiting the 
proliferation of MMR-deficient cancer cells over isogenic MMR-proficient cells. General 
DNA damaging agents, such as cisplatin and etoposide, in contrast, are less effective in 
the induced cell line defective in MMR. 
Finally, we describe a new subclass of metalloinsertors with enhanced potency 
and selectivity, in which the complexes show Rh-O coordination. In particular, it has 
been found that both  and  enantiomers of [Rh(chrysi)(phen)(DPE)]2+ bind to DNA 
with similar affinities, suggesting a possible different binding conformation than previous 
metalloinsertors. Remarkably, all members of this new family of compounds have 
significantly increased potency in a range of cellular assays; indeed, all are more potent 
than the FDA-approved anticancer drugs cisplatin and MNNG. Moreover, these activities 
are coupled with high levels of selectivity for MMR-deficient cells. 
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Chapter 1: Introduction
*,†
 
1.1 Metal-Based Chemotherapeutics 
 Since the successful application of cisplatin as an anticancer drug, the field of 
inorganic medicinal chemistry has undergone a revolution.
1-4
 For many years, the field 
focused on the development of more potent analogues (second and third generation 
derivatives), leading to the FDA approval of two additional cis-platinum(II) complexes, 
carboplatin and oxaliplatin (Figure 1.1).
5
 Cisplatin and carboplatin, in particular, have 
been highly successful in the treatment of a variety of cancers, including testicular, 
ovarian, cervical, and non-small cell lung cancers.
6
 However, these treatments are often 
associated with severe side effects and a build-up of resistance. In addition, two 
ruthenium complexes are currently in clinical trials,
7,8
 and studies on the biological 
effects of potential metal-based therapeutics are being published at an increasing rate. 
Anticancer compounds have a myriad of targets (DNA, proteins, membranes, etc.), and in 
fact the true lesion responsible for the biological activity of a compound is difficult to 
determine.
9
 These issues have led researchers to focus more recently on the development 
of novel non-platinum chemotherapeutics.  
The rich photophysical and photochemical properties of metal complexes, in 
addition to their basic coordination chemistry, make them ideal scaffolds for a wide 
variety of biological applications. Though the pharmaceutical industry in general has 
shied away from “heavy metal” pharmaceuticals, with the exception of cisplatin and its 
derivatives, there are in fact real opportunities in the development of transition metal  
                                                 
*
 Komor, A.C.; Barton, J. K. The Path for Metal Complexes to a DNA Target. Chem. Commun. 2013, 49, 
3617-3630 – Adapted by permission of The Royal Society of Chemistry. 
†
 Adapted from Weidmann, A. G.; Komor, A. C.; Barton, J. K. Targeted Chemotherapy with Metal 
Complexes. Comments in Inorg. Chem.2014, DOI: 10.1080/02603594.2014.890099. 
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Figure 1.1 Chemical structures of classical platinum-based chemotherapeutics. 
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pharmaceuticals, given their high modularity, ease of synthesis in preparing molecules of 
complex shapes and symmetries, and the ability to monitor their fate within the cell using 
a variety of spectroscopies.  
The focus of many laboratories has been on the preparation of more potent metal 
complexes that function like cisplatin in coordinating to DNA, but are more effective due 
to either more optimum uptake characteristics or the inability of lesions formed to be 
easily detected and repaired.  Much time and attention have been spent in this arena. 
However, the goal has moved also to the design of complexes with a new strategy based 
upon selectivity, with the preparation of transition metal complexes that are more 
selective than cisplatin, owing to a design strategy where the complex interacts with a 
specific biological target found prominently in cancer cells.  
Here I describe recent results on a variety of transition metal complexes targeted 
to DNA to illustrate many of the issues involved in new therapeutic design. This is 
followed by a short discussion on metal complexes as targeted chemotherapeutics; 
complexes that are tailored towards various biomolecules associated with cancer. I 
discuss studies of “classical” metal complex chemotherapeutics to explore their 
differences in structural interactions with DNA, their biological fates inside the cell, and 
the tools and techniques being used to probe the path taken by the small molecule in 
reaching its DNA target. Establishing cellular uptake and even the subcellular 
distributions of the metal complexes are critically important in understanding and 
optimizing their activity. While the subtle hydrolysis reactions associated with cisplatin 
uptake probably could not have been strategically designed, they are key to its mode of 
action. 
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1.2 DNA as a Target 
 DNA represents a fruitful target for metal complexes. DNA can function as a 
ligand either through interactions with the sugar-phosphate backbone or coordination to 
the bases. Moreover, non-covalent interactions with DNA lead to additional targets, and 
greater specificity, through an ensemble of interactions in the DNA grooves and base 
stack. 
1.2.1 Covalent Interactions  
It has been widely accepted since the 1970s that DNA is the biological target of 
cisplatin in vivo.
10,11
 However, the nature of the adduct formed between cisplatin and 
DNA was not determined until the 1980s. This interaction was proposed to be an 
intrastrand cross-link between the N7 atoms of adjacent guanines and cisplatin based on 
the results of numerous biochemical studies.
12,13 
This adduct was further characterized by 
gel electrophoresis, and it was found that the DNA duplex was  e t  y      14 However, 
this adduct was not fully structurally characterized by x-ray crystallography until 1995, 
when the Lippard group published the 2.6-Å resolution crystal structure of cisplatin 
bound to a double-stranded DNA dodecamer (Figure 1.2).
15
 
 In this structure, the duplex is bent considerably toward the major groove but 
without disruption of the Watson-Crick hydrogen bonding.  In fact, the duplex is 
distorted to such a degree that the duplex changes conformation from B-DNA to A-DNA 
throughout most of the duplex. Such a significant distortion of the DNA is likely readily 
recognized by a host of cellular proteins. How efficiently such lesions are recognized and 
repaired rather than initiating a protein response and signaling cascade is a question we 
still need to understand and which may make the difference between biological efficacy  
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Figure 1.2 Crystal structure at 2.6-Å resolution of the intrastrand crosslink between 
cisplatin and the N7 atoms of adjacent guanines.
15
 The platinum center is shown as a light 
grey sphere, and its four nitrogen-based ligands are shown in blue. DNA is shown in 
grey. The dodecamer duplex is bent considerably towards the major groove, and the 
structure is no longer B-form DNA, but mostly A-form throughout the duplex. 
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and little reaction.
16
 
1.2.2 Intercalation  
 Metallointercalation is a DNA binding mode that has been extensively studied. 
The term was coined by Lippard and coworkers in studies of square planar Pt complexes 
with DNA.
17
 As with organic intercalators, these planar complexes contain aromatic 
heterocyclic ligands that could stack among the DNA base pairs. However, the lack of 
site-specificity inherent in intercalation by a planar complex made detailed structural 
characterization difficult. The first structural characterization of metallointercalation was 
the 1.1-Å resolution crystal structure of the platinum complex [Pt(SEtOH)(terpy)]
+
 
intercalated into the dinucleotide dimer deoxy CpG.
18
 Although not able to establish 
long-range structural perturbations to DNA associated with intercalation,  this structure 
did reveal that, associated with intercalation, the DNA unwinds to accommodate the 
metal complex between bases and the pucker of the sugar rings changes geometry. This 
alter ate sugar puckeri g was suggested as the  asis for the “neighbour exclusion 
pri ciple” associated with DNA i tercalatio , where, at most, intercalators bind in every 
other interbase-pair site.  
 In succeeding years, the Barton laboratory focused on intercalation by octahedral 
complexes containing at least one aromatic heterocyclic ligand for stacking, or partial 
intercalation, in between base pairs. The symmetry and functionality associated with the 
non-intercalated ligands could then provide the basis for highly specific interactions with 
several bases along the groove of DNA, once oriented by stacking in the helix of the 
intercalated ligand. In particular, we found the enantioselective intercalative binding of 
right-handed -complexes into right-handed B-DNA.19  One of the first structural 
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characterizations of metallointercalation into a long DNA duplex was thus provided from 
the 1.2-Å resolution crystal structure of the sequence-specific rhodium i tercalator, Δ-α-
[Rh[(R,R)-Me2trien]phi]
3+
, bound to a duplex octamer (Figure 1.3).
20
  The complex was 
desig ed to target the seque ce 5’-TGCA-3’ through a mix of hydroge   o di g a d 
methyl-methyl interactions in the DNA major groove. The complex was also shown as a 
result of its sequence-specificity to inhibit the binding of sequence-specific DNA-binding 
proteins, a first step in specifically inhibiting gene expression.
21
   
 Critically, the structure obtained provided detailed information on how 
metallointercalation in general modifies the conformation of DNA. In this structure, 
i tercalatio  occurs from the major groove, with the aromatic i tercalati g phi liga d π-
stacki g with the π-orbitals of the flanking base pairs, similar to the stacking of 
consecutive base pairs in duplex DNA. This structure also confirmed the conformational 
changes revealed by shorter intercalated oligonucleotides, such as doubling of the rise, 
buckling of the base pairs flanking the intercalation site, and a slight unwinding of the 
DNA localized at the site of intercalation. Interestingly, there were no long range effects 
on the DNA structure- no bending or kinking of the helix. Indeed, even the alternating 
sugar-pucker was not evident. The metallointercalator was simply like another base pair 
in the helical stack.  
 Structural characterization of intercalation from the minor groove was recently 
obtained from two independent crystal structures of dppz complexes of Ru(II) 
intercalated into duplex DNA. The first is the 0.92-Å resolutio  structure of two Δ-
[Ru(bpy)2(dppz)]
2+
 complexes intercalated from the minor groove into a duplex 12-mer 
containing two mismatched sites.
22
 There are also two ruthenium complexes bound to the  
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Figure 1.3 The 1.2-Å resolution crystal structure of the sequence-specific rhodium 
i tercalator, Δ-α-[Rh[(R,R)-Me2trien]phi]
3+
, bound to a duplex octamer.
20
 The 
complex  i ds specifically to 5’-TGCA-3’  There are two Va  der Waals Me-Me 
interactions between the metal complex ligand and T (T shown in blue, interaction 
shown with the black dotted line), and a hydrogen bond between the NH group on the 
metal complex ligand and the O6 of G (G shown in green, interaction shown with the 
black dotted line). This structure displays the doubling of the rise of the DNA, 
buckling of the adjacent base pairs, and a slight unwinding of the DNA upon 
intercalation. 
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mismatched sites via insertion (vide infra), as well as the extruded ade osi es π-stack 
with the bpy ligands of the intercalated complexes, serving to stabilize the intercalated 
complex in the minor groove (Figure 1.4). Intercalation of this complex from the minor 
groove was in contrast to NMR
23,24
 and competitive fluorescence studies
25
, both of which 
suggested that intercalation of the ruthenium complex occurred from the major groove. 
Crystal packing forces may play a role here in directing intercalation from the minor 
groove side; in any case, it is clear that the energetic differences between intercalation 
from the major groove versus minor groove must be small. Furthermore, this structure 
showed the doubling of the rise of the DNA at each intercalation site, and an unwinding 
of the base pairs to accommodate the complexes. Interestingly, while the rise is doubled 
at each intercalation site, the rise between the base pairs with no metal complex bound is 
reduced from the 3 3Å that is expected, co siste t with π-stacking interactions between 
the extruded mismatches and the ancillary bpy ligands being the dominating interaction 
that may be directing intercalation from the minor groove. 
 The seco d set of structures show the  i di g of Λ-[Ru(phen)2(dppz)]
2+
 to two 
different duplex 10-mers.
26
 These structures reveal three different conformations of 
intercalation for the same complex. Namely, when intercalated at the TA/TA central step 
of the oligonucleotide d(CCGGTACCGG)2, the complex is intercalated deeply, 
perpendicularly, and symmetrically into the base stack from the minor groove. However, 
when the complex intercalates at the terminal GG/CC step, the intercalation geometry is 
shallower and angled. Finally, this angled intercalation allows for the phenanthroline 
ligands to semi-i tercalate i to the  eigh ori g duplex  This “semi-i tercalatio ” was 
also see  i  a structure of Λ-[Ru(TAP)2(dppz)]
2+
 bound to a duplex 10-mer.
27
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Figure 1.4 The 0.92-Å resolutio  structure of two Δ-[Ru(bpy)2(dppz)]
2+
 complexes 
intercalated from the minor groove into a duplex 12-mer containing two AA mismatched 
sites.
22
 The mismatches are extruded from the  ase stack  y two other Δ-
[Ru(bpy)2(dppz)]
2+
 complexes that are metalloinserted at these sites. The extruded bases 
(show  i   lue) π-stack with the bpy rings of the intercalated metal complexes 
(interactions shown in black, metal complexes shown in red). 
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 These various structural characterizations of metallointercalation highlight the 
versatility of this binding mode, and likely also the shallow energy profile among 
different intercalative binding modes. Likely the structural diversity reflects the sequence 
selectivity associated with the different complexes, where the non-intercalating 
interactions in the DNA groove lead to some structural variations. But none of these 
conformational changes yield dramatic changes in DNA structure, like the bend in DNA 
generated by a Pt crosslink. In the context of therapeutic design, the fact that 
metallointercalators cause no major structural distortions in DNA needs to be considered.  
Intercalators generally, especially those that have no sequence-specificity, have little 
therapeutic applicability. It may be because a strongly defined DNA lesion is not 
produced with intercalation that limits the biological consequences for 
metallointercalators.   
1.2.3 Insertion   
 Rhodium metalloinsertors, as described in the Barton laboratory, bind to 
mismatches in DNA with high affinity and specificity.
28,29
 While it was known that these 
compounds could preferentially target thermodynamically destabilized mismatches in 
DNA over matched base pairs by a factor of over 1000,
 30 
for ten years there was no 
structural information on the interaction between these metal complexes and mismatched 
DNA.  The 1.1-Å resolution crystal structure of [Rh(bpy)2(chrysi)]
3+
 bound to an AC 
mismatch revealed the binding mode to be metalloinsertion, where the chrysi ligand 
inserts into the base stack via the minor groove and ejects both mismatched bases (Figure 
1.5).
31
  
 Metalloinsertion of this complex results in only small conformational changes in  
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Figure 1.5 The 1.1-Å resolutio  structure of Δ-[Rh(bpy)2(chrysi)]
3+
 bound to an AC 
mismatch.
31
 The rhodium complex, shown in red, inserts into the DNA from the minor 
groove and completely ejects the mismatched bases, shown in blue. 
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the duplex near the binding site, but a large perturbation is associated with the ejection of 
the mismatched bases into the DNA groove. The structure also explains the 
enantiospecificity of binding of [Rh(bpy)2(chrysi)]
3+
;
 
the deep insertion of the complex 
within the minor groove with no increase in base pair rise results in a steric clash between 
the ancillary ligands and the sugar phosphate backbone if the left-handed isomer were to 
be bound. For intercalation, in contrast, where there is an increase in rise at the binding 
site, enantioselective intercalation requires a much bulkier ancillary ligand than bpy.
32
 As 
with the case of cisplatin, this structure may also suggest the basis for the biological 
activity of these complexes. Ejection of the mismatched bases results in a large lesion 
that could be easily recognized in vivo. This lesion likely is responsible for the selective 
cell death of MMR-deficient cells over MMR-proficient cells following rhodium 
treatment, as there are 1000 times as many mismatches in the MMR-deficient cells. 
 This binding conformation has been corroborated by additional crystal structures 
of this same compound bound to different mismatches.
33
 Furthermore, the generality of 
metalloinsertion as a binding mode for different bulky metal complexes has been 
established by the crystal structure me tio ed earlier, that of Δ-[Ru(bpy)2(dppz)]
2+
 bound 
by insertion at two mismatched sites.
22
 Again, the information garnered from these 
structures is instrumental in unraveling the mechanism of action of these therapeutic 
agents, and thus in the development of future agents with improved biological activity. 
1.3 Biological Activities of Metal Complexes   
 Undeniably, optimizing a compound as a therapeutic requires the complete 
assessment of its biological activity in vitro. Here I discuss the biological activity in 
cellulo of several classes of transition metal complexes that are thought to target DNA.  
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Figure 1.6 Chemical structures of four ruthenium polypyridyl complexes studied by 
Novakova and coworkers.
38 
Out of all four complexes, only the mer-[Ru(terpy)Cl3] 
complex displays significant cytotoxicity in human and murine tumor cell lines. 
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As the activities of cisplatin and other platinum compounds have been extensively 
discussed elsewhere,
16,34,35
 non-platinum-based therapeutics are the focus here. 
1.3.1 Polypyridyl Complexes 
 The biological activities of countless ruthenium polypyridyl complexes have been 
reported in the literature and have been the subject of many reviews.
36
 Indeed, the 
exploration of biological activities of polypyridyl complexes began more than fifty years 
ago in classic studies by Dwyer and coworkers.
37
 At that stage, no biological target was 
identified, but more recent studies on coordinatively saturated metal complexes suggest 
that DNA was likely the target for the full family of complexes examined earlier.  
 Many more studies have been conducted on ruthenium complexes that bind DNA 
covalently, by analogy to cisplatin, than those which are coordinatively saturated and 
inert to substitution, binding non-covalently.  In one of the earliest studies, Novakova and 
coworkers studied four chloropolypyridyl ruthenium complexes (Figure 1.6) in murine 
and human tumor cell lines. Interestingly, only the complex with three leaving chloride 
ligands, mer-[Ru(terpy)Cl3], displayed significant cytotoxicity. While the binding 
affinities of the different complexes could not explain this discrepancy, it was discovered 
that only the mer-[Ru(terpy)Cl3] complex had the ability to form interstrand crosslinks in 
the DNA, thus harkening on the importance of specific lesions and structural distortion in 
determining biological activities, not simply avidity for binding DNA.
38
 
 In a more recent study conducted by Tan and coworkers, several inert ruthenium 
polypyridyl complexes were studied, three ruthe ium complexes co tai i g a β–
carboline ligand, along with the control compound [Ru(phen)2(dppz)]
2+ 
(Figure 1.7). 
They observed that upon substitution of the dppz liga d for the β–carboline ligand, the  
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Figure 1.7 Four Ru(II) polypyridyl complexes studied by Tan and coworkers.
39
 All three 
complexes with -carboline as a ligand were cytotoxic towards HeLa cells, whereas the 
control [Ru(phen)2(dppz)]
2+
 complex was not. 
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complex now accumulates in the nucleus as well as the cytoplasm. Furthermore, the 
complexes with β–carboline ligands are significantly more cytotoxic towards HeLa cells, 
inducing apoptosis and autophagy, while[Ru(phen)2(dppz)]
2+ 
does not. Since the 
cytotoxicities of the β–carboline complexes correlated well with their DNA binding 
affinities, they concluded that genomic DNA may be their primary target in cellulo.
39
 The 
comparative results with these complexes, however, also suggest that the differential 
activities of the complexes may depend on more than just affinities. Both cellular uptake 
and localization may be issues. Moreover, the bulkiness and geometry of the coordinated 
carboline ligand may indicate that metalloinsertion plays some role in the binding 
interaction. 
The Sheldrick laboratory has focused on studies of a variety of rhodium 
polypyridyl complexes that can bind both covalently and non-covalently with DNA.
40,41
 
A series of polypyridyl rhodium complexes containing a facial tripodal (tpm), Cp*, or 
thioether ([9]aneS3) ligand (Figure 1.8) were synthesized and their cytotoxicities towards 
the MCF-7 and HT-29 cell lines examined. They observed, in general, while keeping the 
facial ligand constant, an increase in potency with increasing surface area and 
hydrophobicity of the polypyridyl ligand. Furthermore, it was found that for the 
polypyridyl ligands phen, dpq, and dppz, the facial ligands had the effect of increasing 
the cytotoxicity in the order [Cp*]
-
<[9]aneS3<tpm. This trend was found to be consistent 
not with binding affinity, but with the magnitude of rhodium uptake into the cells.
42-44
 
Some of these complexes were furthermore found to selectively target lymphoma (BJAB) 
cells over healthy leukocytes.
45
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Figure 1.8 Chemical structures of various compounds studied by the Sheldrick 
laboratory.
42-45
 An extensive structure-activity study was undertaken on all complexes in 
the MCF-7 and HT-29 cell li es  Upo  i creasi g the surface area of the “L” liga d, the 
cellular uptake of the drug increased, resulting in an increased potency of the drug. 
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1.3.2 Ruthenium Arene Complexes   
 There have  ee  ma y studies explori g the cytotoxicities of “pia o stool” 
complexes.
46
 Compou ds of the type [(η6-arene)Ru(L)(X)]+ (where L is a bidentate 
ligand and X is a halide, Figure 1.9) have been shown to exhibit anticancer activity,
47
 
while their analogs with three monodentate ligands are completely inactive towards 
A2780 human ovarian cancer cells.
48
 In particular, the results from a few studies by the 
Sadler laboratory revealed that while the identity of the halide and chelating ligand had 
minor effects on the biological activities of these complexes towards A2780 cells, the 
size of the arene ligand had a major effect. The potency of the drug followed the trend 
benzene < p-cymene < biphenyl < dihydroanthracene < tetrahydroanthracene, which 
suggests that increased cellular accumulation enhances their activity.
 48,49
 It was also 
 oted that the are e complexes of the form type [(η6-arene)Ru(en)(Cl)]+ 
(en=ethylenediamine) did not display cross-resistance with cisplatin, suggesting an 
entirely different mechanism of action of these types of compounds.  
Further studies confirmed that these complexes bind to DNA and induce 
structural distortions to the DNA that are distinct from those induced by cisplatin.
50
 
Specifically, they have been found to bind selectively to G bases in DNA 
oligonucleotides, regardless of the presence of other biologically relevant binding sites,
51
 
along with partial intercalation of the arene ligand into the base stack.
52
 
1.3.3 Rhodium Metalloinsertors  
 The biological activities of rhodium metalloinsertors, showing a preferential 
activity in mismatch repair (MMR) –deficient cells, reflect well on the initial strategy 
used for their design, namely targeting DNA mismatches and therefore cells that have a  
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Figure 1.9 Compounds studied by the Sadler laboratory.
48-52
 It was discovered that as the 
lipophilicity of the arene ligand increased, the potency of the drug towards A2780 cells 
increased. It was also found that complexes with L=en have a mechanism of action 
distinct from cisplatin. 
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higher frequency of DNA mismatches, the MMR-deficient cells. First studies were 
designed and carried out to establish in vitro that the complexes bind to DNA mismatches 
with high affinity and specificity.
28,29
 Several years later, their unique biological activity 
was characterized. Two metalloinsertors were found to preferentially inhibit growth in 
MMR-deficient cells over MMR-proficient cells (Figure 1.10).
53
 Furthermore, while 
o ly the Δ-[Rh(bpy)2(chrysi)]
3+
 enantiomer binds to mismatches in vitro, likewise only 
this enantiomer was found to possess this biological activity, implying that the biological 
activity of these complexes originates from binding to mismatches in cellulo. Further 
evidence to support this notion was achieved in a succeeding study in which the ability of 
several different metalloinsertors with varying ancillary ligands to preferentially target 
MMR-deficient cells was directly correlated with their mismatch binding affinities.
54
 A 
subsequent study on the mechanism of activity of these metalloinsertors revealed that not 
only do they selectively inhibit growth of MMR-deficient cells, but after longer 
incubation times, they are also selectively cytotoxic, inducing necrosis in the MMR-
deficient cells.
55
 The ability of these complexes to target MMR-deficient cells over 
MMR-proficient cells with this selectivity is distinctive. Commonly used 
chemotherapeutics, alkylators, DNA damaging agents as well as cisplatin, all suffer from 
a selective toxicity instead with MMR-proficient cells, leading to a build-up in resistance 
to MMR-deficient cancers (Figure 1.10).
56
 Moreover, it appears that the selective activity 
of metalloinsertors in MMR-deficient cells is not only unique but also general to the full 
family of metalloinsertors. The further development of this class of compounds, then, 
might help overcome one of the largest issues we have with current platinum-based 
therapeutics: acquired or inherent resistance. 
 22 
 
 
  
Figure 1.10 Chemical structures (top) and biological activities (bottom) of the rhodium 
metalloinsertor [Rh(bpy)2(chrysi)]
3+
 (left), and the DNA alkylating agent MNNG (right) 
studied in the Barton laboratory.
53
 MMR-proficient (green) and MMR-deficient (red) 
cells were treated with varying concentrations of each compound, and the proliferation of 
growth was quantified via a BrdU incorporation assay. With the rhodium metalloinsertor, 
the MMR-deficient cells are preferentially targeted over MMR-proficient cells, whereas 
the DNA alkylating agent targets the MMR-proficient cells, a trend seen with many 
commonly used DNA-targeted therapeutics. 
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1.4 Cellular Uptake of Metal Complexes   
 Establishing biological activity of small molecules and complexes in the cellular 
milieu is clearly more complicated than establishing chemical targets and structures in a 
test tube. A key element underlying this complexity is whether and how the complex 
enters the cell. Does it ever make it to its test tube target?  
1.4.1 Methods to Monitor Cellular Uptake 
 Because transition metals like Rh, Ru, and Pt are not inherently found in the cell, 
techniques that focus on detecting metals, such as atomic absorption spectroscopy (AAS) 
or inductively coupled plasma mass spectrometry (ICP-MS), are invaluable to monitor 
cellular uptake. The foundation of AAS is the aspect that metal ions absorb strongly at 
discrete, characteristic wavelengths. In this technique, the sample is suctioned into an 
atomizer, which reduces everything in the sample to its atomic states. The atoms are then 
irradiated, during which time they will absorb light of a certain energy which equals a 
specific electronic transition of a particular element. The remaining radiation then passes 
through a monochromator, which picks out the wavelength of light specific to the metal 
of interest, and sends it to the detector. Quantitative information is obtained by taking the 
ratio of the flux without a sample to the flux with the sample and converting to 
concentration using the Beer-Lambert Law.
57,58
 
 ICP-MS is highly sensitive and is applicable to a wide range of metals. 
Furthermore, it is compatible with a wide range of sample matrices, including many 
biologically relevant ones. The sample is introduced into a spray chamber, where it is 
nebulized into an aerosol. These small droplets are then transferred to the inductively 
coupled plasma. The sample droplets are atomized and ionized by the plasma, leading to 
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atomic, singly charged ions which are subsequently transferred to the mass spectrometer, 
which is used to determine the concentration of the metals of interest.
59
 
 Confocal fluorescence microscopy allows for the acquisition of high-resolution 3-
D images with low background interference, and can be used to observe intracellular 
fluorescent compounds.
60
 As such, confocal fluorescence microscopy has been utilized in 
countless studies to probe the cellular uptake of metal complexes, but only those that are 
luminescent.
61
 However, due to differences in the quantum yields among different 
luminescent compounds, this technique cannot be utilized to quantify the amount of drug 
localized inside the cell. Another technique that can be used to monitor uptake of 
luminescent molecules is flow cytometry. In this technique, cells are individually counted 
based on the amount of luminescence inside of them. A stream of cells is passed through 
a laser beam, and the instrument records their light scatter and luminescence. The readout 
is a histogram showing the number of cells versus luminescence intensity. Importantly, 
combining either of these techniques with ICP-MS or AAS can give much more 
information than either technique alone.  
1.4.2 Relationships Between Drug Uptake and Activity  
 One major disadvantage to cisplatin treatment is acquired resistance.
62
 While 
there are several different explanations that can account for this resistance, one important 
mechanism of cisplatin resistance is decreased cellular accumulation of the drug.
63
 
Specifically, in an early study by Andrews and coworkers, AAS was used to quantify 
cisplatin accumulation into parent and cisplatin-resistant 2008 human ovarian carcinoma 
cells. The resistant cells, which exhibited a 3.3-fold resistance, displayed 50% less 
intracellular platinum than the parental cell line.
 64
 Since this study, there have been  
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Figure 1.11 Chemical structures of Rh(III) polypyridyl complexes synthesized and 
studied to monitor uptake. As complexes increased in lipophilicity (bpy to phen to dpq to 
dppz to dppn derivatives), their cellular uptake into MCF-7 and HT-29 cells increased, 
resulting in increased potency.
65
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numerous investigations on various different cell lines, many of which employed AAS or 
ICP-MS, to corroborate this observation.  
 In a study done by the Sheldrick laboratory, a series of rhodium(III) polypyridyl 
complexes (Figure 1.11) was synthesized and their cytotoxicities towards MCF-7 and 
HT-29 cancer cells determined. It was noted that as the lipophilicity of the polypyridyl 
ligand was increased, the cytotoxicity increased as well, and they therefore measured the 
cellular accumulation of each compound using AAS. As with the cisplatin example, the 
most potent complexes exhibited the greatest amount of cellular rhodium accumulation.
65
 
 The relationship between intracellular drug concentration and efficacy is not 
always as straightforward as in the above studies, however. For example, in a study 
conducted by Bugarcic and coworkers, three isomeric terphenyl Ru(II) piano-stool 
complexes (Figure 1.12) were examined.  Their cytotoxicities against two cisplatin-
sensitive and two cisplatin-resistant cancer cell lines were determined, and their 
intracellular ruthenium concentrations were determined by AAS. Surprisingly, the extent 
of ruthenium uptake of the three complexes did not correlate at all with their different 
cytotoxicities. In fact, the most potent of the three complexes (the p-terp complex) 
displayed the least amount of ruthenium uptake into the cells. After numerous DNA 
binding studies, the authors attributed the enhanced cytotoxicity of this complex to its 
ability to not only covalently interact with DNA (as the other two isomers could) but also 
intercalate into DNA.
66
 Perhaps the structural distortions generated in this bound lesion 
produced a great cellular response. In any case, this study nicely highlights the fact that in 
many cases more information than just intracellular drug concentration is necessary in 
order to explain biological activity. 
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Figure 1.12 Chemical structures of three isomeric terphenyl Ru(II) piano-stool 
complexes studied by Bugarcic and coworkers.
66
 Uptake of the complexes into two 
cisplatin-resistant and two cisplatin-sensitive cell lines was found not to correlate with 
their potencies. 
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 One study that combines ICP-MS and fluorescence microscopy to study the 
relationship among structure, activity, and uptake was done by Louie and coworkers. In 
this work, a series of luminescent rhenium(I) polypyridyl was examined (Figure 1.13). 
Here there was a direct correlation found between intracellular rhenium concentrations, 
determined by ICP-MS, and cytotoxicities in HeLa cells. Due to the luminescent nature 
of the complexes, the authors were also able to monitor uptake in live cells via confocal 
microscopy, and even observe the localization of the complexes in the mitochondria of 
the cells.
67
  
 1.4.3 Mechanisms of Uptake   
 While knowing the relationship between the amount of a therapeutic taken into a 
cell and the activity of the drug is important, understanding how the compound gains 
entry into the cell is likewise crucial for optimization of next-generation complexes. The 
mechanism of cellular uptake of a drug can direct its localization within the cell as well 
as the specificity of a given compound for one cell type versus others. The different 
routes of entry into the cell include passive diffusion, facilitated diffusion, active protein 
transport, and endocytosis (Figure 1.14). Passive diffusion is the movement of the 
molecule of i terest across the cell’s lipid  ilayer, facilitated  y the co ce tratio  
gradient. Facilitated diffusion is the tra sport of the molecule of i terest across the cell’s 
lipid bilayer, facilitated by a membrane-bound transport protein such as a channel or a 
passive carrier. Active transport is very similar, but the proteins involved in this type of 
transport are membrane-bound ATPases, meaning that the process of moving a substance 
from the outside of the cell to the inside uses ATP. Endocytosis is a general term for the 
process  y which the cell will “e gulf” a molecule usi g a vesicle formed from the  
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Figure 1.13 Chemical structures (top) of a series of luminescent rhenium(I) polypyridyl 
complexes by Louie and coworkers.
67
  Using ICP-MS, the authors were able to correlate 
the cytotoxicities of these complexes in HeLa cells with intracellular rhenium 
concentrations. Using fluorescence microscopy (bottom), the authors were able to 
observe the localization of one such complex (structure shown in bold, fluorescence 
shown on bottom left in red) in HeLa cells. The authors then used MitoTracker (bottom 
middle in green) to show that the complex localizes mainly in the mitochondria (bottom 
right, yellow shows the overlap). 
 30 
 
plasma membrane.
68
 Endocytosis can be broken down into five different categories: 
macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated endocytosis, 
clathrin- and caveolin-independent endocytosis, and phagocytosis.  All forms of 
endocytosis involve the formation of a membrane compartment, and simply differ in the 
size and composition of the compartments involved. Phagocytosis involves the uptake of 
particles larger than 0.5 µm in diameter, and thus is not applicable to small transition 
metal complexes.
69
 Macropinocytosis i volves “ruffli g” of the mem ra e to form large 
pockets greater than 1 µm in diameter, or endocytic vesicles, which are filled with both 
extracellular solvent and solute molecules. These vesicles are then broken down by 
endosomes or lysosomes. Clathrin-mediated e docytosis is mediated  y “clathri -coated 
pits”, which are a out 1    m i  diameter, a d have a crystalli e coat made up of 
transmembrane receptors associated with the protein clathrin. These receptors bind their 
respective ligands (or a therapeutic agent that resembles their ligand) and then pinch off 
to form clathrin-coated vesicles (CCVs), which are internalized into the cell. In caveolin-
mediated endocytosis, flask-shaped pits in the plasma membrane, about 60 to 80 nm in 
diameter, are shaped by caveolin, a protein that binds cholesterol. Finally, in clathrin and 
caveolin-independent endocytosis, small structures that are 40 to 50 nm in diameter act as 
“rafts”, freely diffusi g alo g the cell surface  These rafts will the   e captured a d 
internalized within any endocytic vesicle.
70,71
 
 However, just as membrane-bound proteins can facilitate the entry of a complex 
into the cell, certain proteins, called efflux transporters, can facilitate the extrusion of 
such compounds from the cell. In fact, multidrug efflux pumps, which can recognize 
multiple structurally dissimilar compounds, are often responsible for chemotherapeutic  
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Figure 1.14 Schematic diagram of the different possible routes of entry into the cell 
taken by small complexes. 
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resistance.
72
 The most well-studied of such mammalian efflux transporters is the ATP-
binding cassette (ABC) family. These efflux transporters use ATP hydrolysis to drive the 
extrusion of drugs from the cell, and can do so against significant concentration 
gradients.
73
 The reason behind the broad substrate specificity of these efflux transporters 
is the presence of a large, flexible hydrophobic binding pocket which allows for substrate 
binding via hydrophobic and electrostatic interactions, rather than the specific hydrogen-
bonding networks present in less promiscuous transport proteins.
74
 
 A basic experiment in elucidating the mechanism of uptake is determining 
whether the mechanism of uptake is energy-dependent or –independent. Both passive and 
active diffusion are energy-independent, while active transport and endocytosis are 
energy-dependent. By incubating cells at a low temperature (  C) or i  the prese ce of 
metabolic inhibitors (2-deoxyglucose and olygomycin), processes that require energy will 
be blocked. If the drug of interest has decreased uptake under these conditions, the 
mechanism of uptake involves an energy-dependent process, while if uptake is 
unchanged the mechanism is an energy-independent process.
75,76
 
 Passive diffusion has the broadest range in substrates out of all uptake 
mechanisms, and is therefore an attractive mode of uptake for therapeutics. Uptake 
mediated by passive diffusion is the most difficult to modulate, but it can be done. 
Uptake of positively charged molecules, such as many inorganic therapeutics, can be 
driven by the plasma membrane potential of the cell. In mammalian cells, the membrane 
potential is generated and maintained by a potassium concentration gradient. This 
potential can be reduced either by using media with a potassium concentration equal to 
the intracellular potassium concentration, or by adding gramicidin A to the media, a 
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polypeptide that will form transmembrane channels which allow unrestricted potassium 
traversal, thus destroying the concentration gradient. In contrast, the cell can be 
hyperpolarized by adding valinomycin to the media, a potassium-specific ionophore that 
will increase potassium transportation across the membrane.
77
 
 Protein-mediated transport, facilitated diffusion, and active transport have the 
capability of being cell-type or tissue-type specific. This allows for the development of 
targeted drugs, thus attenuating dose-limiting side effects.
78
 This type of uptake can be 
repressed by using known inhibitors of specific transport proteins. If uptake of the 
compound of interest is decreased in the presence of the inhibitor, then the respective 
transport protein most likely is involved in uptake. Likewise, many efflux transporters 
have known inhibitors; if uptake of a compound is increased in the presence of an 
inhibitor, then the compound is likely a substrate for the respective efflux protein. 
 As with protein-mediated transport, the different types of endocytosis can be 
mediated by using known inhibitors of the different processes. Ammonium chloride and 
chloroquine diphosphate are general endocytosis inhibitors.
79
 Chlorpromazine 
hydrochloride, monodansylcadaverine (MDC), and phenylarsine oxide are inhibitors of 
clathrin-mediated endocytosis and macropinocytosis.
80
 Filipin and nystatin selectively 
inhibit caveolin-mediated endocytosis via cholesterol sequestration.
81
 Amiloride, as well 
as 5-(N,N-dimethyl) amiloride (DMA) and 5-(N-ethyl-N-isopropyl) amiloride (EIPA) 
inhibit macropinocytosis and phagocytosis by obstructing Na
+
/H
+
 exchange.
82
  
 Cisplatin is the prototypical medicinal inorganic drug. There have been many 
studies on the activity, uptake, and subcellular distribution of this molecule, and these 
serve as illustrations of how mechanism may be elucidated. For many years it was widely 
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accepted that cisplatin entered the cell via passive diffusion. In one such study on the 
mechanism of uptake of cisplatin, Binks and Dobrota measured the amount of uptake of 
cisplatin into rat small intestines using AAS. They found that uptake of the drug was 
linear with respect to time and not saturable up to a concentration of 1.0 mM. The authors 
also found no change in uptake of cisplatin when the experiments were repeated under 
metabolic inhibition, confirming that the mechanism of uptake is energy-independent and 
through passive diffusion.
83
 More recently, however, it was found that several protein-
mediated transport pathways can also be responsible for cisplatin uptake. The most 
important of these pathways are the organic cation transporters and the copper influx 
transporter CTR1.
84
 To demonstrate the contribution of CTR1 to cisplatin uptake, Howell 
and coworkers measured cisplatin uptake in A2780 human ovarian cancer cells using 
ICP-MS. They increased expression of CTR1 20-fold and found that intracellular 
platinum levels increased by 55% after 24 hours of platinum incubation.
85
 
 Many ruthenium complexes are easy to monitor in uptake studies owing to their 
strong luminescence. For example, the Barton lab has used flow cytometry to study the 
uptake of the luminescent lipophilic ruthenium complex [Ru(DIP)2(dppz)]
2+
 into HeLa 
cells (Figure 1.15). It was found that under metabolic inhibition, uptake of the ruthe ium 
complex remai ed u cha ged  Additio ally, i creasi g the i cu atio  temperature from 
  C to 3  C had  o effect o  uptake  These experime ts showed that the mecha ism of 
uptake was energy-independent. To rule out facilitated diffusion by organic cation 
transporters (OCTs), uptake of the ruthenium complex was also studied in the absence 
and presence of a variety of OCT inhibitors (tetra-n-alkylammonium salts, procainamide, 
and cimetidine), and was found to be unaffected by the presence of these compounds.  
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Figure 1.15 [Ru(DIP)2(dppz)]
2+
, a luminescent polypyridyl ruthenium complex that 
enters HeLa cells via passive diffusion.
86
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Lastly, the effect of changes in the membrane potential on uptake of the ruthenium 
compound was studied.  When incubated with 170 mM potassium (which reduces the 
membrane potential to zero), uptake decreased substantially. Furthermore, in the presence 
of valinomycin (which will increase the membrane potential), uptake of the compound 
increased substantially. Taken together, it was concluded that uptake of 
[Ru(DIP)2(dppz)]
2+
 was solely via passive diffusion.
86
 It is interesting to consider this 
complex being taken up at all efficiently. The complex has a diameter of approximately 
21 Å, not unlike many small proteins, yet it is efficiently taken up through the cell 
membrane to the cytoplasm and, to some extent, to the nucleus of the cell.   
 In one last study by Pisani and coworkers, the mechanism of cellular uptake of a 
dinuclear polypyridylruthenium(II) complex (Figure 1.16) into L1210 murine leukemia 
cells was determined through flow cytometry experiments. In this study, the authors 
fou d that varyi g the temperature of i cu atio  from   C to 2  C to 3  C had a  effect 
o  uptake, with the   C sample havi g the least amou t of i tracellular ruthe ium  
Furthermore, when the cells were incubated with an increased amount of glucose, uptake 
of the ruthenium complex was significantly enhanced. Conversely, under metabolic 
inhibition, uptake marginally decreased. In order to rule out endocytosis, the authors 
measured ruthenium uptake in the presence of a variety of different endocytosis inhibitors 
(chloroquine diphosphate, filipin, dimethyl amiloride, ammonium chloride, and 
chlorpromazine hydrochloride), and found that uptake was either unchanged or increased 
in the presence of these inhibitors. Furthermore, when incubated with a variety of OCT 
inhibitors (tetra-n-alkylammonium salts or procainamide), uptake remained unchanged. 
The authors concluded that uptake was in large part due to passive diffusion, with a  
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Figure 1.16 [Ru2(phen)4((bpy')2(CH2)16))]
4+
, a compound shown to enter L1210 murine 
leukemia cells via an energy-dependent mechanism as well as passive diffusion.
87
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minor contribution from protein-mediated active transport.
87
 It is important to consider 
that complexes so similar in chemical structure need not have similar mechanisms of 
uptake. Experiments need to be determined in each case to establish the uptake 
mechanism. 
1.5 Subcellular localization of the Metal Complex 
 Once a therapeutic has entered the cell, there are a plethora of different organelles 
in which it can localize. Moreover, activities and targets depend on where within the cell 
the complex becomes localized. This localization can also determine unwanted toxicities 
associated with a given complex. 
 1.5.1 Methods to monitor Localization  
 The most commonly exploited technique for the subcellular mapping of inorganic 
therapeutics is fluorescence microscopy. However, this technique can only be used if the 
complex of interest is inherently luminescent. Cells can be treated with the luminescent 
drug of interest concomitantly with any of the various fluorescent organelle-specific 
probes. The extent of overlap between the drug and the probe will provide information on 
the localization of the drug. For example, Matson and coworkers synthesized a variety of 
dppz complexes of Ru derivatized with alkyl ether chains of various lengths and used 
confocal laser scanning microscopy to study their subcellular localization in CHO-K1 
cells.
88
 Using various RNA and membrane-specific dyes, they found, perhaps not 
surprisingly, that the least lipophilic compound localized in the nucleus, while the most 
lipophilic localized in membranes.  
 While fluorescence microscopy has the capability of providing a qualitative 
assessment of the localization of therapeutics in living cells, due to differences in the 
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quantum yields among different luminescent compounds, this technique cannot be 
utilized to quantify the amount of drug localized inside the cell. Furthermore, many 
metal-based luminescent compounds have been shown to exhibit different quantum 
yields depending on the environment surrounding the compound,
89
 which further 
complicates the quantitation of the localization of luminescent metal complexes using 
this technique. 
 In a study by Groessl and co-workers, ICP-MS was used to track the uptake and 
subcellular localization of cisplatin as well as two ruthenium-based chemotherapeutics 
currently in clinical trials, NAMI-A and KP1019. Reduced mitochondrial accumulation 
of cisplatin was observed in cisplatin-resistant cells, while the ruthenium-based drugs 
were found to have different localization patterns than cisplatin, which did not change 
from one cell type to the other.
 90
 
 While AAS and ICP-MS can provide quantitative information on the subcellular 
localization of inorganic complexes, the process of sample preparation for these methods 
involves the destruction of the cells, and, therefore, no structural information is obtained. 
One method for the visualization of the subcellular localization of metal-based 
therapeutics while obtaining the structural integrity of the cell is electron microscopy. 
Electron microscopy has the advantage of providing spatial resolution that is almost three 
orders of magnitude better than conventional light microscopy, allowing for the 
resolution of structural details in the nanometer range.
91
 Furthermore, the electron-dense 
property of metal ions can be detected inside cells by electron microscopy due to mass 
contrast. In transmission electron microscopy (TEM), cells are fixed, dehydrated with 
organic solvent, embedded in resin, and then thinly sliced (50 to 400 nm thick). These 
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thin samples are then exposed to an electron beam, which will be either scattered by 
regions of high electron density (metal ions), or transmitted through low electron density 
regio s of the sample to a detector, which the  co structs a “co trast image” of the 
sample, where areas of high electron density have higher contrast. In a study by van Rijt 
and coworkers, the distribution of a osmium(II) arene complex in ovarian cancer cells 
was determined by TEM. It was observed that upon treatment of A2780 cells with 5 µM 
osmium complex, increased contrast was observed in the mitochondria, nucleolus, and 
nuclear membrane. The morphological changes associated with apoptosis were able to be 
observed at the same time, illustrating the utility of electron microscopy.
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 Electron microscopy can in certain cases be combined with elemental mapping to 
obtain a technique called energy-filtered transmission electron microscopy (EFTEM). In 
this technique, as the electrons from the electron beam hit the sample, some will undergo 
an inelastic collision, losing an amount of energy that is equivalent to the core atomic 
level of the element that it just collided with. In this way, not only will an image be 
created with the resolution of electron microscopy, but also element distribution maps of 
the sample can be obtained.
93
  
 The last technique to consider here is nano-scale secondary ion mass spectrometry 
(NanoSIMS). In this technique, a high-energy primary ion beam bombards the surface of 
a sample, “sputteri g” seco dary io s, which are then detected and analyzed by a mass 
spectrometer.
94
 In this way, NanoSIMS can provide spatial resolution up to 50 nm, as 
well as elemental and isotopic information of the sample. This technique is in its infancy 
and, as such, has not been widely utilized in the subcellular mapping of metal-based 
therapeutics. However, in one study by the Berners-Price lab, a complementary EFTEM 
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and NanoSIMS study was performed on an antitumor gold(I) phosphine complex.
95
 In 
this study, human breast cancer cells (MDA) were treated with the gold complex and 
analyzed by both EFTEM and NanoSIMS for subcellular gold localization. Using 
EFTEM, the localization of gold could be observed, as well as the morphological changes 
accompanying gold treatment. NanoSIMS allowed for the mapping of 
12
C
14
N
- 
(to show 
cell morphology), 
31
P
-
 (to show the location of nucleic acids), 
197
Au
-
 (to show localization 
of the therapeutic), and 
34
S
-
 (to show the localization of thiols). The gold signal clearly 
co-localized with the sulfur signal, thus supporting the idea that the mechanism of action 
of Au(I) compounds involves the inhibition of thiol-containing protein families. 
 1.5.2 Peptide Conjugation 
 DNA is the cellular target of many inorganic chemotherapeutic agents. As such, it 
is important for these complexes to localize mainly in the nucleus of cells. One strategy 
to alter the subcellular localization of a compound is through peptide conjugation. 
Nuclear localization sequences (NLS) are small peptides which, when appended to a 
protein, will in essence allow the protein to be imported into the nucleus by nuclear 
transport.
96
  As an example, Kirin and coworkers utilized the NLS Pro-Lys-Lys-Lys-Arg-
Lys-Val to enhance the uptake and nuclear localization of the cobalt complex shown in 
Figure 1.17 into HT-29 cells. AAS experiments revealed that not only does the conjugate 
have enhanced uptake compared to the unconjugated cobalt complex, but also the 
intracellular cobalt concentration of the conjugate is higher than the extracellular cobalt 
concentration. Furthermore, the fraction of intracellular cobalt localized in the nucleus 
increased for the conjugates compared to the unconjugated cobalt complex.
97
 
 However, in the design of peptide-therapeutic conjugates, care must be taken to  
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Figure 1.17 The peptide conjugate studied by Kirin and coworkers. Upon conjugation of 
the cobalt complex to the nuclear localization peptide, uptake of the complex into the 
nucleus of HT-29 cells increased significantly.
97
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ensure that the conjugate itself still has the same biological target as the unconjugated 
molecule. For example, in an attempt to increase and accelerate the cellular uptake of 
rhodium metalloi sertors, the [Rh(phe )( py’-Arg8)(chrysi)]
11+
 complex shown in 
Figure 1.18 was synthesized. Uptake studies conducted on the fluorescein-appended 
analogue confirmed fast (within 60 min) nuclear uptake into HeLa cells. However, DNA 
binding studies revealed that, with the octaarginine appendage, the nonspecific binding 
affinity of both complexes for mismatched and matched DNA increased, due to the 
substantial added positive charge of the peptide.
98
 In fact, studies of cellular proliferation 
with the metalloinsertor-peptide conjugate confirmed that the complexes no longer 
showed the preferential inhibition of MMR-deficient cells, as expected if specific binding 
only to mismatched DNA was lost. One route to restore specificity would be to include a 
self-cleavable linker so that the conjugate would be removed once inside the nucleus.  
The work thus illustrates the utility but also subtle new issues that arise with peptide 
conjugates for therapeutic applications. 
 Many laboratories append fluorescent tags onto molecules of interest to follow 
their subcellular localization.  The process of appending a fluorescent tag to the molecule 
of interest can, however, also alter the subcellular localization.
99
 As an illustration, the 
localization properties of two Ru(dppz)-peptide conjugates, one with and one without a 
fluorescent tag (Figure 1.19) were explored. The conjugate with only the octaarginine 
peptide was localized throughout the cytoplasm in punctate distributions and was 
completely absent from the nucleus. On the other hand, the conjugate with both 
octaarginine and fluorescein exhibited nuclear staining when incubated under the same 
conditions as the previous conjugate. This study clearly shows the consequences of  
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Figure 1.18 The rhodium metalloinsertor-peptide conjugate synthesized in order to 
accelerate uptake. While uptake is accelerated upon conjugation of the metalloinsertor to 
the octaarginine peptide, the presence of the octaarginine increases the nonspecific 
binding affinity of the complex for matched and mismatched DNA. 
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Figure 1.19  Chemical structures (top) and confocal microscopy images (bottom) of the 
two metal-peptide fluorophore conjugates examined in our laboratory. The octaarginine 
conjugate (left) displays only cytosolic localization, while the octaarginine fluorescein 
conjugate (right) exhibits nuclear localization. 
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appending fluorescent tags to non-fluorescent molecules in order to study their 
subcellular localizations. 
1.6 Targeted Therapeutics 
Cisplati  a d its a alogues were developed as “classical” chemotherapeutics  
These types of drugs are meant to interfere with replication and/or the mitotic processes 
of tumor cells.
100
 In this way, they achieve potency by damaging cancer cells more than 
healthy cells. While this approach has been fruitful, it has been known to cause a litany of 
side effects, such as nephrotoxicity, neurotoxicity, leukopenia, and thrombocytopenia, as 
well as nausea, vomiting, and hair loss.
101
 For these reasons, research efforts in recent 
years have shifted towards the developme t of targeted chemotherapy  I  “targeted” 
therapy, a drug is developed to target a specific cellular signaling pathway on which 
cancer cells depend for growth, metastasis, or angiogenesis.
102
 These types of compounds 
aim to damage cancer cells instead of healthy cells. Targeted therapy focuses on the 
development of selective therapeutics, whereas classical therapy has focused on the 
development of increasingly cytotoxic compounds. The next generation of 
chemotherapeutics has focused on targeting biomolecules, including proteins, organelles, 
and specific DNA lesions (Figure 1.20). 
1.6.1 Proteins as Targets 
As an illustration, the high levels of mutagenesis in cancerous cells often lead to 
upregulation and overexpression of proteins, making them attractive candidates for 
targeting. Metal complexes, due to their modular nature and inherent chirality, are 
uniquely able to selectively target these chiral biomolecules. In particular, this approach 
has been applied toward the selective inhibition of kinase activity. Phosphorylation of  
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Figure 1.20 Chemical structures of targeted chemotherapeutics: (top, left to right) The 
octasporine complex OS1, a potent inhibitor of the protein kinase GSK3; General 
architecture of RAPTA cathepsin B inhibitors; Ruthenocene analogues of tamoxifen for 
the selective targeting of ER; (bottom, left to right) The first generation rhodium 
metalloinsertor, [Rh(bpy)2(chrysi)]
3+
,  selectively binds to mismatched and abasic sites in 
duplex DNA; Structure of mtPt, a cisplatin analogue designed to localize to the 
mitochondria. 
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proteins by kinases is a highly important regulatory activity. However, over-
phosphorylation of proteins is common in many types of cancer.
103
 In a recent study by 
Meggers et al., inert metal complexes, inspired by the natural product staurosporine and 
termed octasporines, were designed as highly selective kinase inhibitors (Figure 
1.20).
104,105
 Six complexes were synthesized, all containing a ruthenium or iridium center 
and a bidentate pyridocarbazole ligand designed to bind the hinge region of the ATP-
binding pocket of the kinase. However, the remaining ligands on each complex were 
designed to make up a unique set of hydrogen-bonding interactions with the glycine-rich 
loop of the ATP-binding pockets of six distinct kinases (Figure 1.21).
104
 In vivo studies 
have revealed the anti-angiogenic properties of one of these types of compounds in 
zebrafish embryos, exemplifying their potential.
105
 
Whereas the previous example utilized the structural complexity of inert metal 
complexes, the reactive nature of certain metal centers can also be exploited in targeted 
therapy. Proteases play a crucial role in tumorigenesis by suppressing cell-death 
pathways and promoting cell-survival pathways.
106
 One such protease, cathepsin B, has 
been targeted by ruthenium arene RAPTA compounds (Figure 1.20).
107,108
 These 
compounds were found to inhibit cathepsin B protease activity and exhibited selective 
anti-metastatic activity in vivo.
108,109
  
Estroge  receptors such as estroge  receptor α (ERα), which is overexpressed i  
several types of breast cancer, have also been the subject of targeted therapy studies.
110
 
Several organometallic analogues of tamoxifen, an antagonist of estrogen receptors, have 
been developed to selectively target ERα (Figure 1.20).111,112 These complexes have 
demo strated cytotoxic activity selectively i  ERα-positive breast cancer cell lines.111 
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Figure 1.21 Design of Octasporine complexes as inhibitors of protein kinases (adapted 
from reference 104). The pyridocarbazole ligand, common to all complexes, binds to the 
hinge region (where the adenine portion of ATP binds) of the ATP-binding pocket. The 
remaining A, B, C, and D ligands make up a set of hydrogen-bonding interactions with 
the glycine-rich loop (where the ribose triphosphate portion of ATP binds) of the ATP 
binding pocket, each unique to a particular kinase. 
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1.6.2 Organelles as Targets 
In addition to protein targeting, the mitochondria can also serve as a valuable 
target for drug design. Mitochondria produce reactive oxygen species as a byproduct of 
metabolism, and they also play a crucial role in the regulation of cell death pathways.
113
 
Targeting mitochondria and mitochondrial DNA can induce apoptosis in tumorigenic 
cells, as was recently demonstrated by Lippard and Kelley.
114
 They constructed a cis-
platinum(II) complex tethered to a mitochondrial penetrating peptide, which contained 
alternating cationic and lipophilic residues to enhance mitochondrial uptake (Figure 
1.20). This complex was shown to localize almost exclusively to mitochondria in several 
cancer cell lines. Moreover, the complex was able to induce apoptosis in cisplatin-
resistant ovarian cancer cells by damaging mitochondrial DNA. 
1.6.3 DNA Lesions as Targets 
The proposed mechanism of action of classical platinum-based chemotherapeutics 
is the formation of covalent DNA adducts, followed by cellular processing of these 
lesions.
6
 The synthesis of new-generation classical therapeutics with enhanced DNA-
binding properties in order to increase cytotoxicity has been extensively explored. 
However, the design and synthesis of therapeutics that bind to specific DNA lesions that 
are more prevalent in cancer cells than normal cells may represent a targeted strategy for 
new chemotherapy. In particular, rhodium metalloinsertors (Figure 1.20) bind 
mismatches in duplex DNA in vitro with high specificity and affinity, preferentially 
targeting thermodynamically destabilized mismatches over matched base pairs by a factor 
of over 1000.
29,30
 The binding mode of these complexes to mismatched DNA is 
illustrated in Figure 1.5; the chrysi ligand inserts into the DNA from the minor groove 
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and ejects both mismatched bases in a binding mode termed metalloinsertion.
31,33 
Ejection of the mismatched bases results in a large lesion that is hypothesized to have the 
potential to be recognized in vivo. 
Mismatches in genomic DNA arise naturally as a consequence of replication, but 
if left uncorrected can lead to mutations.
115,116
 The mismatch repair (MMR) pathway 
serves as a checkpoint to increase the fidelity of DNA replication ~1000 fold.
117
 
Importantly, deficiencies in the mismatch repair machinery have been associated with 
several types of cancer, as well as increased resistance to classical chemotherapeutics 
such as cisplatin.
118
 Therefore, the development of a targeted therapy for MMR- deficient 
cancers would be invaluable in the clinic. Due to the unique DNA mismatch-binding 
properties of rhodium metalloinsertors, their biological properties in MMR-deficient cells 
were investigated. The compounds have been found to inhibit growth and selectively 
induce necrosis in MMR-deficient colorectal cancer cells over MMR-proficient cells.
53,55
 
Clearly, the strategy of targeting a specific lesion in DNA is a promising alternative to the 
classical approach. 
 
1.7 Conclusion 
 The development of new therapeutic agents with improved effectiveness is 
imperative, and metal complexes offer a wealth of possibilities. The thorough 
examination of current therapeutics is vital to this process. Structural characterization of 
the interaction between a given complex and its target can provide insight as to what 
changes can be made to the complex in order to strengthen the interaction. Likewise, 
structure-function relationships can provide further information for improvement by 
noting how the hydrophobicity of a given compound affects the activity. The relationship 
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between uptake and activity is also an important one, and knowing the mechanism of 
uptake can provide the means with which to improve uptake. The knowledge of where 
within the cell the complex is being shuttled is a powerful tool, and the correlation 
between activity and subcellular localization will provide the researcher with the insight 
of how to make new therapeutics with improved effectiveness.  
 Targeted chemotherapy holds the potential to combat the severe side effects and 
acquired resistance associated with classical chemotherapeutics such as cisplatin. Many 
years of study have focused on achieving high potency for metal complex therapeutics, 
but such potency has been achieved.  Just as the design of organic chemotherapeutics has 
shifted from potent alkylators and other inhibitors of DNA synthesis to far more tailored, 
subtle reagents, the design of novel metallotherapeutics now requires a targeted approach. 
There has really been a paradigm shift in next-generation chemotherapeutic drug design 
that focuses on specifically tailored therapies. The unique reactivity and coordination 
geometry of metal complexes make them the ideal scaffold for this new tailor-made 
design of targeted therapeutics. The examples discussed herein exemplify the enormous 
potential of this new strategy in transition metal chemotherapy and perhaps lay the 
groundwork for this burgeoning new field. 
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Chapter 2: Selective Cytotoxicity of Rhodium Metalloinsertors in 
Mismatch Repair-Deficient Cells
‡
 
2.1 Introduction 
The cell has evolved a complex replication mechanism containing multiple 
checkpoints in order to minimize the incorporation of errors during replication and 
correct errors that result from chemical damage to DNA after replication.
1
 Left 
uncorrected, these DNA defects will lead to mutations in subsequent rounds of 
replication.
2,3
 The mismatch repair (MMR) pathway provides one such checkpoint and 
increases the fidelity of DNA replication ~1000-fold.
4
 Not surprisingly, defects in this 
pathway have been associated with several types of cancer. For example, about 18% of 
solid tumors and 15% of sporadic colorectal cancer cases have been found to exhibit 
MMR deficiencies.
5,6
 Furthermore, many commonly used chemotherapeutics, such as 
cisplatin, DNA alkylating agents, and anti-metabolites, have decreased effectiveness 
against MMR-deficient cancer cells.
7
 In fact, repeated chemotherapeutic treatments with 
these agents enrich tumors with MMR-deficient cells.
8,9
 Undeniably, then, the synthesis 
and study of small molecules that possess the ability to specifically target DNA defects 
may afford progress in the development of new cancer diagnostics and therapeutics that 
are specific for MMR-deficient cancers.  
The Barton laboratory has previously developed a class of compounds, called 
rhodium metalloinsertors (Figure 2.1), that target DNA mismatches in vitro with high 
specificity and affinity.
10  
The first generation compound, [Rh(bpy)2(chrysi)]
3+
 (chrysi =  
                                                 
‡
 Adapted with permission from Ernst, R. J.; Komor, A.C.; Barton, J. K. Selective Cytotoxicity of Rhodium 
Metalloinsertors in Mismatch Repair-Deficient Cells. Biochemistry 2011, 50, 10919-10928. © 2011 ACS. 
Acknowledgements: Russell Ernst performed the flow cytometry experiments; I assisted with all 
metalloinsertor synthesis and all cell culture assays. 
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Figure 2.1 Chemical structures of rhodium metalloinsertors [Rh(HDPA)2chrysi]
3+
 and 
[Rh(MeDPA)2chrysi]
3+
. 
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chrysene-5,6-quinonediimine), binds 80% of DNA mismatches in all sequence contexts 
and preferentially targets thermodynamically destabilized mismatches over matched base 
pairs by a factor of over 1000.
11
 Specifically, it has been shown to bind only at the single 
mismatch site in a 2725 base-pair plasmid.
12
 Additional work focused on incorporating 
nitrogen atoms into the intercalating ligand in order to increase π-stacking stabilization 
and led to the development of the second generation compound, [Rh(bpy)2(phzi)]
3+
 (phzi 
= benzo [a] phenazine-5,6-quinonediimine). This complex exhibits a 50-fold increase in 
binding affinity compared to [Rh(bpy)2(chrysi)]
3+
 without a loss in selectivity, allowing 
for mismatch detection at nanomolar Rh concentrations.
13
 The binding mode of these 
mismatch-specific complexes was determined through the 1.1 Å resolution crystal 
structure of [Rh(bpy)2(chrysi)]
3+
 bound to an AC mismatch. The structure revealed the 
chrysi ligand to insert from the minor groove with ejection of both mismatched bases.
14
 
NMR studies of [Rh(bpy)2(chrysi)]
3+ 
bound to a CC mismatch further confirmed this 
binding mode for the complex at mismatched sites in solution.
15
 Additional crystal 
structures of the Rh complex bound to different mismatches 
16
 as well as of a Ru complex 
bound by insertion to a mismatched site
17
 established the generality of metalloinsertion.
 
It 
is noteworthy that these studies represented the first illustration of the insertion binding 
mode, originally proposed by L. S. Lerman in the early 1960’s.18  
Confocal microscopy and flow cytometry studies with [Ru(L)2dppz]
2+
 
(dppz=dipyrido[3,2-a:2',3'-c]phenazine) analogues have demonstrated that cellular 
accumulation occurs through passive diffusion, facilitated by the negative potential 
difference across the cell membrane.
19,20
 Taken together, the observations that (i) 
rhodium metalloinsertors are capable of recognizing mismatches with high selectivity and 
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(ii) analogous ruthenium complexes accumulate within cells and nuclei form a sound 
basis for the hypothesis that rhodium metalloinsertors recognize mismatched DNA within 
cells and predict that these complexes should selectively target MMR-deficient cells, 
which harbor ~1,000 fold more mismatches than MMR-proficient cells. 
In an effort to characterize the in cellulo effects of these metalloinsertors, several 
cell assay experiments have been undertaken on the isogenic cell lines HCT116N and 
HCT116O. The HCT116 parent cell line is a human colorectal carcinoma line deficient in 
the hMLH1 gene. This gene encodes for part of the mismatch repair (MMR) machinery; 
consequently, this cell line is MMR deficient. The HCT116N cell line has been 
transfected with human chromosome 3 (ch3), which restores MMR proficiency, while the 
HCT116O cell line has been transfected with human chromosome 2 (ch2), leaving it 
MMR deficient.
21
 These rhodium metalloinsertors have been found to selectively inhibit 
DNA synthesis in the MMR-deficient HCT116O cell line over the MMR-proficient 
HCT116N cell line,
22
 as measured by an ELISA assay for DNA synthesis.
23
 
Significantly, the binding affinities of the metalloinsertors were found to correlate 
directly with the selectivity of the rhodium complexes for the MMR-deficient cell line, 
lending credence to the idea that these complexes target DNA mismatches in cellulo as 
well as in the test tube.
24
 
However, the proliferation assay does not distinguish between senescence and cell 
death, and therefore is insufficient to demonstrate cytotoxicity.  Here, we show that 
rhodium metalloinsertors are preferentially cytotoxic to the MMR-deficient HCT116O 
cell line.  This rhodium-induced death is shown to be necrotic rather than apoptotic, and 
is preceded by cell cycle arrest at the G1/S-phase boundary.  This observation is 
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consistent with activation of the DNA damage response by rhodium metalloinsertors. 
2.2 Experimental Protocols 
2.2.1 Materials 
RhCl3 was purchased from Pressure Chemical, Inc. (Pittsburgh, PA).  
[Rh(NH3)5Cl]Cl2 was obtained from Strem Chemical, Inc. (Newburyport, MA).  2,2'-
dipyridylamine (HDPA) and Sephadex ion exchange resin were obtained from Sigma-
Aldrich (St. Louis, MO).  Sep-Pak C18 solid phase extraction cartridges were purchased 
from Waters Chemical Co. (Milford, MA). Media and supplements were purchased from 
Invitrogen (Carlsbad, CA). The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromide (MTT) labeling reagant and acidified lysis buffer (10% SDS in 10 mM HCl) 
were purchased in kit format from Roche Molecular Biochemicals (Mannheim, 
Germany).  Z-VAD-FMK caspase inhibitor was purchased from Promega. All PARP 
inhibitors were purchased from Santa Cruz Biotechnology, Inc.  All commercial 
materials were used as received. 
2.2.2 Synthesis of Metal Complexes 
 2.2.2.1  [Rh(NH3)6][OTf]3 
[Rh(NH3)6][OTf]3 was prepared according to an adaptation of previously 
described procedures.
25,26
 A 100 mL schlenk flask was charged with [Rh(NH3)5Cl]Cl2 
(2.045 g, 7.0 mmol) and put under an Ar atmosphere. HOTf   10    66.6 mm l   as 
a  e  t  the tan s li   an  the res ltin   ran e s l ti n  as   r e   ith  r   r 1 m  then 
heate  t  100     r   h.  t2    0 mL  at -      as    re   nt  the re  s l ti n  an  the 
resulting oran e  reci itate  as c llecte   n a me i m  rit.  he c llecte   reci itate  as 
trans erre  t  a   0 mL   en- rie  schlen   las  an  c  le  t  -     in a  ry ice acet ne 
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bath. The flask was evacuated and refilled with NH3(g), which condensed in the flask to 
a   r  a  ee   ran e s l ti n   hich  as stirre  at -    .   ter 1  m  the  las   as 
disconnected from the NH3(g) tank, opened up to the atmosphere, and allowed to warm to 
ambient temperature. The resulting  yellow solid was crystallized from water (20 mL) to 
afford colorless crystals. Yield: 3.166 g, 71.5 %.
  1
H NMR (300 MHz, d6-DMS  : δ 3.6  
(s, 18H). ESI-MS (cation): m/z calc. 503.0 (M-OTf
+
), obs. 502.7. 
 2.2.2.2  [Rh(NH3)4(chrysi)]Cl3 
[Rh(NH3)4(chrysi)]
3+
 was prepared according to an adaptation of previously 
described procedures.
24
 [Rh(NH3)6][OTf]3 (0.50 g, 0.77 mmol) and chrysene-5,6-dione 
(0.200 g, 0.77 mmol) were dissolved in a 1:9 mixture of water:acetonitrile (500 mL). A 
1M solution of NaOH (3 mL) was added to the orange solution, and the reaction was 
allowed to stir at ambient temperature for 3 h, at which time a 1M solution of HCl (3 mL) 
was added to neutralize the reaction mixture. The acetonitrile was evaporated in vacuo, 
and the resulting red solution was loaded onto a SPE cartridge, eluted with 25% 
acetonitrile in 0.1% TFA(aq), and lyophilized to give a red solid.  The chloride salt can be 
obtained from a Sephadex QAE anion exchange column equilibrated with 0.1M MgCl2.  
Yield: 0.072 g, 18%. 
1
H NMR (300 MHz, d6-DMS  : δ 13.46 (s, 1H); 12.33 (s, 1H); 
8.90 (t, J =8.0 Hz, 1 H); 8.72 (d, J = 8.4 Hz, 1H); 8.51 (m, 2H); 8.38 (d, J = 8.6 Hz, 1H); 
8.17 (t, J = 6.8 Hz, 1 H); 7.71-7.90 (m, 4H); 4.68 (br s, 3H); 4.53 (br s, 3H); 3.98 (br s, 
6H). ESI-MS (cation): m/z calc. 522.07 (M-NH3-H+TFA
+
), obs. 522.1. UV-Vis (H2O, pH 
7): 260 nm (60,900 M
-1
 cm
-1
), 325 nm (12,600 M
-1
, cm
-1
), 410 nm (12,000 M
-1
, cm
-1
). 
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 2.2.2.3  N-methyl-N-(pyridin-2-yl)pyridin-2-amine (MeDPA) 
   a sl rry    s  i m hy ri e   0 m    .9 mm l  in  HF  10 ml   as a  e  
HDP    00 m    .9 mm l  in   ml  HF at 0 °   n er 1 atm r.  he reacti n  as   r e  
 ith ar  n   r 1  min  an  the a  r  riate 1-br m al ane  3.  mm l   as a  e  
 r   ise an   arme  t  ambient tem erat re.  he reacti n  as stirre  an a  iti nal 1  h 
 n er ar  n at re l x tem erat re.  he reacti n mixt re  as extracte   ith  il te s  i m 
bicarb nate  an  the aq e  s  hase  as extracte   ith  H  l   3 x  0 ml .  he  r anic 
 racti ns  ere c mbine  an   rie    er ma nesi m s l ate  an  the s l ent  as rem  e  
in vacuo.  hese li an s  ere   ri ie   ia  lash chr mat  ra hy  Si    1:9 
 t  c:hexanes . Yiel :  3%. 1H-NMR   D l3  300 MHz : δ  .3      J = .0 Hz   H ; 
 . 3  m   H ;  .1      J = .  Hz   H ; 6. 6  m   H ; 3.6   s  3H .  SI-MS  cati n : m/z 
calc. 1 6.1  M+H+    bs. 1 6. 
2.2.2.4  [Rh(XDPA)2(chrysi)]Cl3 (X=H, Me) 
[Rh(XDPA)2chrysi]Cl3
 
was prepared according to an adaptation of previously 
described procedures.
24
 A 500 mL round bottomed flask was charged with 
[Rh(NH3)4(chrysi)]Cl3 (80.5 mg, 0.15 mmol) and XDPA (0.4 mmol), and 1:1 EtOH:H2O 
(250 mL) was added. The resulting red solution was allowed to reflux overnight after 
which time the solvent was removed in vacuo. The red solid was redissolved in H2O (10 
mL), filtered, and purified via flash chromatography (C18-SiO2, 17:3 0.1% TFA (aq): 
MeCN).  The chloride salt can be obtained from a Sephadex QAE anion exchange 
column equilibrated with 0.1M MgCl2.  
[Rh(HDPA)2(chrysi)]Cl3: Yield: 74.0 mg, 61%. ESI-MS (cation): m/z calc. 699.2 
(M-2H
+
), 350.1 (M-H
2+
), obs. 699.1, 350.3. 
1
H NMR (300 MHz, (CD3)2SO : δ 12.84 (s, 
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1H); 12.34 (s, 1H); 11.78 (s, 1H); 10.32 (d, J =8.7 Hz, 1H); 8.63 (d, J = 6.9 Hz, 1H); 
8.40 (d, J = 8.4 Hz, 1H); 8.31 (d, J = 9.3 Hz, 1H); 8.14 (m, 2H); 8.07 (d, J = 8.7 Hz, 
1H); 8.04 (d, J = 5.4 Hz, 1H); 7.94 (m, 4H); 7.77 (m, 5H); 7.58 (m, 2H); 7.48 (d, J = 8.1 
Hz, 1H); 7.41 (d, J = 8.4 Hz, 1H); 7.32 (s, 1H); 7.14 (m, 2H); 7.04 (t, J = 6.8 Hz, 1H); 
6.98 (t, J = 6.9 Hz, 1H); 6.81 (t, J = 6.5 Hz, 1H). UV-Vis (H2O, pH 7): 290 nm (42,200 
M
-1
 cm
-1
), 320 nm (23,000 M
-1
, cm
-1
), 440 nm (8,800 M
-1
, cm
-1
). 
[Rh(MeDPA)2chrysi]Cl3: Yield: 0.103 g, 84%. 
1
H NMR (500 MHz, CD3CN : δ 
14.39 (s, 1H); 10.66 (d, J =8.8 Hz, 1H); 9.56 (d, J =7.9 Hz, 1H); 9.30 (d, J = 6.0 Hz, 
1H); 8.14-8.21 (m, 3H); 8.16 (t, J = 7.2 Hz, 1H); 8.02 (d, J = 8.8 Hz, 1H); 7.87-7.93 (m, 
4H); 7.85 (d, J =8.0 Hz, 1H); 7.77 (d, J =8.6 Hz, 1H); 7.67-7.74 (m, 2H); 7.60 (m, 2H), 
7.50 (m, 2H); 7.35 (d, J = 8.4 Hz, 1H); 7.15 (t, J = 5.7 Hz, 1H); 7.06-7.11 (m, 3H); 6.92 
(t, J = 6.0 Hz, 1H); 4.07 (s, 3H); 3.82 (s, 3H). ESI-MS (cation): m/z calc. 727.2 (M-2H
+
), 
364.1 (M-H
2+
), obs. 727.1, 364.3. UV-Vis (H2O, pH 7): 295 nm (55,000 M
-1
 cm
-1
), 320 
nm (39,700 M
-1
, cm
-1
), 390 nm (14,000 M
-1
, cm
-1
). 
 2.2.3 Cell Culture 
HCT116N and HCT116O cells were grown in RPMI medium 1640 supplemented 
with: 10% FBS; 2 mM L-glutamine; 0.1 mM nonessential amino acids; 1 mM sodium 
pyruvate; 100 units/mL penicillin; 100 g/mL streptomycin; and 400 g/mL geneticin 
(G418). Cells were grown in tissue culture flasks and dishes (Corning Costar, Acton, 
MA) at 37°C under 5% CO2 and humidified atmosphere. 
  2.2.3.1  ICP-MS Assay for Cellular Rhodium Levels 
Each cell line was treated with 10 M of [Rh(bpy)2chrysi]
3+
, 
[Rh(HDPA)2chrysi]
3+
, or [Rh(NH3)4chrysi]
3+
 for 48 hours. After rhodium incubation, the 
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cells were harvested from adherent culture by trypsinization, washed with cold PBS, and 
counted by hemacytometer.  The samples were pelleted and resuspended in 1% HNO3 
(v/v), homogenized by three freeze/thaw cycles in liquid nitrogen, and analyzed for 
rhodium content on an HP-4500 ICP-MS unit.  Rhodium counts were normalized to the 
number of cells counted in each sample before lysate preparation.  Standard errors for 
three independent experiments are shown. 
  2.2.3.2  Cellular Proliferation ELISA 
HCT116N and HCT116O cells were plated in 96-well plates at 2,000 cells/well 
and allowed 24 hours to adhere.  The cells were then incubated with rhodium for the 
durations specified.  For incubation less than 72 hours, the Rh-containing media was 
replaced with fresh media, and the cells were grown for the remainder of the 72-hour 
period.  Cells were labeled with BrdU 24 hours before analysis.  The BrdU incorporation 
was quantified by antibody assay according to established procedures.
23,27
 Cellular 
proliferation was expressed as the ratio of the amount of BrdU incorporated by the treated 
cells to that of the untreated cells. 
  2.2.3.3  MTT Cytotoxicity Assay 
Cytoxicity assays were performed as described in the literature.
28
 HCT116N and 
HCT116O cells were plated in 96-well plates at 50,000 cells/well and incubated with 
rhodium for the durations specified.  After rhodium incubation, cells were labeled with 
MTT for 4 hours at 37°C under 5% CO2 and humidified atmosphere.  The resulting 
formazan crystals were dissolved with solubilizing reagant (purchased from Roche) 
acc r in  t  the man  act rer’s instr cti ns.   he  iss l e  formazan was quantified as 
the absorbance at 570 nm minus the background absorbance at 690 nm.  Percent viability 
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was determined as the ratio of the amount of formazan in the treated cells to that of the 
untreated cells.  For caspase inhibition assays, Z-VAD-FMK was added to a final 
concentration of 20 µM.  For poly-ADP ribose polymerase (PARP) assays, the inhibitor 
3,4-Dihydro-5[4-(1-piperindinyl)butoxy]-1(2H)-isoquinoline (DPQ) was added to a final 
concentration of 0, 25, or 50 µM; the inhibitor 3-aminobenzamide (3-AB) was added to a 
final concentration of 0, 2, or 3 mM; the inhibitor 4-amino-1,8-napthalimide (4-AN) was 
added to a final concentration of 0, 10, or 20 µM; and the inhibitor 2-((R)-2-
Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide (ABT-888) was added to a 
final concentration of 0, 5, or 10 µM.   
 2.2.4 Cell Cycle Distribution Flow Cytometry Assay 
Cells were harvested from adherent culture by trypsinization and washed with 
cold PBS. The resultant pellet was resuspended in PBS (chilled to 4 C), and ice-cold 
ethanol was added dropwise to a final concentration of 70% (v/v), with continuous gentle 
agitation.  Cells were fixed at 4C for 30 minutes and stored for up to one week.  Prior to 
analysis, the fixed cells in 70% ethanol were diluted 1:3 in cold PBS and centrifuged at 
1,400 x g for 5 minutes.  The resultant pellet was washed twice and resuspended in ice-
cold PBS.  Ribonuclease was added to a final concentration of 30 g/mL and the cells 
were incubated overnight at 4 C.  The next day propidium iodide was added to a final 
concentration of 20 g/mL and cells were analyzed by flow cytometry.  Data analysis 
was performed using the FloJo software package (v 8.7.1). 
 2.2.5 Cell Death Mode Flow Cytometry Assay 
Cell death was characterized by a dye exclusion assay.
29
 After 24-, 48-, or 72-
hour incubation with rhodium, cells were harvested from adherent culture by 
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trypsinization, washed with cold PBS, and centrifuged at 2,000 rpm for 5 minutes.  The 
resultant pellets were resuspended in PBS to a concentration of 10
6
 cells/mL and stained 
with propidium iodide to a final concentration of 1µg/mL and with YO-PRO-1 to a final 
concentration of 200 nM for 30 minutes prior to analysis by flow cytometry. 
2.3 Results 
 2.3.1 ICP-MS of whole cell lysates 
Each cell line was treated with 10 M of [Rh(bpy)2chrysi]
3+
, 
[Rh(HDPA)2chrysi]
3+
, or [Rh(NH3)4chrysi]
3+
 for 48 hours.  Whole cell lysates were 
analyzed for rhodium levels by ICP-MS (Figure 2.2). As expected, the HDPA complex 
exhibits a higher degree of cellular uptake than the other complexes. This supports the 
notion that the early activity displayed by the complex in the ELISA assay results from 
accelerated uptake.
24
 It should be noted that these treatment conditions directly reflect 
those used previously. 
2.3.2 MTT cytotoxicity assay 
The cytotoxicities of [Rh(HDPA)2chrysi]
3+
 and [Rh(MeDPA)2chrysi]
3+
 were 
determined by MTT assay.
28
  Briefly, reduction of the MTT reagant by mitochondrial 
enzymes leads to the production of formazan, which can then be dissolved in acidified 
SDS to produce a characteristic absorbance at 570 nm.  This absorbance reflects the 
relative metabolic activity, which in turn reflects the percentage of viable cells in each 
sample.  HCT116N and HCT116O cells were plated and treated with 0-25 µM of 
[Rh(bpy)2chrysi]
3+
, [Rh(HDPA)2chrysi]
3+
, or [Rh(MeDPA)2chrysi]
3+
 for 48 or 72 hours.  
The results are shown in Figure 2.3. At 48 hours [Rh(HDPA)2chrysi]
3+
 and 
[Rh(MeDPA)2chrysi]
3+
 clearly display an enhanced toxicity in the MMR-deficient  
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Figure 2.2 ICP-MS assay for rhodium accumulation. Normalized rhodium counts for 
whole cell lysates treated with 0 or 10 µM [Rh(bpy)2chrysi]
3+
, [Rh(HDPA)2chrysi]
3+
, or 
[Rh(NH3)4chrysi]
3+
 for 48 hours. Standard error bars for three trials are shown. Cellular 
concentrations were determined by counting on hemacytometer prior to lysis.  Rhodium 
counts were normalized to total cells per sample. 
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Figure 2.3 Selective toxicity of [Rh(HDPA)2chrysi]
3+
 and [Rh(MeDPA)2chrysi]
3+
 in 
MMR-deficient cells.  HCT116N and HCT116O cells were plated in 96-well format at 
densities of 5 x 10
4 
cells/well and treated with 0 – 25 µM of [Rh(bpy)2chrysi]
3+
, 
[Rh(HDPA)2chrysi]
3+
, or [Rh(MeDPA)2chrysi]
3+
.   After 48–72 hours, the cells were 
labeled with MTT for 4 hours. While the first generation complex [Rh(bpy)2chrysi]
3+
 is 
non-toxic up to 72 hours, the dipyridylamine derivatives [Rh(HDPA)2chrysi]
3+
 and 
[Rh(MeDPA)2chrysi]
3+
 exhibit toxicity specifically in the MMR-deficient HCT116O cell 
line at 48 hours. 
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HCT116O cell line versus the HCT116N cell line.  For example, 72 hours after treatment 
with 20 µM [Rh(HDPA)2chrysi]
3+
, the number of viable HCT116N cells is 80 ± 5.2 % of 
untreated controls, whereas the number of viable HCT116O cells is 37 ± 4.4 % of 
untreated controls. [Rh(MeDPA)2chrysi]
3+
 also shows differential toxicity against the 
HCT116O cell line in this assay comparable to that of [Rh(HDPA)2chrysi]
3+
. 
2.3.3 Cell cycle distribution 
Given the observation that the complexes inhibit DNA synthesis, a flow 
cytometry assay was performed to determine if the cytotoxicity of [Rh(HDPA)2chrysi]
3+
 
is accompanied by disruption of the cell cycle.  MMR-proficient HCT116N and MMR-
deficient HCT116O cells were treated with 20 µM [Rh(HDPA)2chrysi]
3+
 for 24 or 48 h. 
After treatment, cells were stained with propidium iodide (PI) and analyzed by flow 
cytometry.  The PI fluorescence reports the amount of DNA in each cell and follows a 
bimodal distribution, where the first peak contains cells with one copy of the genome, i.e, 
cells in G0/G1-phase, and the second peak contains cells with two copies of the genome, 
i.e, cells in G2- or M-phase.  Cells in S-phase occupy the region between the two peaks.  
Figure 2.4 shows these distributions for both cell lines, with or without rhodium 
treatment.  In both cases, a decrease in the area under the curve between the peaks can be 
seen, indicating a depletion of the S-phase populations.  Fitting the raw distributions to 
G1-, S-, or G2/M-phases confirms the depletion of the S-phase population, concomitant 
with an increase in the G1-phase population. Notably, at this concentration of 
[Rh(HDPA)2chrysi]
3+
 large differentials in both the ELISA and MTT assay were 
observed.  The changes to the cell cycle are more pronounced in the mismatch-repair-
deficient HCT116O cell line, which continues to grow aggressively at 48 hours (> 50%  
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Figure 2.4 Cell cycle distribution assay.  HCT116N (top) and HCT116O (bottom) cells 
were treated with 20 µM [Rh(HDPA)2chrysi]
3+
 for 24 or 48 hours.  After fixation and 
staining with PI, cells were analyzed by flow cytometry.  The raw distributions were 
analyzed for cell cycle phase using commercially available software.  Upon rhodium 
treatment, the S-phase population is depleted, with a concomitant increase in the G1-
phase population. 
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S-phase) in the absence of rhodium treatment, whereas growth of the HCT116N cell line 
slows slightly as the density of the culture increases. Furthermore, the HCT116O cell line 
also shows a significant increase in the G2/M population as well as the G1 population. 
2.3.4 Mode of cell death 
To characterize the cell death occurring in response to rhodium treatment, a dye 
exclusion flow cytometry assay was employed.
29
 The assay differentiates between live 
cells, dead cells, and cells undergoing apoptosis or necrosis through concurrent staining 
with propidium iodide (a dead-cell-permeable dye) and YO-PRO-1 (an apoptotic-cell-
permeable dye).  By plotting the fluorescence of the YO-PRO-1 channel against the PI 
channel, a pattern emerges.  Healthy cells are seen in the lower lefthand corner of the 
plot.  Apoptotic cells exhibit higher YO-PRO-1 fluorescence, but still exclude propidium 
iodide, placing them in the upper lefthand quadrant of the pattern.  Dead cells admit both 
dyes and are therefore seen in the upper righthand quadrant of the image. Upon flow 
cytometry analysis, cells can be classified as live, apoptotic, necrotic, or dead by defining 
regions in the fluorescence plane corresponding to each category. 
The HCT116N and HCT116O cell lines were incubated with 0–25 M of 
[Rh(HDPA)2chrysi]
3+
 for 24–72 hours.  After harvesting the cells and staining with both 
PI and YO-PRO-1, the cells were analyzed by flow cytometry to obtain raw fluorescence 
data.  Representative data for 20 µM rhodium treatment for 72 hours are shown in Figure 
2.5. YO-PRO-1 fluorescence is shown on the y-axis, and PI fluorescence is shown on the 
x-axis.  The color scale represents the number of cells, with blue indicating fewer cells at 
a given pair of fluorescence levels, and orange representing a greater number of cells at a 
given pair of fluorescence levels.  The raw data were analyzed by gating the fluorescence  
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Figure 2.5 Flow cytometry assay of cell death. (Left) HCT116N and HCT116O cells 
were treated with 20 µM [Rh(HDPA)2chrysi]
3+
 for 72 hours. Rhodium treatment causes 
cells to move away from the origin, along the necrotic pathway (lower branch of pattern).  
The effect is more pronounced in the HCT116O cell line. (Right) HCT116N and 
HCT116O cells were treated with 15 µM or 20 µM [Rh(HDPA)2chrysi]
3+
 for 72 hours.  
Rhodium treatment causes a sharp decrease in the live population of the HCT116O cell 
line with a corresponding increase in the necrotic and dead cell populations.  Minimal 
effect is seen in the HCT116N cell line. Thus, [Rh(HDPA)2chrysi]
3+
 preferentially 
induces necrosis in the MMR-deficient HCT116O cell line. 
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events into one of four categories, depending on the fluorescence levels of the two dyes. 
Figure 2.5 also shows histograms of live, apoptotic, necrotic, and dead cells for the 
HCT116N and HCT116O cell lines based on the flow cytometry. Rhodium treatment was 
either 15 or 20 µM [Rh(HDPA)2chrysi]
3+
 for 72 hours. As before, rhodium treatment 
alone induces necrosis preferentially in the MMR-deficient HCT116O cell line; there is 
no significant change in the percentage of cells in the apoptotic region in either cell line.  
The effect is significantly more pronounced in the MMR-deficient HCT116O cell line, 
which drops from 79 ± 3.8 %  to 37 ± 5.3 % after treatment with 20 µM 
[Rh(HDPA)2chrysi]
3+
, versus the MMR-proficient HCT116N cell line, which shows a 
minimal decrease in live cells from 62 ± 0.6 % to 54 ± 5.1 % after treatment with 20 µM 
[Rh(HDPA)2chrysi]
3+
. 
2.3.5 Caspase inhibition 
As a complement to the dye exclusion flow cytometry assay, the MTT 
cytotoxicity assay was repeated in the absence and presence of the pan-caspase inhibitor 
Z-VAD-FMK.
30
 This inhibitor works by irreversibly binding to the active site of 
caspases. As before, the HCT116N and HCT116O cell lines were treated with 0 – 30 µM 
of the [Rh(HDPA)2chrysi]
3+
 complex for 24 – 72 hours. In addition, each treatment was 
also combined with the inhibitor at a final concentration of 20 µM (Figure 2.6). As 
before, the rhodium complex exhibited selective toxicity in the repair-deficient 
HCT116O cell line, with cell viability dropping to 9.7 ± 4.4 % after treatment with 30 
µM metal complex for 72 hours, versus 63 ± 5.7 % viability in the repair-proficient 
HCT116N cell line. Addition of the caspase inhibitor at 20 µM offered no protection 
from rhodium to the HCT116N cell line (63 ± 5.7 % without inhibitor, 52 ± 9.8 % with  
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Figure 2.6 Caspase inhibition assay. HCT116N and HCT116O cells were plated in 96-
well format at densities of 5 x 10
4 
cells/well and treated with 0 – 30 µM of 
[Rh(HDPA)2chrysi]
3+
 with or without 20 µM of the pan-caspase inhibitor Z-VAD-FMK.  
After 24 – 72 hours, the cells were labeled with MTT for 4 hours.  The resulting formazan 
crystals were dissolved by addition of 10% SDS acidified with 10 mM HCl, and 
absorbance was measured at 570 nm.  The caspase inhibitor confers no protection from 
rhodium-induced toxicity in either cell line. 
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inhibitor) or to the HCT116O cell line (9.7 ± 4.4 % without inhibitor, 9.8 ± 7.8 % with 
inhibitor). At a final concentration of 40 µM, the caspase inhibitor provided some 
protection from rhodium to the HCT116O cell line (16 ± 10 % without inhibitor, 28 ± 3.7 
% with inhibitor), but this difference was small in relation to the differential between the 
HCT116N and HCT116O cell lines and roughly within error (data not shown). 
 2.3.6 PARP inhibition 
The MTT cytotoxicity assay was also repeated in conjunction with a panel of 
poly-ADP ribose polymerase (PARP) inhibitors: DPQ, 3-AB, 4-AN, and ABT-888.
31-34
 
As before, the HCT116N and HCT116O cell lines were treated with 0 or 20 µM of the 
[Rh(HDPA)2chrysi]
3+
 complex for 72 hours, with or without one of the four inhibitors.  
In each case, treatment with the inhibitor completely abolished the selective MMR-
dependent effects of the rhodium compound (Figure 2.7), as determined by the 
difference between the percentage of viable cells in the HCT116N cell line and the 
percentage of viable cells in the HCT116O cell line.  For example, in the case of the 
compound DPQ, this difference was 43 ± 2.7 % without inhibitor and 0.6 ± 3.0 % with 
inhibitor. Similar results are seen with each of the other three compounds as well; taken 
together, these data implicate PARP in the MMR-dependent response to 
[Rh(HDPA)2chrysi]
3+
. 
2.4 Discussion 
 2.4.1 Uptake 
The direct correlation between the binding affinity of rhodium metalloinsertors 
for DNA mismatches and the differential in their activity between the HCT116N and 
HCT116O cell lines fails to predict the high selective activity of [Rh(HDPA)2chrysi]
3+
.   
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Figure 2.7 PARP inhibition assay. HCT116N and HCT116O cells were plated in 96-well 
format at densities of 5 x 10
4 cells  ell an  treate   ith 0 µM  “-”   r  0 µM  “+”     
[Rh(HDPA)2chrysi]
3+
  ith  r  ith  t P RP inhibit r  “-” = 0 µM DPQ  3-AB, 4-AN, or 
ABT-   ; “+” =    µM DPQ    mM 3-AB, 10 µM 4-AN, or 5 µM ABT-   ; “++” =  0 
µM DPQ, 3 mM 3-AB, 20 µM 4-AN, or 10 µM ABT-888).  After 72 hours, the cells 
were labeled with MTT for 4 hours.  The resulting formazan crystals were dissolved by 
addition of 10% SDS acidified with 10 mM HCl, and absorbance was measured at 570 
nm.  All four PARP inhibitors confer protection from rhodium-induced MMR-dependent 
toxicity, reducing the differential activity significantly. 
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In light of the shorter incubations required for this complex, it seemed likely that 
accelerated cellular uptake is a contributing factor in the increased cellular response.  As 
[Rh(HDPA)2chrysi]
3+
 is not luminescent, another method was needed to examine its 
cellular uptake. The high atomic mass and monoisotopic distribution of rhodium make 
the cellular accumulation of rhodium metalloinsertors well suited to analysis by 
inductively coupled plasma – mass spectrometry (ICP-MS).35-37 ICP-MS affords a direct 
comparison of the cellular accumulation of a series of rhodium metalloinsertors after 
treatments similar to those applied in ELISA assays for activity. The highest levels of 
cellular accumulation are clearly seen for the complex bearing the HDPA ligand, which 
was expected in light of the previous observation that [Rh(HDPA)2chrysi]
3+
 exhibits 
increased anti-proliferative activity against the HCT116 cell lines at shorter incubation 
times than other rhodium metalloinsertors.  Significant activity is seen with 
[Rh(HDPA)2chrysi]
3+
 in as little as 12 hours, while [Rh(bpy)2chrysi]
3+
 and 
[Rh(NH3)4chrysi]
3+
 display no activity at this incubation time. 
 2.4.2 Cytotoxicity
 
Rhodium metalloinsertors have shown differential anti-proliferative activity in an 
ELISA assay for DNA synthesis.  This assay directly reports on the amount of BrdU label 
incorporated during DNA replication, and, as such, does not distinguish between cells 
that are viable but not replicating, e.g, G0 cells that have exited the cell cycle, and cells 
that are inviable, or dead.  Therefore, this assay can be used to determine inhibitory, but 
not cytotoxic activity.  In contrast, the MTT assay reports directly on cell viability as 
measured by metabolic activity, with the action of mitochondrial reductases catalyzing 
the cleavage of the labeling agent MTT.  Here cells that are viable still produce signal, 
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i.e, formazan absorbance, whether or not they are actively dividing.  Thus, this assay can 
distinguish between senescence and true cell death, and the effects observed in response 
to rhodium treatment are truly cytotoxic.  Importantly, the concentration ranges and 
incubation times of the treatments applied in the MTT assays for [Rh(HDPA)2chrysi]
3+
 
and the closely related complex [Rh(MeDPA)2chrysi]
3+
 (0 – 25 µM, 24 – 72 hours) are 
identical to those that inhibit DNA synthesis as seen by ELISA. 
Accordingly, the result that [Rh(HDPA)2chrysi]
3+
 and [Rh(MeDPA)2chrysi]
3+
 
trigger cell death selectively in the MMR-deficient HCT116O cell line versus the MMR-
proficient HCT116N cell line (as measured by MTT assay) represents a significant 
advance in the development of these complexes as anti-cancer agents; clearly, these 
agents are more potent than previously considered.  Although [Rh(bpy)2chrysi]
3+
 does not 
appear to be selectively toxic at these concentrations, it is likely that this is due to 
differences in the kinetics of cellular uptake, rather than fundamental differences in its 
mode of action as compared to [Rh(HDPA)2chrysi]
3+
, since both bind DNA mismatches 
with equal affinity.
24 
For either activity assay, the complex must first accumulate within 
the cell, and then cellular response must be triggered.  While [Rh(HDPA)2chrysi]
3+
 
displays activity in ELISA after 12 h incubations, [Rh(bpy)2chrysi]
3+
 requires 48 h or 
more to show significant differential activity.  In light of the higher levels of rhodium 
accumulation seen by ICP-MS after treatment with the HDPA complex versus the bpy 
complex, it seems likely that accumulation of the bpy complex is delayed by ~36 h 
relative to the HDPA complex.  Cellular responses that occur quickly after accumulation, 
such as the inhibition of DNA synthesis, can still be observed within the 72-hour 
timeframe of the ELISA assay, and both complexes display activity. However, a lag time 
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will exist between the inhibition of DNA synthesis and the onset of cell death, and when 
combined with the slow uptake of [Rh(bpy)2chrysi]
3+
, (t > 48 h), cell death is delayed 
accordingly and cannot be observed within the timeframe of the MTT assay (also 72 h). 
The fact that the [Rh(MeDPA)2chrysi]
3+
 complex displays differential toxicity 
against the HCT116O cell lines comparable to that of the [Rh(HDPA)2chrysi]
3+
 complex 
suggests that it shares the accelerated uptake of the HDPA complex.  This was certainly 
expected, as the complexes are almost identical, but does not address the question of 
uptake mechanism, and clearly refutes the hypothesis that accelerated uptake requires a 
hydrogen-bonding interaction with the bridging secondary amine of the HDPA ligand.  
More importantly, this suggests that selective toxicity as a function of MMR-competency 
is a general property of rhodium metalloinsertors with dipyridylamine ancillary ligands, 
and establishes these ligands as the basis for the development of the next generation of 
complexes. 
2.4.3 Cell Cycle Distribution 
Flow cytometry analysis reveals that cell death is preceded by disruption of the 
cell cycle.  Treatment with 20 µM [Rh(HDPA)2chrysi]
3+
 for 24 hours leads to a marked 
depletion of the S-phase population with a concomitant increase in the G1 population.  
These data suggest that the G1/S-phase DNA damage checkpoint may be activated in 
response to rhodium treatment.  In the case of the HCT116O line, the G2/M-phase 
population also increases in response to rhodium treatment.  This could represent a 
secondary checkpoint activation occurring at the G2/M-phase transition, and might signal 
a “t  -alarm  ire” that acc m anies the enhance  activity against this cell line. 
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2.4.4 Necrotic Mode of Cell Death 
 The biochemical events associated with apoptosis have been extensively 
studied.
38
 An extensive network of regulatory proteins controls the initiation of this 
process in response to both internal and external signals.
39
 Upon activation, the cascade 
of initiator and effector caspases cleaves a variety of substrates to bring about the 
morphological changes associated with this mode of cell death, including nuclear 
condensation and fragmentation, plasma membrane blebbing, decomposition of the cell 
into apoptotic bodies, and ultimately, the engulfment of these bodies by neighboring cells 
through phagocytosis.
40
 Importantly, apoptotic cells retain their membrane integrity until 
the very last stages of this process, preventing release of cytokines and thus avoiding 
inflammation.  By comparison, both the causes and the progression of necrosis are much 
less defined at the molecular level, and this mode of cell death is most frequently 
characterized by morphological criteria.
40-42 
Perhaps the most reliable marker of necrosis 
then, is the early rupture of the plasma membrane, in direct contrast to apoptosis.  These 
differences in membrane integrity enable the facile characterization of cell death by flow 
cytometry.  The admission of the dead cell stain propidium iodide by the HCT116 cell 
lines upon rhodium treatment reveals that cell death proceeds through a necrotic, rather 
than apoptotic pathway.  This conclusion is supported by the observation that the caspase 
inhibitor Z-VAD-FMK is unable to block rhodium-induced toxicity in the MTT assay, 
indicating that death occurs in a caspase-independent fashion. 
It is interesting to consider that rhodium metalloinsertors selectively induce 
necrosis in MMR-deficient cells.  Traditionally, necrotic cell death has been considered 
t  be “acci ental”   cc rrin  mainly in res  nse t  n n-physiological insults.43,44 More 
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recently however, the notion that necrosis may in fact be an ancestral mode of 
programmed cell death has gained attention in the literature and community of cell death 
research.
40,41,45
 Hitomi et al. screened an siRNA library covering the mouse genome and 
identified 432 gene knockdowns that blocked the induction of necrosis.
46
 Chan et al. 
found anti-necrotic proteins encoded in the genomes of several viruses.
47
 While these 
studies present some of the most compelling evidence for the notion that necrosis is in 
fact a regulated process, several other groups are also working to provide a molecular 
definition for the process as has been done for apoptosis.
44,45
 
Thompson and co-workers have reported that the DNA repair protein poly ADP-
ribose polymerase-1 (PARP-1) mediates the induction of necrosis in response to DNA 
damage by the alkylator MNNG.
48
 Upon activation at sites of DNA damage, PARP-1 
covalently modifies itself with long chains of ADP-ribose polymers in order to recruit 
downstream components of the repair machinery.
49
 As a result, PARP-1 along with 
PARP-2 has attracted much attention as a therapeutic target recently, and several specific 
and potent inhibitors of the enzyme are currently in clinical trials.
50
 Here, treatment with 
a panel of PARP-1 inhibitors confers protection from MMR-dependent toxicity, 
abolishing differential activity between the HCT116 cell lines by Rh.  This result strongly 
suggests that PARP activation is required for the differential biological effects of 
rhodium metalloinsertors.  Importantly, the fact that each of the four PARP inhibitors on 
the panel abolishes differential activity argues against the notion that off-target effects of 
any particular inhibitor are responsible for blocking rhodium activity. Although the role 
of PARP in regulating necrosis is still emerging, the requirement for PARP activation is 
consistent with the notion that these rhodium complexes elicit a damage response upon 
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binding to DNA mismatches.  This is supported by flow cytometry analysis, which 
reveals that cell death is preceded by disruption of the cell cycle. Upon rhodium 
treatment, there is a sharp decline in the population of cells that are actively synthesizing 
DNA. This observation suggests that the G1/S-phase DNA damage checkpoint is 
activated. 
As necrosis triggers a pro-inflammatory response by releasing cytokines, selective 
induction of necrosis in cancerous tissues may be a way to activate the immune system 
against cancer cells and ultimately improve efficacy of a therapeutic agent.
51
 One 
accepted trigger of necrosis is bioenergetic catastrophe, i.e, severe ATP depletion.
43,44
 
Rhodium metalloinsertors might trigger such a catastrophe by targeting mitochondrial 
DNA. Previously, it was thought that damaged mitochondrial genomes would simply be 
degraded and replaced by the replication of undamaged DNA.
52
 However, emerging 
research has uncovered DNA repair processes in mitochondria, including mismatch 
repair capability.
52,53
 As lipophilic cations, rhodium metalloinsertors likely accumulate in 
mitochondria,
54-59
 as we have seen with analogous ruthenium complexes in our 
laboratory.
19
 If mitochondrial DNA mismatches are in fact a target for rhodium 
metalloinsertors, then the resultant disruption of mitochondrial function would lead to 
energy depletion and necrosis.  Future mechanistic work must explore the biochemical 
consequences of mismatch binding in nuclear DNA versus mitochondrial DNA.  It 
should be noted that these mechanisms are not mutually exclusive; as such, both might 
contribute to the biological response to rhodium metalloinsertors. 
2.4.5 General Implications 
These studies support the notion that rhodium metalloinsertors bearing HDPA 
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ligands benefit from increased cellular accumulation, and thus provide an explanation for 
the observation that [Rh(HDPA)2chrysi]
3+
 exceeds the activity predicted by its binding 
affinity for DNA mismatches. This increased uptake allows us to observe additional 
cellular responses to these agents, and, as a whole, a picture of the biological response to 
rhodium metalloinsertors, exemplified by [Rh(HDPA)2chrysi]
3+
 in particular, is 
beginning to emerge (Figure 2.8).  Over the course of the first 12 hours, the rhodium 
complex accumulates in cells, binding to either mitochondrial or genomic DNA 
mismatches.  Within 24 hours, DNA synthesis is inhibited, and cells accumulate in G1-
phase.  Over the next 24–48 hours, the DNA damage response is likely activated, and 
ultimately leads to cell death by a caspase-independent, necrotic mechanism. These 
biological effects are more pronounced at each stage of the response in the MMR-
deficient HCT116O cell line relative to the MMR-proficient HCT116N cell line, strongly 
suggesting that DNA mismatches are in fact the cellular target of rhodium 
metalloinsertors. 
2.5 Conclusions 
This work shows that dipyridylamine ancillary ligands serve to accelerate the 
cellular uptake of rhodium metalloinsertors, triggering a selective cytotoxic effect as a 
function of MMR status and forming the foundation for the next generation of complex 
development.  This new class of agents is significantly more potent than previously 
considered, and the work begun here on understanding their mechanism of action 
advances their development as novel anti-cancer agents. 
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Figure 2.8 Model for the cellular response to rhodium metalloinsertors. Within 12 h of 
treatment with [Rh(HDPA)2chrysi]
3+
, cellular accumulation is observed (Figure 2.2). 
Following cellular accumulation and mismatch binding, inhibition of DNA synthesis is 
observed (ELISA data not shown) concurrently with S-phase depletion (Figure 2.4). 
Finally, 48 to 72 h following rhodium treatment, PARP activation  and necrotic cell death 
are observed (Figure 2.5 and Figure 2.7). 
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Chapter 3: Cell-Selective Biological Activity of Rhodium 
Metalloinsertors Correlates with Subcellular Localization
§
 
3.1 Introduction 
Recent work in the Barton laboratory discovered that the rhodium 
metalloinsertors that display activity at relatively short incubation times in the ELISA 
assay also show preferential cytotoxicity towards the MMR-deficient HCT116O cell line, 
inducing death via a necrotic pathway.
1
 As one generally accepted trigger of necrosis is 
severe ATP depletion,
2,3
 this observation prompted the investigation of subcellular 
localization. These metalloinsertors may trigger necrosis through mitochondrial DNA 
targeting. As lipophilic cations, mitochondrial accumulation is a possibility;
4
 real-time 
monitoring of the cells with confocal microscopy could not be used to monitor organelle 
accumulation, however, since the rhodium complexes are not luminescent. Nonetheless, 
an understanding of the subcellular localization of these compounds is crucial for the 
development of next-generation metalloinsertors with improved selectivity for MMR-
deficient cells.
5
 Rhodium uptake can be easily probed by inductively coupled plasma 
mass spectrometry (ICP-MS), as no interfering ion exists within the cell. The sensitivity 
of ICP-MS allows for biologically relevant concentrations of rhodium to be determined,
6
 
and combined with organelle isolation procedures can be used to give estimates on the 
subcellular localization of our metalloinsertors. 
There have been few studies to date investigating the subcellular localization of 
common therapeutic agents. Non-fluorescent organic molecules pose a particular problem 
                                                          
§
 Adapted with permission from Komor, A.C.; Schneider, C. J.; Weidmann, A. G.; Barton, J. K. Cell-Selective 
Biological Activity of Rhodium Metalloinsertors Correlates with Subcellular Localization J. Am. Chem. Soc. 2012, 
134, 19223-19233. © 2012 American Chemical Society. 
Acknowledgements: Curtis Schneider synthesized the [Rh(chrysi)(phen)(L)]Cl3 (L= HDPA, MeDPA, PrDPA) 
compounds, and Alyson Weidmann synthesized [Rh(DPAE)2(chrysi)]
3+ and [Rh(PrDPA)2(chrysi)]
3+. 
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in this regard owing to their lack of spectroscopic handle for detection unless the drug is 
tethered to a fluorescent tag. However, this process of appending a fluorescent molecule 
to a drug has been shown in itself to alter the subcellular localization of the compound.
7
 
There have been instances where appending an organelle-specific peptide to a therapeutic 
agent resulted in drastically altered activity of the agent, which was attributed to altered 
subcellular localization.
8,9
 Fluorescent organic therapeutics, as well as metal-based 
therapeutics, do contain spectroscopic or spectrometric handles for detection, and can 
therefore be mapped within the cell. Doxorubicin, a chemotherapeutic that intercalates 
DNA, is one such fluorescent molecule. In one study, doxorubicin resistance was 
correlated with subcellular localization of the compound. Specifically, the subcellular 
distribution of the drug shifted from nuclear to cytosolic as drug resistance increased.
10 
Furthermore, in a study by Liu and coworkers on a series of Au(I) and Ag(I) bidentate 
pyridyl phosphine anticancer agents, it was observed that increased lipophilicity resulted 
in increased potency of the drug, with preferential accumulation of the drug in the 
mitochondria.
11
  In a final study, ICP-MS was used to track the uptake and subcellular 
localization of cisplatin as well as two ruthenium-based chemotherapeutics currently in 
clinical trials, NAMI-A and KP1019. Reduced mitochondrial accumulation of  cisplatin 
was observed in cisplatin resistant cells, while the ruthenium-based drugs were found to 
have different localization patterns than cisplatin that did not change from one cell type to 
the other.
12
 
Here we correlate the selectivity of a variety of rhodium metalloinsertors that 
target MMR-deficient cells with the subcellular localization of the complexes. We find 
that all complexes studied are localized at a sufficient concentration in the nucleus for 
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mismatch binding. Furthermore, we find that, in general, higher levels of mitochondrial 
rhodium reduce the cell-selective biological activity of these metalloinsertors. These 
observations give credence to the theory that mismatches in genomic DNA are the 
ultimate target of our metalloinsertors and that this mismatch targeting is responsible for 
their unique cell-selective biological activity. 
3.2 Experimental Protocols 
3.2.1 Materials 
Commercially available chemicals were used as received. The Rh complex 
[Rh(NH3)5Cl]Cl2 was obtained from Strem Chemical, Inc. RhCl3 was purchased from 
Pressure Chemical, Inc. All organic reagents and Sephadex ion-exchange resin were 
obtained from Sigma-Aldrich unless otherwise noted. Sep-pak C18 solid-phase extraction 
(SPE) cartridges were purchased from Waters Chemical Co. (Milford, MA). Media and 
supplements were purchased from Invitrogen (Carlsbad, CA). BrdU, antibodies, buffers, 
peroxidase substrate, MTT, and acidified lysis buffer (10% SDS in 10 mM HCl) solution 
were purchased in kit format from Roche Molecular biochemical (Mannheim, Germany). 
Phosphoramidites were purchased from Glen Research (Sterling, VA). 
3.2.2 Oligonucleotide Synthesis 
Oligonucleotides were synthesized on an Applied Biosystems 3400 DNA 
synthesizer using standard phosphoramidite chemistry. DNA was synthesized with a 5ʹ-
dimethoxytrityl (DMT) protecting group. The oligonucleotides were cleaved from the 
beads by reaction with concentrated ammonium hydroxide at 60° C overnight. The 
resulting free oligonucleotides were purified by HPLC using a C18 reverse-phase column 
(Varian, Inc.) on a Hewlett-Packard 1100 HPLC. The DMT group was removed by 
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reaction with 80% acetic acid for 15 min at ambient temperature. The DMT-free 
oligonucleotides were precipitated with absolute ethanol and purified again by HPLC. 
Positive identification of the oligonucleotides and their purity were confirmed by 
MALDI-TOF mass spectrometry. Quantification was performed on a Cary 100 Bio UV-
Visible Spectrophotometer using the extinction coefficients at 260 nm (ε260) estimated for 
single-stranded DNA. 
3.2.3 Synthesis and Characterization of Metal Complexes 
The complexes [Rh(bpy)2(chrysi)]
3+
, [Rh(HDPA)2(chrysi)]
3+
, 
[Rh(NH3)4(chrysi)]
3+
, [Rh(DIP)2(chrysi)]
3, 
[Rh(DPAE)2(chrysi)]
3+
, and 
[Rh(PrDPA)2(chrysi)]
3+
 were prepared according to published procedures.
13-15
  
 3.2.3.1  [Rh(chrysi)(phen)(NH3)2]Cl3 
[Rh(chrysi)(phen)(NH3)2]Cl3 was prepared according to an adaptation of 
previously described procedures.
16
 A 1 L round bottomed flask was charged with 
[Rh(NH3)4(phen)][OTf]3 (0.500 g, 0.626 mmol) and chrysene-5,6-dione (0.162 g, 0.626 
mmol), and 1:9 H2O:MeCN was added (400 mL). A 1M solution of NaOH (1.5 mL) was 
added to the orange solution. Over the next hour, the solution changed color from orange 
to red, after which time a 1M solution of HCl (1.5 mL) was added to quench the reaction. 
The MeCN was evaporated in vacuo and the resulting red solution was loaded onto a SPE 
cartridge, eluted with 25% acetonitrile in 0.1% TFA(aq), and lyophilized to give a red 
solid.  The chloride salt can be obtained from a Sephadex QAE anion exchange column 
equilibrated with 0.1M MgCl2.  Yield:  0.536 g, 94%.
 1
H NMR (300 MHz, d6-DMSO): δ 
13.59 (s, 1H); 13.43 (s, 1H); 9.56 (d, J =5.3 Hz, 1 H); 9.16 (m, 2H); 8.93 (d, J =8.3 Hz, 
1H);  8.77 (d, J = 5.3 Hz, 1H);  8.35-8.57 (m, 7H); 8.23 (d, J =8.3 Hz, 1H); 7.99 (m, 2H); 
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7.83 (m, 2H); 7.54 (t, J =7.6 Hz, 1H); 4.95 (s, 3H); 4.79 (s, 3H). ESI-MS (cation): m/z 
calc. 571.13 (M-2H
+
), obs. 570.9. 
 3.2.3.2  1,1-di(pyridin-2-yl)ethanol (DPE) 
DPE was synthesized according to an adaptation of previously described 
procedures.
17
 A 250-mL oven dried schlenk flask was cooled to -     in a     
ice/acetone bath and charged with di(pyridin-2-yl)methanone (0.508 g, 2.8 mmol). 
Anhydrous Et2O (50 mL) was added via cannula transfer, and the resulting yellow 
solution was allowed to stir for 10 m. A 1.6M solution of MeLi (5 mL) was then added 
dropwise over 15 m, during which time the solution turned deep purple. After 30 m of 
stirring at -    , sat. NH4Cl (aq) (15 mL) was added. The resulting yellow solution was 
allowed to warm to ambient temperature, and was then extracted with Et2O (3 x 50 mL). 
The organic fractions were combined and dried over magnesium sulfate, and the solvent 
was removed in vacuo. The ligand was further purified via flash chromatography (SiO2, 
1:1 Et2O:hexanes). Yield: 0.560 g, 100% .
 1
H-NMR (CDCl3, 300 MHz): δ  .5  (d, J =5.1 
Hz, 2H); 7.92 (d, J =6.9 Hz, 2H); 7.80 (m, 2H); 7.27 (m, 2H); 6.60 (s, 1H); 2.08 (s, 3H). 
ESI-MS (cation): m/z calc. 201.09 (M+H
+
), obs. 201.0. 
 3.2.3.3  N-alkyl-N-(pyridin-2-yl)pyridin-2-amine (alkyl = methyl 
or propyl; MeDPA, PrDPA) 
To a slu    of so ium h   i e ( 0 mg, 2.9 mmol) in THF (10 mL) was a  e  
HDPA (500 mg, 2.9 mmol) in THF (5 mL) at 0 °  un e  1 atm A . The  eaction was 
pu ge  with a gon fo  15 min, an  the app op iate 1-b omoalkane (3.  mmol) was a  e  
  opwise an  wa me  to ambient tempe atu e. The  eaction was sti  e  an a  itional 1  h 
un e  a gon at  eflux tempe atu e. The  eaction mixtu e was ext acte  with  ilute so ium 
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bica bonate, an  the aqueous phase was ext acte  with  H2 l2 (3 x 40 mL). The o ganic 
f actions we e combine  an    ie  ove  magnesium sulfate, an  the solvent was  emove  
in vacuo. These ligan s we e pu ifie  via flash ch omatog aph  (SiO2, 1:9 
EtOAc:hexanes). 
MeDPA: Yield: 23%.
 1
H-NMR (CDCl3, 300 MHz): δ  .35 ( d, 2H); 7.54 (t, 2H); 
7.17 (d, 2H); 6.86 (t, 2H), 3.62 (s, 3H). ESI-MS (cation): m/z calc. 186.1 (M+H
+
), obs. 
186. 
 PrDPA: Yiel : 25%. 1H NMR ( D l3, 300 MHz): δ  .34 ( , J =  .  Hz, 2H); 
 .5  –  .45 (m, 2H);  .06 ( , J = 0.  Hz, 2H); 6.90 – 6. 9 (m, 2H); 4.19 – 4.0  (m, 2H); 
1. 9 – 1.65 (m, 2H); 0.99 – 0. 5 (m, 3H). ESI-MS (cation): m/z calc. 214.1 (M + H+), 
obs. 214. 
 3.2.3.4  [Rh(NH3)4(phzi)]Cl3 
[Rh(NH3)6][OTf]3 (0.50 g, 0.   mmol) an  benzo[]phenazine-5,6- ione (0.200 
g, 0.   mmol) we e  issolve  in a 1:5 mixtu e of wate :acetonit ile (500 mL). A 1M 
solution of NaOH (1 mL) was a  e  to the  ellow solution an  the  eaction was allowe  
to sti  at ambient tempe atu e fo  45 min, at which time a 1M solution of H l (1 mL) was 
a  e  to neut alize the  eaction mixtu e. The Me N was evapo ate  in vacuo an  the 
 esulting  ellow solution was loa e  onto a SPE ca t i ge, elute  with 25% acetonit ile in 
0.1% TFA(aq), an  l ophilize  to give a  ellow soli .  The chlo i e salt can be obtaine  
f om a Sepha ex QAE anion exchange column equilib ate  with 0.1M Mg l2.  Yiel :  
0.45 g,  6%.  1H NMR (300 MHz,  6-DMSO): δ 13.9  (s, 1H); 13.   (s, 1H);  .96 ( , J 
= .  Hz, 1 H);  .62 ( , J =  .6 Hz, 1H);  .34 (m, 2H);  .92- .21 (m, 4H); 4.4  ( , J = 
20.1 Hz, 6 H); 3. 9 (s, 6H). ESI-MS (cation): m/z calc. 524.0  (M-NH3+TFA
+), obs. 
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523. . UV-Vis (H2O, pH  ): 250 nm (36, 00 M
-1 cm-1), 310 nm (20, 00 M-1, cm-1), 340 
nm (23,400 M-1, cm-1). 
3.2.3.5  [Rh(chrysi)(phen)(L)]Cl3 (L= HDPA, MeDPA, PrDPA) 
Rh(chrysi)(phen)(NH3)2]Cl3 (25 mg, 0.02 mmol) was reacted with L (0.022 
mmol) in a 4:1 mixture of ethanol:water (10 mL). The bright red solution was refluxed 
overnight. The solvent was removed in vacuo and the resulting red solid dissolved in 
0.1% TFA(aq) (10 mL).  The red solution was loaded onto a SPE cartridge and rinsed with 
copious amount of 0.1% TFA(aq). The SPE cartridge was eluted with 10% acetonitrile in 
0.1% TFA(aq), and fractions were collected.  The fractions containing product were 
identified by HPLC, combined, and lyophilized. The chloride salt can be obtained from a 
Sephadex QAE anion exchange column equilibrated with 0.1M MgCl2. 
[Rh(chrysi)(phen)(HDPA)]Cl3: Yield: 17-28%. ESI-MS (cation): m/z calc 
708.14 (M-2H
+
), obs. 708.2. UV-Vis (H2O, pH 7): 303 nm (34,200 M
-1
 cm
-1
), 391 nm 
(8,000 M
-1
, cm
-1
), 440 nm (3,600 M
-1
, cm
-1
). 
[Rh(chrysi)(phen)(MeDPA)]Cl3: Yield: 12-32%. 
1
H NMR (500 MHz, DMSO-
d6) δ 12.45 (s, 1H), 10.4  (s, 1H), 9.34 – 6.83 (m, 26H), 3.87 (s, 3H). ESI-MS (cation): 
m/z calc. 722.15 (M-2H
+
) 361.6 (M-H
2+
), obs. 722, 362. UV-Vis (H2O, pH 7): 303 nm 
(55,500 M
-1
 cm
-1
), 391 nm (13,800 M
-1
, cm
-1
), 440 nm (5,700 M
-1
, cm
-1
). 
[Rh(chrysi)(phen)(PrDPA)]Cl3: Yield: 10-22%. ESI-MS: calc. 750.18 (M-2H
+
), 
375.6 (M-H
2+
), obs. 750, 376. UV-Vis (H2O, pH 7): 303 nm (53,500 M
-1
 cm
-1
), 391 nm 
(13,900 M
-1
, cm
-1
), 440 nm (9,900 M
-1
, cm
-1
). 
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3.2.3.6  [Rh(chrysi)(phen)(DPE)]Cl2  
A 125 mL round-bottomed flask was charged with 
[Rh(chrysi)(phen)(NH3)2]TFA3 (62.0 mg, 0.068 mmol) and DPE (25.6 mg, 0.128 mmol) 
in ethanol (50 mL) to give a red solution.  The reaction was heated to reflux (80° C) and 
stirred for 48 h.  The ethanol solution was evaporated to dryness and dissolved in 0.1% 
TFA(aq)(50 mL).  The red solution was loaded onto a SPE cartridge and rinsed with 
copious amount of 0.1% TFA(aq). The SPE cartridge was eluted with 10% acetonitrile in 
0.1% TFA(aq), and fractions were collected.  The fractions containing product were 
identified by HPLC, combined, and lyophilized.  The chloride salt can be obtained from a 
Sephadex QAE anion exchange column equilibrated with 0.1M MgCl2. Yield: 30%. ESI-
MS (cation): m/z calc. 737.15 (M-H
+
), 369.1 (M
2+
), obs. 737, 369. UV-Vis (H2O, pH 7): 
272 nm (102,100 M
-1
 cm
-1
), 303 nm (35,400 M
-1
, cm
-1
), 440 nm (10,600 M
-1
, cm
-1
). 
1
H 
NMR (CD3 N, 500 MHz): δ 15.10 (s, 1 H); 11.30 (s, 1 H); 9.62 ( , J = 5.5 Hz, 1H); 8.98 
(d, J = 7.0 Hz, 1H); 8.92 (d, J = 8.0 Hz, 1H); 8.88 (m, 2H); 8.36 (m, 4H); 8.27 (d, J = 8.5 
Hz, 1H); 8.21 (m, 1H); 8.13 (d, J = 8.5 Hz, 1H); 8.00 (m, 2H); 7.94 (d, J = 8.5 Hz, 1H); 
7.73-7.78 (m, 4H); 7.62 (t, J = 8.0 Hz, 1H); 7.57 (d, J = 8.0 Hz, 1H); 7.50 (t, J = 7.0 Hz, 
1H); 7.32 (d, J = 6.5 Hz, 1H); 7.14 (m, 1H); 6.95 (t, J = 7.5 Hz, 1H); 6.33 (t, J = 6.0 Hz, 
1H); 1.98 (s, 3H).  
3.2.4 Photocleavage Competition Titrations 
The oligonucleotide was 
32
P-labeled at the 5ʹ-end by incubating DNA with 32P-
ATP and polynucleotide kinase (PNK) at 37°C for 2 h, followed by purification using gel 
electrophoresis. A small amount of the labeled DNA (less than 1% of the total amount of 
DNA) was a  e  to 2 μM DNA in 100 mM Na l, 20 mM NaPi, pH 7.1 buffer. The DNA 
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hairpin was annealed by heating at 90°C for 10 min and cooling slowly to ambient 
temperature over a period of 2 h. Racemic solutions of non-photocleaving rhodium 
complex  anging f om nanomola  to mic omola  concent ation, as well as a 4 μM 
[Rh(bpy)2(chrysi)]
3+
 solution were made in Milli-Q wate . Anneale  2 μM DNA (10 μL), 
4 μM [Rh(bpy)2(chrysi)]
3+
 (5 μL), an  5 μL of non-photocleaving Rh solution at each 
concentration were mixed in a microcentrifuge tube and incubated at 37 °C for 10 min.  
A light cont ol (ØRh), in which the DNA was mixe  with 10 μL of wate  an  i  a iate , 
an  a  a k cont ol (Øhν), in which the DNA was mixe  with the highest concentration of 
rhodium complex without irradiation, were also prepared. The samples were then 
irradiated on an Oriel (Darmstadt, Germany) 1000-W Hg/Xe solar simulator (340-440 
nm) for 5 min. The irradiated samples were dried and electrophoresed in a 20% 
denaturing polyacrylamide gel. The gel was then exposed to a phosphor screen, and the 
relative amounts of DNA in each band were quantitated by phosphorimagery 
(ImageQuant). 
3.2.4.1  Binding Constant Determination 
The fraction of DNA cleaved in each lane on the gel (See Figure 3.1 for a typical 
autoradiogram) was normalized and plotted against the log of the concentration of 
rhodium complex. At least three photocleavage titrations were carried out for each 
racemic metal complex. The pooled data were fit to a sigmoidal curve using OriginPro 
6.1 (Figure 3.2). The resulting midpoint value (i.e., the log of [rhodium complex] at the 
inflection point of the curve) was converted to units of concentration ([Rh50%]). The 
binding and dissociation constants of the non-photocleaving complex were calculated by  
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Figure 3.1 Binding affinities determined through DNA photocleavage. The DNA hairpin 
sequence is 5*’-GGCAGGCATGGCTTTTTGCCATCCCTGCC-3’ (un e line  enotes 
the mismatch, asterisk denotes the radiolabel). Samples were irradiated and 
electrophoresed through a 20% denaturing PAGE gel. A light control (ØRh, without 
 ho ium) an   a k cont ol (Øhν, without i  a iation) we e inclu e . A  ep esentative 
autoradiogram of a photocleavage competition tit ation between 1 μM rac-
[Rh(bpy)2(chrysi)]
3+
 and 0-100 μM [Rh(NH3)4(phzi)]
3+
 is shown. Arrow indicates the 
position of the mismatch. 
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Figure 3.2 Representative sigmoidal curve for binding affinity determination. Shown 
is a plot of data pooled from photocleavage competition titrations between 1 μM rac-
[Rh(bpy)2(chrysi)]
3+
 and 0-100 μM [Rh(NH3)4(phzi)]
3+
. 
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solving simultaneous equlibria involving DNA, [Rh(bpy)2(chrysi)]
3+
, and the complex in 
question in Mathematica 6.0. 
3.2.5 Cell Culture 
HCT116N and HCT116O cells were grown in RPMI medium 1640 supplemented 
with: 10% FBS; 2 mM L-glutamine; 0.1 mM nonessential amino acids; 1 mM sodium 
pyruvate; 100 units/mL penicillin; 100 μg/mL st eptom cin; an  400 μg/mL Geneticin 
(G418). Cells were grown in tissue culture flasks (Corning Costar, Acton, MA) at 37 °C 
under 5% CO2 and humidified atmosphere.  
3.2.5.1  Cellular Proliferation ELISA 
HCT116N and HCT116O cells were plated in 96-well plates at 2000 cells/well 
and allowed 24 h to adhere. The cells were then incubated with rhodium for the 
concentration and durations specified. For incubations less than 72 h, the Rh-containing 
media was replaced with fresh media, and the cells were grown for the remainder of the 
72 h period. Cells were labeled with BrdU 24 h before analysis. The BrdU incorporation 
was quantified by antibody assay according to established procedures.
18
 Cellular 
proliferation was expressed as the ratio of the amount of BrdU incorporated by the treated 
cells to that of the untreated cells. 
3.2.5.2  MTT Cytotoxicity Assay 
Cytotoxicity assays were performed as described in the literature.
19
 HCT116N 
and HCT116O cells were plated in 96-well plates at 50,000 cells/well and incubated with 
rhodium for the durations specified. After rhodium incubation, cells were labeled with 
MTT for 4 h at 37°C under 5% CO2 and humidified atmosphere. The resulting formazan 
crystals were dissolved with solubilizing reagent purchased from Roche according to the 
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manufactu e ’s inst uctions. The  issolve  fo mazan was quantifie  as the abso bance at 
570 nm minus the background absorbance at 690 nm. Percent viability was determined as 
the ratio of the amount of formazan in the treated cells to that of the untreated cells. 
3.2.6 Nuclear Isolation Protocol 
Approximately 10 million HCT116N/O cells were harvested from adherent 
culture by trypsinization, washed with cold PBS, and resuspended in 1 mL hypotonic 
buffer (20 mM TrisHCl pH 7.4, 10 mM NaCl, 3 mM MgCl2). The  esulting suspension 
was incubate  on ice fo  15 min. 50  μL of a 10% NP-40 solution was added to the 
solution and immediately followed by vortexing at the highest setting for 10 seconds. The 
solution was then centrifuged at 3,000g for 10 min. The supernatant was discarded and 
the pellet saved as the nuclear fraction. 
3.2.7 Mitochondrial Isolation Protocol 
The followed protocol is an adaptation of that used by Ahmad, et al.
20
 
Approximately 20 million HCT116N/O cells were harvested from adherent culture by 
t  psinization, washe  with col  PBS, an   esuspen e  in 500 μL mitochon  ial 
extraction buffer (200 mM mannitol, 68 mM sucrose, 50 mM pipes, 50 mM KCl, 5 mM 
EGTA, 2 mM MgCl2, 1 mM DTT, protease inhibitors). The resulting suspension was 
incubated on ice for 20 min, then homogenized by 35 passes through a 21-gauge needle 
and 1-mL syringe. The resulting lysate was centrifuged at 150g for 5 min. The 
supernatant was then transferred to a new microcentrifuge tube and centrifuged for an 
additional 10 min at 14,000g. The supernatant was discarded and the pellet saved as the 
mitochondrial fraction. 
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3.2.8 ICP-MS Assay for Whole-Cell Rhodium Levels 
HCT116O cells were plated at 1x10
6
 cells/well in a 6 well plate. The cells were 
allowe  24 h to a he e, then t eate  with 10 μM of  ho ium complex (except 
[Rh(DIP)2(chrysi)]
3+, which was a ministe e  at 2 μM). After the appropriate amount of 
time, the media was decanted, the cell monolayer washed with 3 mL PBS, and the cells 
l se  with  00 μL of 1% SDS. The cell l sate was fu the  l se  b  sonication on a 
Qsonica Ult asonic p ocesso  fo  10 sec at 20% amplitu e.  50 μL of the l sate was then 
combine  with  50 μL of a 2% HNO3 (v/v) solution, while the remainder of the lysate 
was quantified for protein by a bicinchoninic assay (BCA).
21
 The 1% HNO3 solution was 
analyzed for rhodium content on an HP-4500 ICP-MS unit. Rhodium counts were 
normalized to the amount of protein determined from the BCA analysis (to obtain ng 
[Rhodium]/mg [protein] values). Standard errors for three independent experiments are 
shown. The experiment was repeated with HCT116N cells for one time point only to 
verify similar uptake of rhodium by the two cell lines. 
3.2.9 ICP-MS Assay for Nuclear Rhodium Levels 
HCT116O cells were plated at 10 x 10
6
 cells/ plate in culture flasks and allowed 
24 h to a he e. The cells we e then t eate  with 10 μM of  ho ium complex (except 
[Rh(DIP)2(chrysi)]
3+, which was a ministe e  at 2 μM) fo  24 h, ha veste  b  
trypsinization, and washed with PBS. The nuclear isolation protocol was then performed 
on the cells. The  esulting pellet was  esuspen e  in  00 μL Milli-Q water and lysed by 
sonication on a Qsonica Ultrasonic processor for 10 sec at 40% amplitude.  50 μL of the 
l sate was then combine  with  50 μL of a 2% HNO3 (v/v) solution, while the remainder 
of the lysate was quantified for protein by a bicinchoninic assay (BCA).
21
 The resulting 
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1% HNO3 solution was analyzed for rhodium content on an HP-4500 ICP-MS unit. 
Rhodium counts were normalized to the amount of protein determined from the BCA 
analysis (to obtain ng [Rhodium]/mg [protein]). The protein content was converted to 
number of nuclei by the conversion factor 3.28 x 10
-8
 mg [nuclear protein]/nuclei (found 
by counting nuclei with a hemacytometer followed by lysing and protein quantification). 
The rhodium concentrations were then divided by nuclei density to obtain ng of rhodium 
per nucleus. Standard errors for three independent experiments are shown. The 
experiment was repeated with HCT116N cells for one time point to verify similar uptake 
of rhodium by the two cell lines. 
3.2.10 ICP-MS Assay for Mitochondrial Rhodium Levels 
HCT116O cells were plated at 15 x 10
6
 cells/ plate in culture flasks and allowed 
24 h to a he e. The cells we e then t eate  with 10 μM of  ho ium complex (except 
[Rh(DIP)2(chrysi)]
3+, which was a ministe e  at 2 μM) for 24 h, harvested by 
trypsinization, and washed with PBS. The mitochondrial isolation protocol was then 
pe fo me  on the cells. The  esulting pellet was  esuspen e  in  00 μL Milli-Q water and 
lysed by sonication on a Qsonica Ultrasonic processor for 10 sec at 40% amplitude. 750 
μL of the l sate was then combine  with  50 μL of a 2% HNO3 (v/v) solution, while the 
remainder of the lysate was quantified for protein by a bicinchoninic assay (BCA).
21
 The 
resulting 1% HNO3 solution was analyzed for rhodium content on an HP-4500 ICP-MS 
unit. Rhodium counts were normalized to the amount of protein determined from the 
BCA analysis (to obtain ng [Rhodium]/mg [protein] values). Standard errors for three 
independent experiments are shown. The experiment was repeated with HCT116N cells 
for one time point only to verify similar uptake of rhodium by the two cell lines. 
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3.3 Results 
3.3.1 Binding Affinities for Metal Complexes at Single Base Mismatches 
 The binding constants of the various rhodium metalloinsertors at a CC mismatch 
in a 29-mer DNA hairpin with the sequence 5ʹ-
GGCAGGCATGGCTTTTTGCCATCCCTGCC-3ʹ (underline denotes the mismatch) 
were measured. The hairpin sequence allows cleavage site determination on either strand 
around the mismatch site. All newly synthesized rhodium complexes promote relatively 
little DNA cleavage upon irradiation, and, as such, their binding affinities were 
 ete mine  th ough bin ing competition tit ations with 1 μM rac-[Rh(bpy)2(chrysi)]
3+
, 
which does cleave DNA upon irradiation.
22-24
 A representative photocleavage titration 
can be found in Figure 3.1. The degree of photocleavage can be plotted against the 
log([Rh]) and fit to a sigmoidal curve (Figure 3.2). On the basis of the binding constant 
of [Rh(bpy)2(chrysi)]
3+
, the binding constants of all subsequent complexes are then 
determined by solving simultaneous equilibria at the inflection point of the photocleavage 
titration curve. The results, along with those of all previously reported compounds,
15,22,25
 
are shown in Figure 3.3. Interestingly, despite the variance in both the ancillary ligands 
and number of hydrogen-bond donors, all compounds (except the extremely bulky 
[Rh(DIP)2(chrysi)]
3+
) exhibit binding affinities within essentially the same order of 
magnitude, varying from 2.3 x 10
6
 M
-1
 to 4.4 x 10
7
 M
-1
.  
3.3.2 Quantitation of Inhibition of Cellular Proliferation using an Enzyme-
Linked Immunosorbent Assay (ELISA) 
An ELISA for DNA synthesis was used to quantify the effects of the 
metalloinsertors on the proliferation of HCT116N cells (MMR-proficient) and HCT116O  
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Figure 3.3 Chemical structures, binding affinities for CC mismatches, and approximated 
nuclear concentration of all compounds studied. Note all compounds are shown as the +3 
complex. pKa’s of the immine p otons va   among complexes an  thus the p otonation 
state of the inserting ligand will vary at physiological pH among the complexes. Binding 
affinities for [Rh(DIP)2(chrysi)]
3+
, [Rh(HDPA)2(chrysi)]
3+
, [Rh(bpy)2(chrysi)]
3+
, 
[Rh(DPAE)2(chrysi)]
3+
, and [Rh(PrDPA)2(chrysi)]
3+
 are previously reported.
13,15,22
 All 
othe  compoun s’ DNA bin ing affinities we e measu e  on the 29me  hai pin 5ʹ-
GGCAGGCATGGCTTTTTGCCATCCCTGCC-3 ʹ (un e line  enotes the mismatch) in 
a competition assay through photocleavage by [Rh(bpy)2chrysi]
3+
. To determine nuclear 
rhodium concentrations, rhodium content was quantified by ICP-MS and first normalized 
to number of nuclei, then divided by the volume of the nucleus of a HCT116O cell, 
which was approximated as a sphere with radius 8 µm.
29
 It is important to note that while 
the structures all illustrate the  isomers, all experiments were done with racemic 
mixtures. 
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cells (MMR-deficient). Both cell lines were incubated with 0-25 μM of each compoun  
(except [Rh(DIP)2(chrysi)]
3+
 and [Rh(chrysi)(phen)(DPE)]
2+
, which were both 
administered at 0-5 μM concent ations  ue to inc ease  potenc ). Incubations we e 
performed for 1, 3, 6, 12 or 24 h. After the incubations, the medium containing Rh was 
replaced with fresh medium, and the cells were grown for the remainder of the 72 h 
period. The extent of cellular proliferation is expressed as the ratio of BrdU incorporated 
by the rhodium-treated cells as compared to untreated controls. Furthermore, we define 
differential inhibition as the difference in BrdU incorporation between the HCT116N and 
HCT116O cells.  Figure 3.4 and Figure 3.5 show data for all compounds. Very little to 
no activity is seen for any of the compounds at 1- or 3-hour incubation times (data not 
shown).  
Figure 3.6 summa izes the ELISA  esults fo  all compoun s teste  at 10 μM 
rhodium concentration and 24 h of incubation (Except [Rh(DIP)2(chrysi)]
3+
, which is 
shown at 2 μM), as these a e the same con itions use  fo  all I P-MS experiments.15,25,26 
There are four compounds with high selectivity for the MMR-deficient HCT116O cells 
([Rh(NH3)4(phzi)]
3+
,
 
[Rh(chrysi)(phen)(DPE)]
2+
, [Rh(DPAE)2(chrysi)]
3+
,  and 
[Rh(HDPA)2(chrysi)]
3+
, all shown
 
in different shades of blue), displaying differential 
inhibitions of 63 ± 5%, 55 ± 3%, 55 ± 3%, and 52 ± 2%, respectively. 
[Rh(chrysi)(phen)(HDPA)]
3+
 and [Rh(bpy)2(chrysi)]
3+
 exhibit modest selectivity with 
differential inhibitions of 27 ± 2%  and 8 ± 2% at 24 h (shown in green in Figure 3.6). It 
should be noted that at longer incubation times the differential inhibition of 
[Rh(bpy)2(chrysi)]
3+
 increases.
25 
 [Rh(chrysi)(phen)(MeDPA)]
3+
, also shown in green, 
exhibits delayed biological activity. At 24 h incubation times, this complex does not  
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Figure 3.4 Inhibitory effects of (from top to bottom) [Rh(NH3)4(phzi)]
3+
, 
[Rh(chrysi)(phen)(DPE)]
2+
, [Rh(DPAE)2(chrysi)]
3+
 , [Rh(HDPA)2(chrysi)]
3+
, and 
[Rh(chrysi)(phen)(HDPA)]
3+
as a function of incubation time on cellular proliferation. 
Shown are plots of BrdU incorporation (a measure of DNA synthesis and therefore 
cellular proliferation) normalized to the BrdU incorporation of untreated cells as a 
function of rhodium concentration. Standard error bars for five trials are shown. 1- and 3-
h plots are not shown, as no activity was observed. 
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Figure 3.5 Inhibitory effects of (from top to bottom) [Rh(bpy)2(chrysi)]
3+
, 
[Rh(chrysi)(phen)(MeDPA)]
3+
, [Rh(chrysi)(phen)(PrDPA)]
3+
 , [Rh(PrDPA)2(chrysi)]
3+
, 
and [Rh(PrDPA)2(chrysi)]
3+
as a function of incubation time on cellular proliferation. 
Shown are plots of BrdU incorporation (a measure of DNA synthesis and therefore 
cellular proliferation) normalized to the BrdU incorporation of untreated cells as a 
function of rhodium concentration. Standard error bars for five trials are shown.  1- and 
3-h plots are not shown, as no activity was observed. 
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Figure 3.6 Inhibitory effects of rhodium metalloinsertors as a function of metalloinsertor 
identity. The percent differential inhibition is defined as the difference of the normalized 
percentages of cellular proliferation between the two cell lines, HCT116O versus 
HCT116N. ELISA analyses were performed as in Figure 3.4 and Figure 3.5. Cells were 
incubate  with 10 μM  ho ium complex fo  24 h (except [Rh(DIP)2(chrysi)]
3+
, which 
was a ministe e  at 2 μM). 
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display significant inhibition of DNA synthesis toward either cell line. The remaining 
compounds ([Rh(chrysi)(phen)(PrDPA)]
3+
, [Rh(PrDPA)2(chrysi)]
3+
and 
[Rh(DIP)2(chrysi)]
3+
, shown in red) exhibit no selectivity for the MMR-deficient 
HCT116O cell line, and inhibit DNA synthesis similarly in both cell lines. It should be 
noted that none of the complexes studied show a differential inhibition favoring the 
HCT116N cell line, although that is the common result for many DNA-damaging agents. 
Many of these compounds exhibit accelerated activity in the ELISA assay, 
displaying substantial differential inhibition of DNA synthesis towards the HCT116O cell 
line at 6- or 12-h incubation times. Motivated by the previous observation that rhodium 
metalloinsertors which display accelerated activity in the ELISA assay exhibit 
preferential cytotoxicity towards the MMR-deficient HCT116O cell line,
1
 we chose also 
to test all compounds for cytotoxicity in the MTT assay. 
3.3.3 MTT Cytotoxicity Assay 
The cytotoxic effects of all compounds were determined by MTT assay.
19
 Briefly, 
reduction of the MTT reagent by metabolically active cells leads to the production of 
formazan, which can then be dissolved in acidified SDS to produce a characteristic 
absorbance at 570 nm. This absorbance reflects the percentage of metabolically active 
cells in each sample. HCT116N and HCT116O cells were plated and treated with the 
various rhodium complexes at the concentrations indicated in Figure 3.7 for 24, 48, or 72 
h. Percent viability is defined as the ratio of the amount of formazan in the treated cells to 
that in the untreated cells, and differential cytotoxicity is defined as the difference 
between the percent viabilities of the two cell lines. The 72-h results are shown in Figure 
3.7. These results are consistent with the ELISA assay results. The same four compounds  
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Figure 3.7 Differential cytotoxicities of rhodium metalloinsertors.  HCT116N (green) 
and HCT116O (red) cells were plated in 96-well format at densities of 5 x 10
4 
cells/well 
and treated with the concentrations of rhodium metalloinsertors indicated. After 72 
hours, the cells were labeled with MTT for 4 hours. 
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that show the best differential inhibition of DNA synthesis in the ELISA assay 
([Rh(NH3)4(phzi)]
3+
, [Rh(chrysi)(phen)(DPE)]
2+
, [Rh(DPAE)2(chrysi)]
3+
, and 
[Rh(HDPA)2(chrysi)]
3+
) exhibit highly selective cytotoxicities towards the MMR-
deficient HCT116O cell line, 72 ± 4%, 69 ± 3%, 47 ± 1%, and 55 ± 1%, respectively (at 
their respective optimal concentrations). The compounds that exhibit delayed activity in 
the ELISA assay ([Rh(chrysi)(phen)(MeDPA)]
3+
 and [Rh(bpy)2(chrysi)]
3+
) do not display 
significant cytotoxicity toward either cell line in the MTT assay, consistent with previous 
observations.
1
 The remaining compounds ([Rh(chrysi)(phen)(HDPA)]
3+
, 
[Rh(chrysi)(phen)(PrDPA)]
3+
, [Rh(PrDPA)2(chrysi)]
3+
, and [Rh(DIP)2(chrysi)]
3+
) exhibit 
either modest or no selective cytotoxicity towards the HCT116O cell line, consistent with 
their activities in the ELISA assay. 
Despite our previous results
25
 that  ho ium metalloinse to s’ biological activit  
correlates directly with their binding affinities, the metalloinsertors discussed herein have 
similar DNA binding affinities (except [Rh(DIP)2(chrysi)]
3+
), yet display biological 
activities that vary drastically. ICP-MS studies were undertaken in order to determine if 
the cellular uptake and distribution of these rhodium metalloinsertors could explain their 
variation in activities. 
3.3.4 ICP-MS Assay for Whole-Cell Rhodium Levels 
H T116O cells we e t eate  with 10 μM of each  ho ium complex (except 
[Rh(DIP)2(chrysi)]
3+, which was a ministe e  at 2 μM) fo  1, 3, 6, 12, o  24 h. Whole 
cell lysates were analyzed for rhodium levels by ICP-MS and normalized to protein 
content (Figure 3.8). The experiment was repeated with HCT116N cells at 24 h to  
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Figure 3.8 ICP-MS assay for whole-cell rhodium accumulation. HCT116O cells were 
t eate  with 10 μM of each  ho ium complex (except [Rh(DIP)2(chrysi)]
3+
, which was 
a ministe e  at 2 μM) fo  1, 3, 6, 12, o  24 h. The cells we e anal ze  fo   ho ium 
content by ICP-MS. The rhodium counts were normalized to protein content, which was 
determined by a BCA assay. See section 2.2.8. 
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confirm that cellular uptake is not different for the HCT116 O versus N cells and to 
verify consistency in trends among the ten compounds.  
There seem to be a variety of modes of uptake at play. The most lipophilic 
compounds ([Rh(chrysi)(phen)(PrDPA)]
3+
, [Rh(PrDPA)2(chrysi)]
3+
, and 
[Rh(DIP)2(chrysi)]
3+
) exhibit gradual uptake into the HCT116O cells, suggestive of 
passive diffusion. This is consistent with previous studies conducted on luminescent 
[Ru(L)2dppz]
2+
 (dppz = dipyrido[3,2-:2’,3’-c]phenazine) analogues, demonstrating 
cellular accumulation through passive diffusion, facilitated by the negative potential 
difference across the cell membrane,
27,28 
The two compounds that exhibit delayed 
biological activity in the ELISA assay ([Rh(chrysi)(phen)(MeDPA)]
3+
 and 
[Rh(bpy)2(chrysi)]
3+ 
) exhibit no increase in cellular rhodium levels after initial uptake at 
1 h. Furthermore, the two compounds with HDPA ligands exhibit an enhanced cellular 
uptake despite reduced lipophilicities. They show a very high initial uptake, followed by 
a slight increase over the next 23 hours. The MeDPA compound does not exhibit the 
increase in uptake that we had expected, given its enhanced lipophilicity compared to the 
HDPA analog. This suggests a completely different mechanism of uptake for the HDPA 
complex. The two compounds with PrDPA ligands do exhibit enhanced uptakes 
compared to their respective HDPA analogs at 24 h, but not nearly to the degree we 
would have expected based on lipophilicities. However, both the PrDPA compounds 
appear to be taken up through passive diffusion, unlike the HDPA compounds. Perhaps 
the fact that the HDPA ligand has the potential to form hydrogen bonds in cellulo is 
important to its path into the cell. The compounds that exhibit the highest selectivities in 
the biological assays ([Rh(chrysi)(phen)(DPE)]
2+
, [Rh(DPAE)2(chrysi)]
3+
, and 
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[Rh(NH3)4(phzi)]
3+
) by no means have the highest overall rhodium levels. In fact, all 
three of them have among the lowest amount of rhodium uptake into cells. 
3.3.5 ICP-MS Assay for Nuclear Rhodium Levels 
The nuclear rhodium concentrations of all compounds were determined via ICP-
MS. Briefly, HCT116O cells were treated with the various rhodium complexes for 24 h, 
the nuclei were isolated, and rhodium concentrations of the various samples were 
determined by ICP-MS and normalized to number of nuclei. The process was repeated 
with HCT116N cells to confirm that the two cell lines behave similarly and to verify 
consistency in trends among the ten compounds (data not shown). These numbers (in ng 
of rhodium per nuclei) can be used to estimate nuclear concentrations by approximating 
the nucleus of a H T116O cell as a sphe e with  a ius 4 μm.29 The approximate nuclear 
rhodium concentrations, so determined, are reported in Figure 3.3. 
As can be seen in Figure 3.9, there is little correlation between cell-selective 
activity and nuclear rhodium concentration. In fact, all nuclear rhodium concentrations 
except for that of [Rh(DPAE)2(chrysi)]
3+
 are within a factor of two of each other and 
hardly vary among the 10 compounds. When we approximate the nuclear concentrations 
in molarity of the 10 compounds, all compounds are present in the nucleus at 
concentrations on the order of 10
-5
 to 10
-4 
M. These concentrations are all more than 2 
orders of magnitude higher than the binding affinities for in vitro mismatch detection (yet 
below non-specific DNA binding levels
23
). Thus, even estimating the error on these 
numbers to be an order of magnitude, all compounds are present in the nucleus at 
concentrations sufficient for mismatch binding. 
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Figure 3.9 ICP-MS assay for nuclear and mitochondrial rhodium accumulation. 
H T116O cells we e t eate  with 10 μM of each  ho ium complex (except 
[Rh(DIP)2(chrysi)]
3+, which was a ministe e  at 2 μM) fo  24 h. The cells we e ha veste  
by trypsinization and appropriate organelle isolation procedures performed. The 
mitochondrial rhodium counts were normalized to protein content, which was determined 
by a BCA assay. The nuclear rhodium numbers were normalized to number of nuclei. 
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3.3.6 ICP-MS Assay for Mitochondrial Rhodium Levels 
The mitochondrial rhodium concentrations of all compounds were determined via 
ICP-MS. Briefly, HCT116O cells were treated with the various rhodium complexes for 
24 h, the mitochondria were isolated, and rhodium concentrations of the various samples 
were determined by ICP-MS and normalized to amount of protein. The results are 
summarized in Figure 3.9 alongside the nuclear rhodium levels. The fact that the three 
compounds with the most cell-selective biological activity ([Rh(NH3)4(phzi)]
3+
, 
[Rh(chrysi)(phen)(DPE)]
2+
,  and [Rh(DPAE)2(chrysi)]
3+
,  shown in blue) have the lowest 
mitochondrial rhodium accumulation, 152 ± 3 ng [Rh]/ mg [mitochondrial protein], 106 ± 
7 ng [Rh]/ mg [mitochondrial protein], and 141 ± 8 ng [Rh]/ mg [mitochondrial protein], 
respectively, is striking. This correlation indicates that the biological target of our 
rhodium metalloinsertors is genomic DNA rather than mitochondrial DNA.  
Furthermore, the three compounds that exhibit no selectivity for the MMR-
deficient HCT116O cell line in both biological assays ([Rh(chrysi)(phen)(PrDPA)]
3+
, 
[Rh(PrDPA)2(chrysi)]
3+
, and [Rh(DIP)2(chrysi)]
3+
, shown in red) display the highest 
levels of mitochondrial rhodium accumulation, 560 ± 30 ng [Rh]/ mg [mitochondrial 
protein], 1260 ± 150 ng [Rh]/ mg [mitochondrial protein]  and 740 ± 70 ng [Rh]/ mg 
[mitochondrial protein], respectively. This result points to mitochondrial targeting as 
responsible for the promiscuous biological activity associated with these three 
compounds that detracts from the cell-selective activity. The two HDPA-containing 
compounds stray from the trends observed with the other eight compounds.  
 
 
 125 
 
3.4 Discussion 
3.4.1 Variations in Complexes Synthesized 
The compounds displayed in Figure 3.3 were initially synthesized in order to 
investigate the biological effects of varying the lipophilicity of the metalloinsertor. 
[Rh(HDPA)2(chrysi)]
3+
 has been shown to exhibit accelerated biological activity, as well 
as an enhanced selectivity for the MMR-deficient HCT116O cell line compared to that 
expected based solely on its binding affinity.
1,25
 By varying L in [Rh(chrysi)(phen)(L)]
3+
 
from HDPA to MeDPA to PrDPA, we sought to examine the effect that changes in 
lipophilicity have on uptake and to determine if the proton associated with the HDPA 
ligand, which is not present in other compounds examined, might play some role in the 
enhanced activity and uptake of [Rh(HDPA)2(chrysi)]
3+
. The DPE ligand was originally 
intended as an analog of HDPA, but without the amine nitrogen which is capable of 
inverting its geometry.  Its unexpected ligand coordination results in a distinctive Rh-O 
bond, which is the subject of future work. The chrysi analog of [Rh(NH3)4(phzi)]
3+
 was 
shown to exhibit excellent differential activity in the ELISA assay,
25
 and therefore its 
phzi analog was synthesized both in the hopes of making a compound with increased 
efficacy, and to look at the biological effects of decreasing lipophilicity. The compounds 
[Rh(DPAE)2(chrysi)]
3+
 and [Rh(PrDPA)2(chrysi)]
3+
 were made as a matched pair to look 
at the biological effects of small structural changes to the ancillary ligands.  
Surprisingly, all compounds exhibited binding affinities within the same order of 
magnitude (except [Rh(DIP)2(chrysi)]
3+
, which was included in the study as a reference 
compound with extreme lipophilicity, poor binding to mismatches, and no selectivity in 
our biological assays). The differences among these nine compounds in the ELISA and 
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MTT assays therefore arise from primarily biological effects rather than mismatch 
binding. 
For all compounds, the cytotoxic effects seen in the MTT assay reflect the 
antiproliferative activity seen in the ELISA assay. Both compounds that exhibit delayed 
activity in the ELISA assay, [Rh(chrysi)(phen)(MeDPA)]
3+
 and [Rh(bpy)2(chrysi)]
3+
, do 
not show any significant cytotoxicity in the MTT assay. Furthermore, the four 
compounds with the largest differential inhibitions in the ELISA assay, 
[Rh(NH3)4(phzi)]
3+
, [Rh(chrysi)(phen)(DPE)]
2+
, [Rh(DPAE)2(chrysi)]
3+
, and 
[Rh(HDPA)2(chrysi)]
3+
, also show the largest differential cytotoxicities by the MTT 
assay. Finally, the three compounds with no differential activity in the ELISA assay, 
[Rh(chrysi)(phen)(PrDPA)]
3+
, [Rh(PrDPA)2(chrysi)]
3+
, and [Rh(DIP)2(chrysi)]
3+
, also 
show no differential cytotoxicity in the MTT assay. It is important to distinguish the 
absence of differential activity, where the compound shows no selectivity for one cell line 
over the other and affects both cell lines to the same degree, versus the absence of all 
activity, where the compound shows no appreciable biological effect on either cell line.  
Significantly, the biological activities of these compounds vary dramatically 
despite their similar binding affinities. Interestingly, the effect of appending a lipophilic 
alkyl chain to the back of the HDPA ligand either significantly slows down all activity, as 
with the MeDPA derivative, or instead abolishes the selectivity of the compound for the 
MMR-deficient HCT116O cell line, as with the PrDPA derivatives. While the 
mechanism of inhibition is not yet fully understood, one possible scenario is protein 
recognition of the metalloinsertor-mismatch complex, generating a covalent protein-DNA 
lesion. Bulky tethers off the back of the metalloinsertor may inhibit the formation of such 
 127 
 
a lesion, leading to the aforementioned observations. Yet another explanation for the 
results might be that the increased lipophilicity of the metalloinsertor enhances uptake 
into the cell but also alters the subcellular localization of the complex once it has entered 
the cell. This altered subcellular localization could be the reason for the lack of selectivity 
of the compound for one cell line over the other. Indeed, the least lipophilic compounds 
have the most selective biological activity, while the more lipophilic compounds exhibit 
no selective biological activity. 
3.4.2 Metalloinsertor Uptake and Nuclear Accumulation 
Table 3.1 displays qualitative nuclear and mitochondrial uptake properties, as 
well as the presence or absence of cell-selective biological activity for all ten 
metalloinsertors. Importantly, the biological effects seen in both assays can be explained 
by the subcellular localization of the metalloinsertors. If passive diffusion were the  
dominant mode of cellular uptake for these metalloinsertors,
27,28
 the more lipophilic 
compounds would be expected to have increased cellular uptake. And indeed, except for 
the HDPA compounds, the most lipophilic compounds do exhibit the greatest cellular 
accumulation. However, the more liphophilic compounds are in general associated with 
little differential biological activity; high accumulations of these metalloinsertors are 
toxic.  
By altering L in [Rh(chrysi)(phen)(L)]
3+
 from HDPA to MeDPA to PrDPA, we 
do not observe an increase in uptake. In fact, the HDPA complex seems to show 
enhanced uptake in comparison with those that are more lipophilic. Furthermore, both 
compounds that possess HDPA ligands display both enhanced and accelerated uptake. 
This is likely due to additional uptake pathways facilitating the influx of complexes  
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Table 3.1 Qualitative nuclear
a
 and mitochondrial
b
 uptake properties, as well as the 
presence or absence of cell-selective biological activity
c
 for all ten metalloinsertors. 
Compound 
 
Nuclear 
Conc.
a
 
Mito. 
Conc.
b
 
Cell-
Selective 
Activity
c
 
[Rh(NH3)4(phzi)]
3+ + 
_
 + 
[Rh(chrysi)(phen)(DPE)]
3+ + 
_
 + 
[Rh(DPAE)2(chrysi)]
3+ + 
_
 + 
[Rh(HDPA)2(chrysi)]
3+ + + + 
[Rh(chrysi)(phen)(HDPA)]
3+ + + + 
[Rh(bpy)2(chrysi)]
3+ + + 
_
 
[Rh(chrysi)(phen)(MeDPA)]
3+
 + + 
_
 
[Rh(chrysi)(phen)(PrDPA)]
3+ + + 
_
 
[Rh(PrDPA)2(chrysi)]
3+ + + 
_
 
[Rh(DIP)2(chrysi)]
3+ + + 
_
 
a
  ompoun  is consi e e  to have “+” nuclea  concent ation if its nuclea  concent ation is 
sufficient for mismatch detection given its binding affinity. 
b
 Compound is considered to have 
“+” mitochon  ial concent ation if its mitochon  ial  ho ium concent ation is ≥200 ng Rh/mg 
[mito protein]. 
c ompoun  is consi e e  to have “+” cell-selective activity if its differential 
inhibition of DNA synthesis as measured by ELISA of the MMR-proficient line versus the 
MMR- eficient line is ≥25% at 24 h  of incubation, 10 µM compound concentration. 
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containing HDPA. Indeed, several bis(cyclometalated) iridium(III) polypyridine 
complexes have been shown to employ more than one mechanism of uptake,
30
 and this 
may be the case for several of our metalloinsertors. In comparing [Rh(PrDPA)2(chrysi)]
3+
 
to [Rh(DPAE)2(chrysi)]
3+
, it appears that by altering the methyl group of PrDPA to an 
alcohol, uptake is decreased by a factor of four, yet only the DPAE compound has cell-
selective activity. Lastly, the most polar compound, [Rh(NH3)4(phzi)]
3+
, displays a peak 
in uptake at 3 hours, after which cellular rhodium levels seem to decrease steadily. This is 
most likely caused by an efflux mechanism, that is, pumping the complex out of the cell.  
The ATP-binding cassette protein ABCG2 has been reported to be overexpressed 
in HCT116 cells,
31
 is known to exhibit substrate promiscuity,
32
 and may be responsible. 
Contrary to what would be expected, three of the four compounds with high activity have 
among the lowest cellular uptake at 24 hours, while the three compounds with no cell-
selective activity have among the highest cellular uptake at 24 hours. It appears as though 
increased cellular uptake is actually detrimental to the unique cell-selective behavior of 
our metalloinsertors. 
 Significantly, the nuclear rhodium concentrations vary only slightly among the 
ten compounds. Importantly, by approximating the nucleus of an HCT116O cell as a 
sphe e with  iamete    μm,29 all of our metalloinsertors are present in the nucleus at 
sufficient concentrations for mismatch binding, given their in vitro binding affinities 
(Figure 3.3). Moreover, all metalloinsertors are below non-specific DNA binding 
concentrations,
23
 which precludes non-specific DNA binding as a possible cause of the 
non-selective toxicity seen with 3 of our metalloinsertors. The only difference between 
the two cell lines is the presence of a functional copy of the MLH1 gene in the HCT116N 
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cell line, which encodes for an MMR protein found in the nucleus.
33
 Therefore, any 
interactions the rhodium complexes have with the cell that are not associated with the 
nucleus may account for their nonspecific biological activity. Consequently, if nuclear 
DNA were the only cellular target for these metalloinsertors, then all compounds should 
exhibit similar differential activity due to their similar nuclear concentrations. However, 
these metalloinsertors could also interact with mitochondrial DNA, or become 
sequestered in lipid membranes throughout the cell (including the nuclear membrane, 
which would cause the nuclear rhodium concentration of such a complex to appear higher 
than it actually is), both of which would result in nonspecific biological activity. 
3.4.3 Mitochondrial Accumulation of Rhodium Metalloinsertors 
 Importantly, the metalloinsertors that display highly cell-selective biological 
activity are generally associated with lower mitochondrial rhodium accumulation (Figure 
3.9, complexes shown in blue), while the metalloinsertors that display non-selective 
toxicity show larger mitochondrial rhodium accumulation (Figure 3.9, complexes shown 
in red). These observations suggest that it is nuclear DNA targeting of our 
metalloinsertors that is responsible for their cell-selective biological activities rather than 
mitochondrial DNA targeting. 
The two compounds [Rh(DPAE)2(chrysi)]
3+
 and [Rh(PrDPA)2(chrysi)]
3+
 exhibit 
this phenomenon quite simply.
15
 The only structural difference between the two 
compounds is the substitution of the methyl group of the PrDPA ligand for a primary 
alcohol in the DPAE ligand. While this substitution is structurally minute, the 
consequences of such a substitution are extreme from a biological standpoint. This 
substitution causes a large increase in polarity for the DPAE complex, as can be 
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quantified by a decrease in the logP values from -1.0 to -1.5.
15
 Significantly, this increase 
in polarity is accompanied by an increase in cell-selective biological activity. While the 
more lipophilic [Rh(PrDPA)2(chrysi)]
3+ 
complex exhibits no selectivity for the MMR-
deficient cell line, the more polar [Rh(DPAE)2(chrysi)]
3+
 complex is highly selective for 
the MMR-deficient line over the MMR-proficient line. Furthermore, this small structural 
change results in dramatic changes in uptake and localization of the compounds. While 
the more lipophilic [Rh(PrDPA)2(chrysi)]
3+ 
complex has about a four-fold greater uptake 
into the cell than the polar [Rh(DPAE)2(chrysi)]
3+
 complex, it exhibits a ten-fold greater 
mitochondrial accumulation than the DPAE complex, and only a two-fold greater nuclear 
accumulation. This suggests that the non-selective behavior of [Rh(PrDPA)2(chrysi)]
3+
 is 
caused by increased mitochondrial accumulation.  
It should be noted, however, that mitochondrial accumulation is not always 
associated with non-selective toxicity. The presence of the HDPA ligand enhances and 
accelerates uptake significantly, and even leads to increased mitochondrial accumulation, 
yet complexes containing HDPA show high selective biological activitites. In fact, it has 
recently been reported that changes in polarity can affect whether mitochondria-targeted 
peptides simply accumulate in the mitochondrial matrix or disrupt the mitochondrial 
membrane activity and result in apoptosis.
34 
Furthermore, while the antimetabolite 
methotrexate normally exhibits toxicity towards mammalian cells, when it is conjugated 
to a mitochondrial-penetrating peptide, the altered subcellular localization reduces its 
toxicity by three orders of magnitude.
8 
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3.4.4 General Implications for Design 
This work supports the hypothesis that nuclear DNA mismatch binding is 
responsible for the unique cell-selective biological activity of our rhodium 
metalloinsertors. Indeed, out of ten compounds studied, all ten exhibit sufficient nuclear 
uptake for mismatch binding. Furthermore, the fact that the three compounds that are not 
selective for the MMR-deficient cell line have enhanced mitochondrial accumulation 
indicates that mitochondrial mismatch DNA targeting is not responsible for cell-selective 
behavior (Figure 3.10). As the only difference between the two cell lines is a functional 
copy of the MLH1 gene, a gene which encodes for a nuclear MMR protein, the cell-
selective behavior of our metalloinsertors must be related to this MMR deficiency.  As 
the mitochondria are the location of oxidative phosphorylation, where reactive oxygen 
species are unavoidably formed as byproducts,
 
mitochondrial DNA has higher levels of 
oxidative damage than nuclear DNA.
35
 While these DNA defects could very well be 
targets of our metalloinsertors, mtDNA repair pathways do exist,
36
 and in most cases are 
distinct from their nuclear counterparts.
37
 Specifically, the nuclear MMR proteins MSH2, 
MSH3, MSH6, and MLH1 have been shown to be absent from the mitochondria.
38
 The 
targeting of defects in mitochondrial DNA therefore cannot be responsible for the unique 
cell-selective behavior of our metalloinsertors. Instead, mitochondrial uptake appears to 
be associated with nonspecific toxicity. 
3.5 Conclusion 
In this work, all compounds tested are present in the nucleus at sufficient 
concentrations for mismatch detection. However, the more liphophilic compounds, which 
display enhanced uptake into the cells, tend to localize more in the mitochondria, thus  
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Figure 3.10 Model for the requirements for MMR-deficient cell-selectivity by rhodium 
metalloinsertors. All metalloinsertors localize to the nucleus in sufficient concentrations 
for mismatch binding. This genomic mismatch binding is thought to be responsible for 
the unique preferential targeting of MMR-deficient cells by rhodium metalloinsertors. If 
the compound is sufficiently lipophilic, mitochondrial targeting will occur, which will 
abolish any cell-selective activity resulting from nuclear localization. 
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giving rise also to nonspecific biological activity. While the more polar compounds, 
([Rh(NH3)4(phzi)]
3+
, [Rh(chrysi)(phen)(DPE)]
2+
, and [Rh(DPAE)2(chrysi)]
3+
), do not 
have the largest amount of cellular rhodium, there is consequently a smaller amount of 
rhodium in the mitochondria. This, coupled with sufficient nuclear rhodium for mismatch 
binding, gives rise to high MMR-deficient cell-selective biological activities for these 
three compounds. It seems that by increasing lipophilicity in an effort to increase uptake 
via passive diffusion, the subcellular localization is altered, leading to a larger amount of 
cellular rhodium residing in the mitochondria and less selectivity for the MMR-deficient 
cell line. This tradeoff in uptake for selectivity is in contrast to current strategies to 
improve the efficacy of cisplatin by increasing uptake of the drug.
39,40
  More generally, 
these results highlight that the relative accumulation of the complexes in different 
organelles needs to be considered, not simply cellular accumulation.  
Most importantly, these data support the notion that the cell-specific activity we 
observe is caused by nuclear DNA mismatch targeting by our metalloinsertors. This 
exciting new result gives us key information in designing the next generation of rhodium 
metalloinsertors as cell-specific chemotherapeutics. 
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Chapter 4: An Inducible, Isogenic Cancer Cell Further Validates 
Rhodium Metalloinsertors as Selective Chemotherapeutic Agents
**
 
4.1 Introduction 
Genome instability is a hallmark of cancer cells and can lead to numerical or 
structural changes to chromosomes (chromosome instability, or CIN), or nucleotide 
mismatch repair (MMR) deficiency (MIN).
1
 While CIN can result from loss of function 
of a number of cellular pathways, MIN results specifically from defects in the MMR 
system and is identifiable by the gain or loss of mono-, di- or tri-nucleotide repeat 
sequences, referred to as microsatellite instability (MSI).
2
 Replication errors such as 
polymerase slippage generate small insertion-deletion loops (IDLs) or single base 
mismatches in the DNA. DNA damage can also modify bases to cause mismatches. In 
human cells that are MMR-proficient, heterodimers that contain the bacterial MutS 
homolog MSH2 bind a mismatch, and then heterodimers that contain the bacterial MutL 
homolog MLH1 associate with the protein-DNA complex to mediate the recruitment of 
repair factors that excise the mismatch and restore the correct DNA sequence. MMR-
deficient cells are unable to correct mismatches, and this results in incorporation of errors 
into the DNA template and a mutator phenotype. 
MMR deficiency is strongly linked with cancer. Germ line mutation of MMR 
genes, particularly MLH1 or MSH2, is the basis of hereditary non-polyposis colorectal 
cancer (HNPCC), or Lynch syndrome, which confers susceptibility to colorectal cancer 
                                                          
**
 Adapted from Bailis, J. M.; Gordon, M. L.; Gurgel, J. L.; Komor, A. C.; Barton, J. K.; Kirsch, I. R. An 
Inducible, Isogenic Cancer Cell Line System for Targeting the State of Mismatch Repair Deficiency PLoS 
ONE 2013, 10, e78726. 
Acknowledgements: Julie Bailis developed the inducible cell line and performed all cell culture 
experiments; I confirmed MLH1 knockdown upon doxycycline treatment in our laboratory and supplied all 
metalloinsertors. 
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but also to other specific cancer types including endometrial and ovarian cancer.
3,4
 
Mutation or hypermethylation of MMR genes in somatic cells is associated with ~15% of 
sporadic colorectal cancers, as well as ~10-15% of ovarian, endometrial and gastric 
cancers.
5
 MMR deficiency and MSI have also been identified in up to 20% of leukemias 
in patients that relapse or develop the disease as a consequence of prior chemotherapeutic 
treatment.
6
  
MMR deficiency and MSI also occur in primary lung cancer associated with 
smoking or exposure to chromium.
7-9
 Cancers with MSI have been reported to be 
resistant to several standard-of-care chemotherapeutic agents, such as the antimetabolite 
5-fluorouracil (5-FU), the platinum compounds cisplatin and carboplatin, the alkylating 
drug temozolomide, and the topoisomerase inhibitor etoposide.
10
 Inactivation of the 
MMR pathway may allow cells to tolerate certain types of DNA damage without 
initiating a pathway of programmed cell death.
11
 
One challenge to identifying therapies for MMR-deficient cancers is that the 
molecular targets and clinical phenotypes resulting from inactivation of MMR genes are 
variable. MMR deficiency can lead to frameshift mutations in genes that contain repeat 
sequences in the DNA, and at least 30 genes have been identified as potential targets of 
MSI, including the oncogenes BRAF and KRAS, and the DNA damage response genes 
MRE11, BRCA1 and ATR.
12,13
 Efforts to identify novel therapeutic targets that exhibit 
synthetic lethality with MMR-deficient cancer cells have revealed different genetic 
interactions with loss of function of MLH1 compared to loss of function of MSH2,
14
 even 
though the MLH1 and MSH2 proteins function in the same biochemical pathway. 
Together, these observations support the idea that cancers with MSI represent a 
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multifaceted, heterogeneous set of diseases. In consideration of the complexity of MSI 
tumors, the end phenotype or “state” of mismatch repair deficiency itself has previously 
been proposed as a target for chemotherapeutics.
15,16
 
In the current effort described here, the goal was to develop tools to enable studies 
of induced mismatch repair deficiency. A completely isogenic cell line system in which 
expression of the MMR gene MLH1 can be switched on or off using shRNA is described.  
The lung adenocarcinoma NCI-H23, a cell line selected based on relatively high levels of 
MLH1 that could be reversibly inactivated by shRNA, is used as a model. In this study, 
MMR deficiency in the NCI-H23 cell line system is induced and results in MSI and 
increased resistance to DNA-damaging agents. As a potential step toward developing a 
therapeutic that targets the end “state” of MMR deficiency, this cell line system is used to 
further validate rhodium metalloinsertors as chemotherapeutic agents. 
4.2 Experimental Protocols 
4.2.1 Antibodies and Western Blots 
Protein lysates were prepared in lysis buffer (50mM HEPES, 1% Triton X-100, 
150mM NaCl, 1mM EGTA, 10% glycerol, 1mM DTT) to which phosphatase and 
protease inhibitors (20mM -glycerophosphate, 100mM sodium fluoride, 0.5mM PMSF, 
0.1mM sodium orthovanadate, 10ug/ml leupeptin) were added. Lysates were cleared by 
centrifugation and then analyzed by SDS-PAGE on 4-12% Bis-Tris gels (Invitrogen), 
followed by immunoblotting. Primary antibodies used were against MLH1 (Becton 
Dickinson #551091), MSH2 (Becton Dickinson #556349), GAPDH (Abcam #ab9484), 
phosphorylated histone H2AX (Millipore #05-636) or tubulin (Cell Signaling #2148). 
Primary antibodies were detected by secondary antibodies conjugated to IRDye700 or 
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IRDye800 (LiCOR) and visualized with the LiCOR Odyssey. Each western blot 
experiment was carried out at least twice, on independent days. 
4.2.2 Cell Viability Assays 
Cells grown in the absence or presence of doxycycline were plated at 2,000-5,000 
cells per well in 96-well plates and allowed to incubate overnight. Cells were then treated 
with compounds in a dose response for 4 days. Cell viability was assessed using a Cell 
Titer Glo assay (Promega) for ATP metabolism. Cell viability assays were performed in 
duplicate in at least 3 independent experiments. 
Phase contrast imaging of cells during the proliferation experiments was carried 
out using an IncuCyte with a 20X objective (Essen BioScience).  
Colony-forming assays were used to further assess cell viability following 
compound treatment. Cells grown in the absence or presence of doxycycline were plated 
at 500-2,000 cells per well of a 6-well plate and allowed to incubate overnight. Cells 
were treated with compounds in a dose response for 24h, and then media was aspirated 
and replaced with fresh media that did not contain compound.  Colonies were visualized 
with crystal violet stain at 10-12 d. 
SA-beta-galactosidase (SA--gal) production was assessed using a histochemical 
stain for beta-galactosidase activity at pH 6.0 (Sigma-Aldrich). Cells were untreated or 
treated with compounds as indicated for 3d, and then cells were fixed, stained for SA--
gal and imaged using a Zeiss Axio inverted microscope equipped with a color camera. 
4.2.3 Statistical Analysis 
For the cell viability assays, paired t tests were used to compare half maximal 
inhibitory (IC50) values or median lethal dose (LD50) from multiple experiments and 
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determine p values. p values less than 0.05 were considered statistically significant. 
Statistical analysis was done with Graph Pad Prism software. 
4.2.4 Synthesis of Chemical Compounds 
Synthesis of [Rh(DIP)2chrysi]
3+
 has been described.
 17
 [Rh(HDPA)2chrysi]
3+
 and 
[Rh(chrysi)(phen)(DPE)]
2+
 were synthesized as previously described (2.2.2.4 and 3.2.3.6, 
respectively).
18,19
 Cisplatin, doxorubicin, etoposide, 6-thioguanineand temozolomide 
were obtained from Sigma-Aldrich and dissolved in DMSO or water. 
4.3 Results 
4.3.1 Inhibition of MLH1 by shRNA Reduces MLH1 Protein Levels  
The NCI-H23 lung adenocarcinoma cell line is proficient for mismatch repair and 
contains relatively high levels of the MMR proteins MLH1 and MSH2.
20
 With the goal of 
generating a matched system that induces MMR deficiency and allows direct comparison 
to MMR-proficient cells, our collaborators at Amgen transduced NCI-H23 cells with 
lentivirus containing inducible shRNA to MLH1, and cells that stably integrated the 
construct into the genome were selected and expanded. Two subclones of this new cell 
line, labeled 4-10 and 4-13, were obtained from Amgen and tested for MLH1 inhibition 
following doxycycline treatment. Under normal growth conditions, the integrated shRNA 
was not active and MLH1 continued to be expressed. However, following addition of 
doxycycline to the media, shRNA was induced, which sequentially led to near complete 
(>90%) inhibition of the MLH1, as measured by Western blot analysis of protein lysates 
(Figure 4.1). 
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Figure 4.1 MLH1 shRNA expression is inducible. NCI-H23 subclones 4-10 and 4-13 
were induced for MLH1 shRNA by splitting into two cultures, one maintained in 
inducing conditions (+ Dox) and the other grown in the absence of doxycycline (- Dox). 
Protein lysates were prepared and analyzed by SDS-PAGE, followed by immunoblotting 
for expression of the MLH1 protein. GAPDH was used as a control for equal protein 
loading across samples. 
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4.3.2 MLH1-Deficient NCI-H23 Subclones Exhibit Increased Resistance to 
Chemotherapeutic Drugs 
We next tested whether induced MMR deficiency would cause resistance to DNA 
damaging agents. We directly compared the MMR-deficient NCI-H23 subclones to 
MMR-proficient cells from the same subclone that were obtained by allowing the cells to 
re-express MLH1. The MMR-deficient and MMR-proficient subclones were treated with 
the topoisomerase inhibitor etoposide or the alkylating agent temozolomide, and cell 
viability was assessed after 4 d (Figure 4.2 and Figure 4.3). The MMR-proficient 
subclones (shRNA uninduced) did not show a significant difference in sensitivity to the 
compounds compared to parental NCI-H23 cells that were either untreated or treated with 
doxycycline (p=0.33) (Figure 4.2). For each matched pair of cells (for example, subclone 
4-10 uninduced compared to 4-10 induced), the MLH1-deficient cells were consistently 
at least two-fold more resistant to these compounds than the isogenic MLH1-proficient 
cells, a finding that is statistically significant (p=0.03 for cells treated with etoposide, and 
p=0.009 for cells treated with temozolomide). The MLH1-deficient subclones were also 
more resistant to the crosslinking agent cisplatin (p=0.02), the purine analog 6-
thioguanine (p=0.05), and another topoisomerase inhibitor, doxorubicin (p=0.04) (Figure 
4.4). The approximately two-fold difference in viability of MMR-deficient cells versus 
MMR-proficient cells in vitro in response to chemotherapeutic agents has been reported 
previously and shown to translate to drug resistance in vivo.
4,10
 To confirm that the 
differential effect on viability is due to the presence or absence of MLH1, we used 
different shRNA sequences, 362 and 2239, to inhibit MLH1 expression and then 
characterized cell sensitivity to chemotherapeutic drugs. We observed that the MLH1- 
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Figure 4.2 NCI-H23 subclones that were uninduced or induced for MLH1 shRNA were 
treated with etoposide. (Top) Cells were treated at the concentrations indicated, and cell 
viability was assessed at 4d using a Cell Titer Glo assay. The graphs indicate the relative 
survival for duplicate samples from a single experiment. (Middle) Representative phase 
contrast images of cells treated with 390M etoposide during the viability experiments. 
0h and 96h time points are shown. (Bottom) Cells were treated with etoposide for 24h at 
the concentrations indicated, and colony-forming ability after compound washout was 
assessed. The graphs display percent survival at 10d for duplicate samples of compound 
treated cells. 
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Figure 4.3 NCI-H23 subclones that were uninduced or induced for MLH1 shRNA were 
treated with temozolomide. (Top) Cells were treated at the concentrations indicated, and 
cell viability was assessed at 4d using a Cell Titer Glo assay. The graphs indicate the 
relative survival for duplicate samples from a single experiment. (Middle) Representative 
phase contrast images of cells treated with 500M temozolomide during the viability 
experiments. 0h and 96h time points are shown. (Bottom) Cells were treated with 
temozolomide for 24h at the concentrations indicated, and colony-forming ability after 
compound washout was assessed. The graphs display percent survival at 10d for 
duplicate samples of compound treated cells. 
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Figure 4.4 MLH1-deficient NCI-H23 subclones display increased resistance to DNA-
damaging drugs. NCI-H23 subclones that were uninduced or induced for MLH1 shRNA 
were treated with (top) cisplatin, (middle) 6-thioguanine or (bottom) doxorubicin as 
indicated, and then cell viability was assessed after 4d using a Cell Titer Glo assay. The 
graphs indicate the relative survival for duplicate samples from a single experiment. 
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deficiency resulting from induction of these independent shRNA triggers led to a similar 
increase in resistance to chemotherapeutic drugs relative to the NCI-H23 cells that 
expressed MLH1 (p=0.001) (Figure 4.5).  
 To explore the differential sensitivity to the compounds in more detail, we imaged 
cells over the 4d treatment period of the cell viability assay and examined cell count and 
morphology. At the 0h time point, the cells are in growth phase and appear healthy by 
phase contrast imaging. However by 96h, the differences between the uninduced and 
induced subclones were apparent: most of the MLH1-proficient cells had undergone cell 
death after treatment with the DNA damaging agents, whereas the MLH1-deficient cells 
continued to proliferate (Figure 4.2 and Figure 4.3).  
 We further investigated cell survival following compound treatment using 
clonogenic assays. Cells were treated with etoposide or temozolomide for 24h, and 
recovery from compound treatment was assessed by colony formation after 10d. The 
MLH1-deficient NCI-H23 subclones were more resistant to compound treatment than the 
isogenic cells proficient for MLH1 (Figure 4.2 and Figure 4.3), showing a significant 
difference in the LD50 values (p=0.03 for etoposide, and p=0.04 for temozolomide). 
Together, these results demonstrate a differential response to DNA damage that is based 
solely on the presence or absence of MLH1. 
4.3.3 MLH1-Deficient NCI-H23 Subclones Display Increased Sensitivity to 
Rhodium Metalloinsertor Compounds 
We previously described metal complexes that noncovalently bind DNA 
mismatches with high affinity specificity, due to thermodynamic destabilization of the 
mismatched base pairs.
21
 We initially demonstrated that this class of compounds  
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Figure 4.5 Independent MLH1 shRNA constructs confer differential sensitivity to 
compounds. NCI-H23 cells transduced with (left) MLH1 shRNA 362 or (right) shRNA 
2239 were divided into two cultures, and grown in conditions that were uninduced 
(MLH1-proficient) or induced for MLH1 shRNA (MLH1-deficient). The cells were 
treated with etoposide, and cell viability was assessed after 4d using a Cell Titer Glo 
assay. Percent viability of duplicate samples from a representative experiment is shown. 
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preferentially inhibits the proliferation of MMR-deficient cells, using a matched HCT116 
colorectal cancer cell line system and a genetic knockout system.
16-19
 This earlier work 
was the foundation and motivation for the creation of the isogenic cell lines described in 
the current study and led us to test whether rhodium metalloinsertor compounds would 
also preferentially inhibit the viability of these cells when MMR deficiency was induced. 
In our inducible cell line system, the rhodium metalloinsertor compound 
[Rh(chrysi)(phen)(DPE)]
2+
 preferentially inhibited the viability of induced MLH1-
deficient NCI-H23 subclones, with at least a three-fold change in the cellular IC50  in a 4d 
Cell Titer Glo assay relative to the MLH1-proficient subclones (p=0.001) (Figure 4.6). 
Another rhodium metalloinsertor compound, [Rh(HDPA)2chrysi]
3+
 also preferentially 
inhibited proliferation of MLH1-deficient cells (Figure 4.7), with a two- to three-fold 
change in cellular IC50 values (p=0.003). To confirm that the difference resulted from 
MLH1 deficiency rather than an off-target effect of the shRNA, we used additional, 
independent MLH1 shRNA constructs to downregulate MLH1 in NCI-H23 cells and 
confirmed the result (p=0.007) (Figure 4.8). In contrast, a related compound that exhibits 
only weak binding to mismatched DNA, [Rh(DIP)2chrysi]
3+
,
19
 did not display a 
differential effect on cell viability of the uninduced and induced NCI-H23 clones 
(p=0.30) (Figure 4.7). Together, our data support the hypothesis that downregulation of 
MLH1 increases cell sensitivity to the rhodium metalloinsertor compounds. 
We examined the cellular morphology of the NCI-H23 subclones treated with 
[Rh(chrysi)(phen)(DPE)]
2+
 during the time course of the proliferation assays, using phase 
contrast imaging. Cells from the MLH1-proficient and MLH1-deficient subclones 
appeared healthy and in growth phase at the 0h time point. By 96h, the uninduced  
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Figure 4.6 MLH1-deficient NCI-H23 cells display increased cell sensitivity to rhodium 
metalloinsertor compounds. NCI-H23 subclones that were uninduced or induced for 
MLH1 shRNA were treated with the rhodium metalloinsertor compound 
[Rh(chrysi)(phen)(DPE)]
2+
. (Top) Cells were treated at concentrations indicated, and cell 
viability was assessed after 4d using a Cell Titer Glo assay. Percent viability of duplicate 
samples from a single experiment is shown. (Middle) Representative phase contrast 
images of cells treated with 5M [Rh(chrysi)(phen)(DPE)]2+ at 0h and 96h during the cell 
viability assay are shown. (Bottom) Cells were treated with [Rh(chrysi)(phen)(DPE)]
2+
 
for 24h, and then assayed for colony formation after 10d. The graphs show percent 
survival of duplicate samples of compound treated cells. 
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Figure 4.7 MLH1-deficient NCI-H23 cells display increased cell sensitivity only to 
rhodium metalloinsertors that exhibit DNA mismatch binding. (Top Left) Chemical 
structure of [Rh(HDPA)2chrysi]
3+
. (Top Right) NCI-H23 subclones that were uninduced 
or induced for MLH1 shRNA were treated with [Rh(HDPA)2chrysi]
3+
 as indicated, and 
cell viability was assessed after 4d using a Cell Titer-Glo assay. (Bottom Left) Chemical 
structure of [Rh(DIP)2chrysi]
3+
. (Bottom Right) NCI-H23 subclones that were uninduced 
or induced for MLH1 shRNA were treated with [Rh(DIP)2chrysi]
3+
 as indicated, and cell 
viability was assessed after 4d using a Cell Titer-Glo assay. Percent viability from 
duplicate samples of a single experiment is shown. 
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Figure 4.8 Independent MLH1 shRNA constructs confer differential sensitivity to 
rhodium metalloinsertors. NCI-H23 cells transduced with MLH1 shRNA 362 or MLH1 
shRNA 2239 were divided into two cultures, and grown in conditions that were 
uninduced (MLH1-proficient) or induced for MLH1 shRNA (MLH1-deficient). (Top) 
Cells were treated with [Rh(DPE)(phen)chrysi]
2+
, and cell viability was assessed after 
4d using a Cell Titer Glo assay. (Bottom) Cells were treated with 
[Rh(HDPA)2chrysi]
3+
, and cell viability was assessed after 4d using a Cell Titer Glo 
assay. Percent viability from duplicate samples of a single experiment is shown. 
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MLH1-proficient cells had continued to proliferate, but fewer cells appeared to be 
undergoing mitosis, suggesting a cell cycle delay or arrest (Figure 4.6). The cells did not 
appear to be undergoing senescence, as evidenced by lack of SA-beta-galactosidase 
production (data not shown). In contrast, most of the MLH1-deficient cells either failed 
to proliferate, or had undergone cell death by 96h (Figure 4.6). We verified that this 
differential effect was due to the absence or presence of MSI in the cells by assessing 
MLH1 protein levels in cells treated with rhodium metalloinsertor compounds (Figure 
4.9). The previously demonstrated effect of shRNA induction on MLH1 protein 
expression was not altered following treatment with the rhodium compounds (Figure 
4.9). 
We also confirmed the increased sensitivity of the MLH1-deficient NCI-H23 
subclones to the rhodium metalloinsertor compounds using clonogenic assays. After 24h 
treatment with [Rh(chrysi)(phen)(DPE)]
2+
, the MLH1-deficient NCI-H23 subclones 
formed fewer colonies than the isogenic MLH1-proficient subclones, exhibiting a 
significant difference in LD50 values (p=0.009) (Figure 4.6).  The differential sensitivity 
of the MLH1-deficient subclones to the rhodium metalloinsertor compounds is consistent 
with the hypothesis that these compounds exert their effects through binding to DNA 
mismatches that are present in MMR-deficient cells. 
4.4 Discussion 
 4.4.1 Generation of Isogenic Cell Lines 
 The MMR pathway maintains genome stability by promoting the recognition and 
repair of single base mismatches and small insertion-deletion loops in the DNA that 
result from replication errors or DNA damage. Loss of function of the MMR pathway  
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Figure 4.9 Treatment of NCI-H23 subclones with rhodium metalloinsertor compounds 
does not alter MSI status. MLH1-proficient and MLH1-deficient NCI-H23 subclones 
were treated with 5uM [Rh(DPE)(phen)chrysi]
3+
 for 24h, and then protein lysates were 
prepared and analyzed for MLH1 protein levels as a marker for MSI. Levels of tubulin 
were also assessed as a control for protein loading. 
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increases the prevalence of cellular mutations and can cause or contribute to cancer. The 
mechanism of carcinogenesis resulting from inherited MMR deficiency has been well 
studied, particularly in colorectal cancer,
4,22
 and has been modeled in cell line systems 
such as HCT116O cells, which are MLH1-deficient but contain an extra copy of 
Chromosome 2, and HCT116N cells, in which the MLH1 deficiency is complemented by 
an extra copy of Chromosome 3 that contains wild type MLH1.
23
 In other cancer types, 
such as in lung cancer, MMR deficiency can be promoted by carcinogen exposure.
7-9
 
Chemotherapeutic treatment also may promote MMR deficiency, leading to secondary 
leukemias.
6 
The cell line system we describe provides the first example of an isogenic 
model for induced MMR deficiency that can be reversibly switched on or off at the level 
of control of gene expression. It provides a model to study questions about induced MMR 
deficiency and to allow identification of molecules that might offer therapeutic benefit in 
MMR-deficient cancers.   
This new cell line system is complementary to matched cell line systems 
commonly used to study MMR, such as the MMR-deficient cancer cell lines HCT116 or 
Hec59, which are complemented by an extra copy of the chromosome containing wild 
type MLH1 or MSH2, respectively.
23,24
 In these models, the MMR-proficient cells and 
MMR-deficient cells are generated as different clones, and are chromosomally distinct 
from each other and the parental cell line. These differences may result in changes in 
chromosome stability or gene expression that are not solely due to MMR deficiency.
25,26
 
Matched normal cell systems, such as MMR-deficient embryonic kidney cells 293T 
compared to 293T cells engineered to overexpress MLH1,
27
 or wild-type mouse 
embryonic fibroblasts (MEFs) compared to MSH2-deficient MEFs
28
 may not be ideal 
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models to study MMR function in cancer. MEFs may be less sensitive to defects in DNA 
repair than cancer cells, and have been reported to exhibit a much lower mutation rate 
than MMR-deficient cancer cells.
25,29  
4.4.2 Implications for Chemotherapy 
There is currently no targeted therapy for patients with MMR-deficient cancers. In 
patients with colorectal cancers, the standard of care remains adjuvant-combined 
chemotherapy that includes the nucleoside inhibitor 5-fluorouracil (5-FU), even though 
multiple clinical studies have now shown that MMR-deficient tumors might not benefit 
from 5-FU treatment.
4,22
 In addition to defects in DNA damage recognition and repair,
11
 
MMR-deficient colorectal tumors display distinct features such as localization to the 
proximal colon, decreased metastasis, increased number of tumor infiltrating 
lymphocytes, and near-diploid DNA content of the cells.
30
 These characteristics may 
contribute to the better overall prognosis reported for patients with MMR-deficient 
colorectal cancer when compared on a stage-by-stage basis to patients with MMR-
proficient cancers.
31
 However, there is still a need for therapeutics that will be efficacious 
in MMR-deficient tumors.  
Synthetic lethality screens have identified several potential therapeutic targets for 
MMR-deficient cancer cells. Methotrexate, an inhibitor of dihydrofolate reductase, was 
reported to show synthetic lethality in MSH2-deficient cancer cells
32
 and is currently in 
clinical trials for MSH2-deficient colorectal cancers (www.clinicaltrials.gov; Identifier: 
NCT00952016). Inhibition of DNA polymerases, Pol B and Pol G, caused synthetic 
sickness or synthetic lethality in cancer cells deficient for MSH2 or MLH1, 
respectively.
32
 MMR-deficient colorectal cancer cells were also reported to be 
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preferentially sensitive to inhibitors of cytosine-based nucleoside analogs such as 
cytarabine,
33
 the PI3 kinase/Akt pathway,
34
 and the PTEN-induced putative kinase 
PINK1.
35
 A disadvantage of the synthetically lethal interactions identified is that in 
several cases, these appear to be specific for a single gene mutation (for example, 
MSH2), and do not necessarily apply to other deficiencies in the pathway. It remains to 
be determined whether the proposed mechanistic basis for these synthetically lethal 
interactions will translate to efficacy in patients with genotypic and phenotypic tumor 
heterogeneity. 
We previously considered targeting the end “state” of genomic instability.15 We 
have demonstrated that rhodium metalloinsertor compounds can bind DNA mismatches 
and preferentially inhibit the proliferation of MMR-deficient cells, including the MLH1-
deficient HCT116 colorectal cancer cell line.
16-19
 Here we verify and extend our previous 
observations by demonstrating, in a completely isogenic system, preferential sensitivity 
of cells induced for MMR deficiency to rhodium metalloinsertor compounds. The 
differential activity of the compounds in MMR-deficient cells correlates with their 
binding affinity to DNA mismatches in vitro.
17 
Recently, the differential cellular activity 
of these compounds has also been shown to correlate with their accumulation in the cell 
nucleus.
19
 Together, these observations support the model that rhodium metalloinsertor 
compounds act directly on DNA mismatches in genomic DNA. The metal complexes 
enter cells by passive diffusion and bind non-covalently to mismatched DNA due to the 
thermodynamic destabilization of mispaired nucleosides.
21
 This mechanism of 
mismatched base pair recognition is distinct from the checkpoint surveillance process 
normally used by cells, which involves proteins associated with the replication fork 
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during S phase.
36
 MMR-deficient cells show a 100- to 1000-fold increase in spontaneous 
mutation rate compared to that of MMR-proficient cells, which is estimated at 1 x 10
-9
 to 
1 x 10
-10 
per cell.
24,37
 It is provocative that the rhodium metalloinsertor compounds have 
the ability to recognize this number of DNA mismatches, and differentially inhibit the 
proliferation of MMR-deficient cells in vitro, in the context of ~6 billion correctly paired 
bases. We speculate that this differential effect may translate to even greater therapeutic 
benefit in vivo. 
4.5 Conclusion 
It is striking that the MLH1-deficient cells, which show increased resistance to 
DNA-damaging agents, are preferentially sensitive to rhodium metalloinsertor 
compounds.  We have observed differential effects for this class of compounds 
consistently across multiple experiments and in different assays for cell proliferation. The 
differential effect on cell proliferation observed with the rhodium metalloinsertor 
compounds cannot be explained simply by the growth rate of the MLH1-deficient NCI-
H23 subclones, which is similar for the MLH1-proficient and the MLH1-deficient cells. 
We do not yet understand the molecular mechanism of the preferential sensitivity of 
MMR-deficient cells to rhodium metalloinsertor compounds. The compounds might 
interfere with cellular DNA replication or transcription. However, the metal complexes 
bind noncovalently to mismatched DNA, suggesting that the compounds may dissociate 
during the DNA unwinding that occurs during replication. It is possible that the 
compounds might also associate with proteins adjacent to a DNA mismatch. 
Alternatively, the replication fork may not be able to synthesize through mismatched 
DNA bound with a metal complex. Current studies are focused on addressing these 
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hypotheses, and also on improving the potency and drug-like properties of the current 
series of rhodium metalloinsertor compounds for applications in cancer therapy. 
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Chapter 5: An Unusual Ligand Coordination Gives Rise to a New 
Family of Rhodium Metalloinsertors with Improved Selectivity and 
Potency 
5.1 Introduction 
 Recently in the Barton laboratory, a family of ten metalloinsertors with varying 
lipophilicites yet similar mismatch binding affinities was synthesized. Their abilities to 
preferentially target MMR-deficient cells over MMR-proficient cells were found to vary 
drastically.
 1
 One metalloinsertor in particular, [Rh(chrysi)(phen)(DPE)]
2+
 (Figure 5.1), 
was found to possess enhanced potency and selectivity compared to the others.  
Crystallization of the compound revealed the solid state structure shown in Figure 5.2; 
the DPE ligand was discovered to coordinate to the rhodium center via one pyridine ring 
and the alcohol oxygen, in contrast to all other previously reported metalloinsertors, 
which coordinate via two pyridine rings (Figure 5.3). It was hypothesized that this new 
ligand coordination environment was responsible for the enhanced biological activity of 
this compound, and we thus sought to synthesize a family of compounds inspired by this 
new ligand scaffold. 
 In this report, we describe the discovery of an unusual ligand coordination for the 
rhodium metalloinsertor [Rh(chrysi)(phen)(DPE)]
2+
 and subsequent development of a 
family of compounds based on this new type of ligand. The family of compounds has 
been found to possess enhanced potency and cell selectivity in our cell assays. All 
compounds have binding affinities that range from 2.6 to 5.5 x 10
6
 M
-1
, and, furthermore, 
it has been discovered that the amount of intracellular rhodium required for optimal 
biological activity for this family of compounds is ≥ 5 times lower than that of previously  
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Figure 5.1 Chemical structures and binding affinities for CC mismatches of all 
compounds studied.  
 166 
 
  
Figure 5.2 X-ray crystal structure of [Rh(chrysi)(phen)(DPE)]Cl2. Displacement of 
ellipsoids are drawn at 50% probability. For clarity, chloride atoms and hydrogen atoms 
(except immine protons) have been omitted. Selected bond lengths (Å): Rh-O 1.996, Rh-
N1 2.006, Rh-N2 1.987, Rh-N3 2.046, Rh-N4 2.059, Rh-N5 2.031. 
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Figure 5.3 X-ray crystal structure of [Rh(HDPA)2(chrysi)]Cl2. Displacement of ellipsoids 
are drawn at 50% probability. For clarity, chloride atoms and hydrogen atoms (except the 
immine proton) have been omitted. Selected bond lengths (Å): Rh-N1 2.002, Rh-N2 
1.974, Rh-N3 2.042, Rh-N5 2.045, Rh-N6 2.041, Rh-N8 2.114. 
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reported metalloinsertors (thus making them significantly more potent). Enantiomeric 
separation of [Rh(chrysi)(phen)(DPE)]
2+
 has led to the discovery that for this family, both 
 and  enantiomers bind to DNA with equal affinity and demonstrate comparable cell-
selective activity, hinting at a possible different DNA mismatch binding conformation 
than previous metalloinsertors. 
5.2 Experimental Protocols 
5.2.1 Materials 
Commercially available chemicals were used as received. All organic reagents 
and Sephadex ion-exchange resin were obtained from Sigma-Aldrich unless otherwise 
noted. Sep-pak C18 solid-phase extraction (SPE) cartridges were purchased from Waters 
Chemical Co. (Milford, MA). Media and supplements were purchased from Invitrogen 
(Carlsbad, CA). BrdU, antibodies, buffers, peroxidase substrate, MTT, and acidified lysis 
buffer (10% SDS in 10 mM HCl) solution were purchased in kit format from Roche 
Molecular biochemical (Mannheim, Germany). Phosphoramidites were purchased from 
Glen Research (Sterling, VA). 
5.2.2 Oligonucleotide Synthesis 
Oligonucleotides were synthesized on an Applied Biosystems 3400 DNA 
synthesizer using standard phosphoramidite chemistry. DNA was synthesized with a 5ʹ-
dimethoxytrityl (DMT) protecting group. The oligonucleotides were cleaved from the 
beads by reaction with concentrated ammonium hydroxide at 60° C overnight. The 
resulting free oligonucleotides were purified by HPLC using a C18 reverse-phase column 
(Varian, Inc.) on a Hewlett-Packard 1100 HPLC. The DMT group was removed by 
reaction with 80% acetic acid for 15 min at ambient temperature. The DMT-free 
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oligonucleotides were precipitated with absolute ethanol and purified again by HPLC. 
Positive identification of the oligonucleotides and their purity were confirmed by 
MALDI-TOF mass spectrometry. Quantification was performed on a Cary 100 Bio UV-
Visible Spectrophotometer using the extinction coefficients at 260 nm (ε260) estimated for 
single-stranded DNA. 
5.2.3 Synthesis and Characterization of Ligands and Metal Complexes 
The complexes [Rh(bpy)2(chrysi)]
3+
 and [Rh(HDPA)2(chrysi)]
3+
 were prepared 
according to published procedures.
2,3
 [Rh(chrysi)(phen)(NH3)2]
3+
 was prepared from 
[Rh(phen)(NH3)4]OTf3  and 5,6-chrysenequinone following an adaptation of the methods 
described by Mürner et. al (3.2.3.1).
4
 The ligand 1,1-di(pyridin-2-yl)ethanol (DPE) was 
synthesized according to an adaptation of published procedures (3.2.3.2).
5
 
[Rh(chrysi)(phen)(DPE)]
2+
 was synthesized as previously described (3.2.3.6).
1
 
5.2.3.1  1-R-1-(pyrid-2-yl) ethanol (R = phenyl, methyl, hexyl; 
PPE, PPO, PyOctanol) 
The appropriate ketone py(CO)(L) (8.3 mmol) was dissolved in dry diethyl ether 
(100 mL) in an oven-dried 250 mL schlenk flask under Ar. The solution was cooled to     
-     an  MeLi (12.9 mL of a 1.6M solution) was added slowly over 15 min. The 
resulting yellow solution was al o e  to sti  at -     fo    h and then warmed to ambient 
temperature. Next, saturated NH4Cl (aq) (30 mL) was added to quench the reaction, and 
the resulting solution was extracted with EtOAc (3 x 75 mL), dried over Na2SO4, and the 
solvent evaporated in vacuo. The crude product was purified via flash chromatography 
(SiO2, 1:1 EtOAc:CH2Cl2 for L=Me and hexyl, 1:3 EtOAc:CH2Cl2 for L=Ph) to afford a 
light yellow oil. 
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PPE: Yield: 97%. 
1
H NMR (CDCl3, 300 MHz): δ  .52 (  of m, J = 5.1 Hz, 1 H); 
7.65 (t of d, J = 7.8 Hz, 1.8 Hz, 1 H); 7.48 (m, 2H); 7.31 (m, 3H); 7.17-7.26 (m, 2H); 
5.85 (s, 1H); 1.94 (s, 3H). 
PPO: Yield: 55% 
1
H NMR NMR (CDCl3, 300 MHz): δ  .52 (  of m, J = 4.8 Hz, 
1 H); 7.71 (t of m, J = 7.8 Hz, 1 H); 7.38 (d of m, J = 8.1 Hz, 1H); 7.21 (t of m, J = 6.2 
Hz, 1H); 5.08 (s, 1H); 1.54 (s, 6H). 
PyOctanol: Yield: 35% 
1
H NMR NMR (CDCl3, 300 MHz): δ  .5  (d of m, J = 
6.0 Hz, 1 H); 7.71 (t of m, J = 9.0 Hz, 1 H); 7.32 (d of m, J = 9.0 Hz, 1H); 7.20 (t of m, J 
= 6.0 Hz, 1H); 5.18 (s, 1H); 1.78 (m, 2H); 1.51 (s, 3H); 1.19 (m, 6H); 0.82 (m, 5H). 
5.2.3.2  [Rh(chrysi)(phen)(L)]Cl2 (L = PPE, PPO, PyOctanol) 
[Rh(chrysi)(phen)(NH3)2]TFA3 (62.3 mg, 0.092 mmol) and L (0.138 mmol) were 
dissolved in 1:12 H2O:EtOH (90 mL). The resulting red solution  as heate  to      an  
allowed to reflux for 18 hours. The resulting solution was dried in vacuo, redissolved in 
H2O (10 mL), filtered, and purified via flash chromatography (C18-SiO2, 17:3 0.1% TFA 
(aq): MeCN). All compounds but [Rh(chrysi)(phen)(PyOctanol)]
2+
 were synthesized as a 
mixture of diasteriomers; only the diasteriomers of [Rh(chrysi)(phen)(DPE)]
2+
 were 
resolvable via HPLC (17:3 0.1% TFA (aq): MeCN to 1:1 0.1% TFA (aq): MeCN gradient 
over 45 m). The chloride salt can be obtained from a Sephadex QAE anion exchange 
column equilibrated with 0.1M MgCl2. 
 [Rh(chrysi)(phen)(PPE)]Cl2: Yield: 80%. ESI-MS (cation): m/z calc 736.2 (M - 
1H
+
), 368.6 (M
2+
), obs. 736.0, 368.8. UV-Vis (H2O, pH 7): 270 nm (165,800 M
-1
 cm
-1
), 
300 nm (56,300 M
-1
 cm
-1
), 430 nm (16,100 M
-1
 cm
-1
).  
1
H NMR (CD3CN, 600 MHz): δ 
15.45 (s, 1 H); 14.38 (s, 1 H); 11.76 (s, 1 H); 11.08 (s, 1 H); 9.71 (d, J = 5.2 Hz, 1H); 
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9.49 (d, J = 5.2 Hz, 1H); 9.12 (d, J = 5.6 Hz, 1H); 8.99 (d, J = 9.0 Hz, 1H); 8.94 (m, 2H); 
8.88 (m, 3H); 8.81 (d, J = 8.0 Hz, 1H); 8.46 (d, J = 8.0 Hz, 1H); 8.35-8.39 (m, 4H); 8.29-
8.33 (m, 3H); 8.20-8.25 (m, 4H); 8.14 (t, J = 8.0 Hz, 1H); 8.10 (m, 2H); 8.03 (m, 1H); 
7.99 (m, 1H); 7.92 (d, J = 7.5 Hz, 1H); 7.89 (d, J = 8.5 Hz, 1H); 7.83 (m, 1H);  7.68-7.80 
(m, 5H); 7.64 (m, 1H);  7.55-7.60 (m, 4H); 7.52 (m, 2H); 7.40 (d, J = 5.7 Hz, 1H); 7.28-
7.34 (m, 4H); 7.23 (t, J = 6.6 Hz, 1H); 7.16 (m, 3H); 6.61 (t, J = 6.6 Hz, 2H); 6.33 (t, J = 
6.6 Hz, 1H); 2.49 (s, 3H); 2.13 (s, 3H) (1:1 mixture of diasteriomers).  Crystals suitable 
for X-ray diffraction were obtained from vapor diffusion of diethyl ether into a 
concentrated solution of [Rh(chrysi)(phen)(PPE)]Cl2 dissolved in methanol. 
[Rh(chrysi)(phen)(PPO)]Cl2: Yield: 40%. ESI-MS (cation): m/z calc 674.1 (M - 
1H
+
), 337.6 (M
2+
), obs. 674.0, 337.7. UV-Vis (H2O, pH 7): 270 nm (122,400 M
-1
 cm
-1
), 
300 nm (41,600 M
-1
 cm
-1
), 430 nm (12,300 M
-1
 cm
-1
).   
1
H NMR (CD3 N, 500 MHz): δ 
13.29 (br s, 1.7 H); 11.68 (br s, 1 H); 9.61 (d, J = 5.2 Hz, 1H); 9.54 (d, J = 5.2 Hz, 1.7H); 
9.09 (d, J = 5.5 Hz, 1H); 8.93 (m, 5.4H); 8.88 (m, 2.7H); 8.30-8.42 (m, 12.5H); 8.26 (m, 
1H); 8.23 (m, 1.7H); 8.14 (m, 4.4H); 7.93-8.04  (m, 11.5H); 7.74-7.85 (m, 5.4H); 7.55 
(m, 4.4H); 7.49 (t, J = 8.0 Hz, 1H); 7.21 (m, 2H); 7.13 (m, 1H); 7.09 (m, 2.7H); 2.00 (s, 
3H); 1.96 (s, 5.1H); 1.67 (s, 3H); 1.66 (s, 5.1H); (1:1.7 mixture of diasteriomers). 
Crystals suitable for X-ray diffraction were obtained from vapor diffusion of diethyl ether 
into a concentrated solution of [Rh(chrysi)(phen)(PPO)]Cl2 dissolved in isopropanol. 
[Rh(chrysi)(phen)(PyOctanol)]Cl2: Yield: 10%. ESI-MS (cation): m/z calc 
744.2 (M - 1H
+
), 372.6 (M
2+
), obs. 744.1, 372.8. ). 
1
H NMR (CD3 N, 500 MHz): δ  5.00 
(s, 1 H); 12.80 (s, 1 H); 9.55 (d, J = 5.0 Hz, 1H); 9.12 (d, J = 8.0 Hz, 1H); 9.09 (d, J = 5.5 
Hz, 1H); 8.94 (d, J = 8.9 Hz, 1H); 8.88 (d, J = 8.5 Hz, 1H); 8.85 (d, J = 8.5 Hz, 1H); 
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8.32-8.44 (m, 5H); 8.17 (m, 2H); 8.08 (m, 1H);  7.91 (t, J = 7.0 Hz, 1H); 7.86 (t, J = 8.0 
Hz, 1H); 7.80 (m, 2H); 7.54 (t, J = 7.5 Hz, 1H); 7.41 (d, J = 8.0 Hz, 1H); 7.31 (d, J = 6.0 
Hz, 1H); 7.05 (t, J = 7.0 Hz, 1H); 1.74 (s, 3H); 1.55 (m, 2H); 0.71-0.96 (m, 11H).  
Crystals suitable for X-ray diffraction were obtained from vapor diffusion of 
diethyl ether into a concentrated solution of [Rh(chrysi)(phen)(DPE)]Cl2 dissolved in 
ethanol. 
Crystals of [Rh(HDPA)2(chrysi)]Cl2 (one chrysi immine deprotonated) suitable 
for X-ray diffraction were obtained from vapor diffusion of diethyl ether into a 
concentrated solution of [Rh(HDPA)2(chrysi)]Cl2 dissolved in ethanol. 
  5.2.3.3  Enantiomeric Separation 
1.5 mL of a 2 mM solution of [Rh(chrysi)(phen)(DPE)]
2+
 was injected, 30 L at a 
time, onto an Astec® CYCLOBOND® I 2000 Chiral HPLC Column that was heated to 
40
o
 C. An isocratic method of 50% acetonitrile, 50% 100 mM KPF6 was used to separate 
the two enantiomers. An automatic fraction collector was used to collect each peak 
separately. The resulting dilute solutions were loaded onto a SPE cartridge and rinsed 
with copious amount of 0.1% TFA(aq). The SPE cartridge was eluted with 10% 
acetonitrile in 0.1% TFA(aq). The chloride salts were obtained from a Sephadex QAE 
anion exchange column equilibrated with 0.1M MgCl2. Circular dichroism spectra were 
taken on an Aviv 62DS spectropolaarimeter in a 1 mm path length cell. 
 5.2.4 X-Ray Structure Determination 
 5.2.4.1  [Rh(HDPA)2(chrysi)]Cl2 
Low-temperature diffraction data (-and -scans) were collected on a Bruker 
Kappa diffractometer coupled to a Apex II CCD detector with graphite monochromated 
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Mo K radiation ( = 0.71073 Å) for the structure of [Rh(HDPA)2(chrysi)]Cl2.  The 
structure was solved by direct methods using SHELXS
6
 and refined against F
2
 on all data 
by full-matrix least squares with SHELXL-2013
7
 using established refinement 
techniques.
8
  All non-hydrogen atoms were refined anisotropically.  All hydrogen atoms 
were included into the model at geometrically calculated positions and refined using a 
riding model.  The isotropic displacement parameters of all hydrogen atoms were fixed to 
1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups).   
[Rh(HDPA)2(chrysi)]Cl2 crystallizes in the monoclinic space group P21/n with 
one molecule in the asymmetric unit along with two molecules of methanol.  One of the 
two chloride ions was disordered over two positions and refined with the help of 
similarity restraints on the displacement parameters.  The occupancies of the two 
components refined to 0.930(4):0.070(4).  The coordinates for the hydrogen atoms bound 
to N1, N4, N7, O1S, O1T, and O1W were located in the difference Fourier synthesis and 
refined semi-freely with the help of a distance restraint.  The N-H distances were 
restrained to be 0.91(4) Å for N1, 0.88(4) Å for N4, N7 and 0.84(4) Å for all O-H bonds.  
 5.2.4.2  [Rh(chrysi)(phen)(DPE)]Cl2 
Low-temperature diffraction data (-and -scans) were collected on a Bruker 
Kappa diffractometer coupled to an Apex II CCD detector with graphite-monochromated 
Mo K radiation ( = 0.71073 Å) for the structure of [Rh(chrysi)(phen)(DPE)]Cl2.  The 
structure was solved by direct methods using SHELXS
6
 and refined against F
2
 on all data 
by full-matrix least squares with SHELXL-2013
7
 using established refinement 
techniques.
8
  All non-hydrogen atoms were refined anisotropically.  Unless otherwise 
noted, all hydrogen atoms were included into the model at geometrically calculated 
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positions and refined using a riding model.  The isotropic displacement parameters of all 
hydrogen atoms were fixed to 1.2 times the U value of the atoms they are linked to (1.5 
times for methyl groups).   
[Rh(chrysi)(phen)(DPE)]Cl2 crystallizes in the triclinic space group P ̅with one 
molecule in the asymmetric unit along with two chloride anions, two waters, and two 
molecules of ethanol.  Each of the ethanol molecules were disordered over three 
positions.  They were refined with the help of similarity restraints on the 1,2- and 1,3- 
distances and displacement parameters as well as rigid bond restraints for anisotropic 
displacement parameters.  The occupancies of the two disordered ethanol molecules were 
freely refined to 0.509(3):0.261(3):0.229(3) and 0.453(3):0.295(3):0.252(3), respectively.  
Additional residual electron density is located near each of the disordered ethanol 
molecules.  However, the refinement of additional ethanol positions was unsuccessful, 
and the current model represents the best model which led to a stable refinement. The 
coordinates for the hydrogen atoms bound to N1, N2, O1W and O2W were located in the 
difference Fourier synthesis and refined semi-freely with the help of a distance restraint.  
The N-H and O-H distances were restrained to be 0.88(4) Å and 0.84(4) Å, respectively.  
The hydrogen atoms bound to oxygen in the ethanol molecules could not be found and 
were included at geometrically calculated positions and refined using a riding model. 
 5.2.4.3  [Rh(chrysi)(phen)(PPE)]Cl2 
  Low-temperature diffraction data (-and -scans) were collected on a 
Bruker Kappa diffractometer coupled to an Apex II CCD detector with graphite-
monochromated Mo K radiation ( = 0.71073 Å) for the structure of 
[Rh(chrysi)(phen)(PPE)]Cl2.  The structure was solved by direct methods using 
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SHELXS
6
 and refined against F
2
 on all data by full-matrix least squares with SHELXL-
2013
8
 using established refinement techniques.
8
  All non-hydrogen atoms were refined 
anisotropically.  Unless otherwise noted, all hydrogen atoms were included into the 
model at geometrically calculated positions and refined using a riding model.  The 
isotropic displacement parameters of all hydrogen atoms were fixed to 1.2 times the U 
value of the atoms they are linked to (1.5 times for methyl groups).  All disordered atoms 
were refined with the help of similarity restraints on the 1,2-distances and displacement 
parameters as well as rigid bond restraints for anisotropic displacement parameters.   
[Rh(chrysi)(phen)(PPE)]Cl2 crystallizes in the triclinic space group P ̅ with one 
molecule in the asymmetric unit along with two chloride anions and four molecules of 
methanol.  One of the methanol molecules hydrogen-bonds to the ruthenium molecule 
and was not disordered.  The three other methanol molecules were modeled as 
disordered.  For the second methanol, only the methyl group was disordered over two 
positions with the occupancy of the two components refined to 0.841(7):0.159(7).  The 
third methanol was completely disordered over two positions with occupancies of 
0.792(6):0.208(6).  The fourth methanol was disordered over three positions with 
occupancies 0.0615(3):0.234(3):0.151(3).  The coordinates for the hydrogen atoms bound 
to N1, N2, and O1M were located in the difference Fourier synthesis and refined semi-
freely with the help of a distance restraint.  The N-H and O-H distances were restrained 
to be 0.88(4) Å and 0.84(4) Å, respectively.  The hydrogen atoms for the remaining 
methanol positions could not be located and were included at geometrically calculated 
positions and refined using a riding model.   
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 5.2.4.4  [Rh(chrysi)(phen)(PPO)]Cl2 
Low-temperature diffraction data (-and -scans) were collected on a Bruker 
three-circle diffractometer coupled to a Bruker Smart 1000 CCD detector with graphite 
monochromated Mo K radiation ( = 0.71073 Å) for the structure of compound ack013.  
The structure was solved by direct methods using SHELXS
6
 and refined against F
2
 on all 
data by full-matrix least squares with SHELXL-2013
7
 using established refinement 
techniques.
8
  All non-hydrogen atoms were refined anisotropically.  All hydrogen atoms 
were included into the model at geometrically calculated positions and refined using a 
riding model.  The isotropic displacement parameters of all hydrogen atoms were fixed to 
1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups).   
Compound ack013 crystallizes in the triclinic space group P ̅ with one molecule 
in the asymmetric unit along with two chloride anions, one molecule of diethyl ether, and 
one molecule of isopropyl alcohol.  The coordinates for the hydrogen atoms bound to N1, 
N2, and O1T were located in the difference Fourier synthesis and refined semi-freely 
with the help of a distance restraint.  The N-H and O-H distance were restrained to be 
0.88(4) Å and 0.84(4) Å, respectively. 
5.2.5 Metalloinsertor pH Titrations 
25 M solutions of [Rh(chrysi)(phen)(DPE)]2+ or [Rh(HDPA)2(chrysi)]
3+
 (3 mL, 
in 0.1 M NaCl) were prepared and absorption-spectra measured on a Cary 100 Bio UV-
Visible Spectrophotometer. The pHs of the solutions and their blanks were adjusted (and 
monitored by an internal electrode) from approximately 4.5 to 10.5 and back via titration 
with either 6mM NaOH or 10 mM HCl. After each acid or base addition, an absorption 
spectrum was taken. A single wavelength was selected for each metal complex where a 
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large change was observed over the course of the titration. The absorbance at this 
wavelength was then plotted as a function of pH to generate a titration curve. The pKa of 
each metal complex was determined from the inflection point of this sigmoidal curve. 
The data from three separate experiments were pooled to determine average pKa values. 
In addition, 25 M solutions of 1:1 [Rh(chrysi)(phen)(DPE)]2+:DNA or 
[Rh(HDPA)2(chrysi)]
3+
:DNA (3 mL, in 100 mM NaCl, 20 mM NaPi, pH 7.1 buffer) were 
prepared and absorption-spectra measured on a Cary 100 Bio UV-Visible 
Spectrophotometer. The DNA hairpin 5ʹ-GGCAGGCATGGCTTTTTGCCATCCCTGCC 
- 3ʹ (underline denotes the CC mismatch) was used. 
5.2.6 Photocleavage Competition Titrations 
The oligonucleotide 3ʹ - GCG ATG CAG ATA TAC CTA CTA GGA TTC ACT 
GTC ATG-5ʹ was 32P-labeled at the 5ʹ-end by incubating DNA with 32P-ATP and 
polynucleotide kinase (PNK) at 37°C for 2 h, followed by purification using gel 
electrophoresis. A small amount of the labeled DNA (less than 1% of the total amount of 
DNA)  as a  e  to 2 μM unlabeled DNA and its corresponding unlabeled complement 
(with a CC mismatch incorporated at the underlined site)  in 100 mM NaCl, 20 mM NaPi, 
pH 7.1 buffer. The duplex DNA was annealed by heating at 90°C for 10 min and cooling 
slowly to ambient temperature over a period of 2 h. Solutions of non-photocleaving 
rhodium complex ranging from nanomolar to micromolar concentration, as well as a 4 
μM [Rh(bpy)2(chrysi)]
3+
 solution were made in Milli-Q  ate . Annea e  2 μM DNA ( 0 
μL), 4 μM [Rh(bpy)2(chrysi)]
3+
 (5 μL), an  5 μL of non-photocleaving Rh solution at 
each concentration were mixed in a microcentrifuge tube and incubated at 37 °C for 10 
min. A  ight cont o  (ØRh), in  hich the DNA  as mixe   ith  0 μL of  ate  an  
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i  a iate , an  a  a k cont o  (Øhν), in  hich the DNA  as mixe   ith the highest 
concentration of rhodium complex without irradiation, were also prepared. The samples 
were then irradiated on an Oriel (Darmstadt, Germany) 1000-W Hg/Xe solar simulator 
(340-440 nm) for 15 min. The samples were dried and electrophoresed in a 20% 
denaturing polyacrylamide gel. The gel was then exposed to a phosphor screen, and the 
relative amounts of DNA in each band were quantitated by phosphorimagery 
(ImageQuant). 
5.2.6.1  Binding Constant Determination 
The fraction of DNA cleaved in each lane on the gel (See Figure 5.4 for a typical 
autoradiogram) was normalized and plotted against the log of the concentration of 
rhodium complex. The data were fit to a sigmoidal curve using OriginPro 6.1 (Figure 
5.5). The resulting midpoint value (i.e., the log of [rhodium complex] at the inflection 
point of the curve) was converted to units of concentration ([Rh50%]). The binding and 
dissociation constants of the non-photocleaving complex were calculated by solving 
simultaneous equlibria involving DNA, [Rh(bpy)2(chrysi)]
3+
, and the complex in 
question in Mathematica 6.0. The data from at least three photocleavage titrations were 
averaged for each metal complex to give an average binding affinity. 
5.2.7 Covalent DNA binding assay 
A 6.0 M solution (250 L) of the DNA hairpin 5ʹ-
GGCAGGCATGGCTTTTTGCCATCCCTGCC-3ʹ (underline denotes the CC mismatch) 
in either in 100 mM NaCl, 20 mM NaPi, pH 7.1 buffer or 100 mM NaCl, 20 mM NaPi, 5 
mM glutathione buffer (to mimic the reducing environment of the cell) was added to a 
6.0 M solution of [Rh(bpy)2(chrysi)]
3+
, [Rh(HDPA)2(chrysi)]
3+
, or  
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Figure 5.4 Binding affinities determined through DNA photocleavage. The DNA 
sequence is as shown (red denotes the mismatch, asterisk denotes the radiolabel). 
Samples were irradiated and electrophoresed through a 20% denaturing PAGE gel. A 
 ight cont o  (ØRh,  ithout  ho ium) an   a k cont o  (Øhν,  ithout i  a iation)  ere 
included. A representative autoradiogram of a photocleavage competition titration 
bet een   μM rac-[Rh(bpy)2(chrysi)]
3+
 and 0- 00 μM [Rh(ch ysi)(phen)(PPO)]2+ is 
shown. Arrow indicates the position of the mismatch. 
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Figure 5.5 Representative sigmoidal curve for binding affinity determination. Shown is a 
plot of data from the photocleavage competition titration between 1 μM rac-
[Rh(bpy)2(chrysi)]
3+
 and 0- 00 μM [Rh(ch ysi)(phen)(PPO)]3+ shown in Figure 5.4 for 
binding constant determination. 
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[Rh(chrysi)(phen)(PPE)]
2+ 
(250 L). The resulting solution was allowed to incubate at 
37
o
 C for 30 min, followed by a 10-min incubation at 90
o
 C. A 3.0 M solution of NaOAc 
(50 L) was added, followed by EtOH (1.5 mL) in order to precipitate the DNA. The 
resulting solution was vortexed and incubated on dry ice for 1.5 h, after which time it was 
spun at 14,000 rpm for 12 min. The supernatant was discarded, and the pellet dissolved in 
water (100 L). A 3.0 M solution of NaOAc (10 L) was added, followed by EtOH (300 
L) in order to precipitate the DNA. The resulting solution was vortexed and incubated 
on dry ice for 1.5 h, after which time it was spun at 14,000 rpm for 12 min. The 
supernatant was discarded, and the pellet dissolved in water (500 L). An electronic 
absorption (UV-Vis) spectrum was then taken of the resulting solution on a Cary 100 Bio 
UV-Visible Spectrophotometer. 
5.2.8 Circular Dichroism Study of -[Rh(chrysi)(phen)(DPE)]2+ Bound to 
Mismatched DNA 
50.0 M solutions of the DNA hairpin 5ʹ-
GGCAGGCATGGCTTTTTGCCATCCCTGCC-3ʹ (underline denotes the CC mismatch) 
and - and -[Rh(chrysi)(phen)(DPE)]2+ (200 L in 100 mM NaCl, 20 mM NaPi, pH 7.1 
buffer) were prepared ,and CD spectra were taken on an Aviv 62DS spectropolarimeter in 
a 1 mm path length cell. 100 L of each metal complex solution was then added to 100 
L of the DNA solution, and CD spectra were immediately recorded. After 30 m, 
additional CD spectra were recorded to confirm that no changes in the spectra occurred. 
5.2.9 Cell Culture 
HCT116N and HCT116O cells were grown in RPMI medium 1640 supplemented 
with: 10% FBS; 2 mM L-glutamine; 0.1 mM nonessential amino acids; 1 mM sodium 
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py uvate;  00 units/mL penici  in;  00 μg/mL st eptomycin; an  400 μg/mL Geneticin 
(G418). Cells were grown in tissue culture flasks (Corning Costar, Acton, MA) at 37 °C 
under 5% CO2 and humidified atmosphere.  
5.2.9.1  Cellular Proliferation ELISA 
HCT116N and HCT116O cells were plated in 96-well plates at 2000 cells/well 
and allowed 24 h to adhere. The cells were then incubated with rhodium for the 
concentration and durations specified. For incubations less than 72 h, the Rh-containing 
media was replaced with fresh media, and the cells were grown for the remainder of the 
72-h period. Cells were labeled with BrdU 24 h before analysis. The BrdU incorporation 
was quantified by antibody assay according to established procedures.
9
 Cellular 
proliferation was expressed as the ratio of the amount of BrdU incorporated by the treated 
cells to that of the untreated cells. 
5.2.9.2  MTT Cytotoxicity Assay 
Cytotoxicity assays were performed as described in the literature.
10
 HCT116N 
and HCT116O cells were plated in 96-well plates at 50,000 cells/well and incubated with 
rhodium for the durations specified. After rhodium incubation, cells were labeled with 
MTT for 4 h at 37°C under 5% CO2 and humidified atmosphere. The resulting formazan 
crystals were dissolved with solubilizing reagent purchased from Roche according to the 
manufactu e ’s inst uctions. The  isso ve  fo mazan  as quantifie  as the abso bance at 
570 nm minus the background absorbance at 690 nm. Percent viability was determined as 
the ratio of the amount of formazan in the treated cells to that of the untreated cells. 
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5.2.9.3  Cell Death Mode Flow Cytometry Assay 
Cell death was characterized by a dye exclusion assay.
11
 After 24-, 48-, or 72-h 
incubation with rhodium, cells were harvested from adherent culture by trypsinization, 
washed with cold PBS, and centrifuged at 2,000 rpm for 5 minutes.  The resultant pellets 
were resuspended in PBS to a concentration of 10
6
 cells/mL and stained with propidium 
iodide to a final concentration of 1µg/mL and with YO-PRO-1 to a final concentration of 
50 nM for 30 minutes prior to analysis by flow cytometry. 
5.2.10 ICP-MS Assay for Whole-Cell Rhodium Levels 
HCT116O cells were plated at 1x10
6
 cells/well in a 6 well plate. The cells were 
a  o e  24 h to a he e, then t eate   ith  0 μM [Rh(HDPA)2(chrysi)]Cl3, 5 μM 
[Rh(chrysi)(phen)(DPE)]Cl2,    μM [Rh(ch ysi)(phen)(PPE)]  2, o  0.5 μM 
[Rh(chrysi)(phen)(PPO)]Cl2. After 24 h, the media was decanted, the cell monolayer 
 ashe   ith 3 mL PBS, an  the ce  s  yse   ith  00 μL of  % SDS. The ce    ysate  as 
sonicated on a Qsonica U t asonic p ocesso  fo   0 sec at 20% amp itu e.  50 μL of the 
 ysate  as then combine   ith  50 μL of a 2% HNO3 (v/v) solution, while the remainder 
of the lysate was quantified for protein by a bicinchoninic assay (BCA).
12
 The 1% HNO3 
solution was analyzed for rhodium content on an HP-4500 ICP-MS unit. Rhodium counts 
were normalized to the amount of protein determined from the BCA analysis (to obtain 
ng [Rhodium]/mg [protein] values). Standard errors for three independent experiments 
are shown. The experiment was repeated with HCT116N cells to verify similar uptake of 
rhodium by the two cell lines. 
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5.3 Results 
 5.3.1 Synthesis and Characterization of Compounds 
 Single crystals of [Rh(chrysi)(phen)(DPE)]Cl2 were grown from a vapor diffusion 
of diethyl ether into a concentrated solution of the complex in ethanol. The solved 
structure revealed the DPE ligand to coordinate via an oxygen instead of the second 
pyridine nitrogen. In order to assess the generality of this coordination environment (and 
determine if the solid state structure of [Rh(chrysi)(phen)(DPE)]Cl2 is the same as its 
solution structure), we synthesized a phenyl (PPE) derivative and a methyl (PPO) 
derivative. Both ligands are notable in their lack of a second nitrogen to coordinate to the 
rhodium center. These new compounds can be synthesized via analogous methods and in 
decent yields. Single crystals grown of both compounds confirmed the generality of this 
unusual ligand coordination (Figure 5.6 and Figure 5.7). 
 These compounds were also designed to ascertain the importance of both the 
ligand coordination environment (the presence of a Rh-O bon ) an  the bu ky “ ang ing” 
pyridine group with regards to the enhanced potency and cell-selective activity of the 
parent compound. An additional compound with a greasy hexyl group appended to this 
ligand scaffold was also synthesized to assess the effects of lipophilicity on the biological 
activity of this family of compounds. 
 In order to determine the acidity constants of the immine protons in 
[Rh(chrysi)(phen)(DPE)]
2+
 as compared to [Rh(HDPA)2(chrysi)]
3+
, pH spectroscopic 
titrations were performed. It has previously been demonstrated that the visible absorbance 
changes which occur as the pH of a rhodium complex solution is titrated can be used for 
the determination of the pK values of the compounds.
13
 As can be seen in Figure 5.8 and  
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Figure 5.6 X-ray crystal structure of [Rh(chrysi)(phen)(PPE)]Cl2. Displacement of 
ellipsoids are drawn at 50% probability. For clarity, chloride atoms and hydrogen atoms 
(except immine protons) have been omitted. Selected bond lengths (Å): Rh-O 1.983, Rh-
N1 1.991, Rh-N2 1.993, Rh-N3 2.053, Rh-N4 2.037, Rh-N5 2.034. 
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Figure 5.7 X-ray crystal structure of [Rh(chrysi)(phen)(PPO)]Cl2. Displacement of 
ellipsoids are drawn at 50% probability. For clarity, chloride atoms and hydrogen atoms 
(except immine protons) have been omitted. Selected bond lengths (Å): Rh-O 1.973, Rh-
N1 1.980, Rh-N2 1.994, Rh-N3 2.039, Rh-N4 2.067, Rh-N5 2.041. 
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Figure 5.8 pH titration of [Rh(HDPA)2(chrysi)]
3+
. Shown are absorption spectra of a 25 
M solution of [Rh(HDPA)2(chrysi)]
3+
 as the pH changes from 4.5 (red) to 8.5 (purple). 
The black arrows exhibit the direction in which the various bands change as the pH 
increases. (Inset) The absorbance at 445 nm was plotted as a function of pH and fit to a 
sigmoidal curve. The pKa was determined from the inflection point of this curve. 
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Figure 5.9, as the pH of the solution increases from 4.5 to 10.5, the band around 440 nm 
(which corresponds to an MLCT from the Rh center to the chrysi ligand) undergoes a 
blue shift. When the absorbance at the max of this band is plotted as a function of pH, a 
titration curve can be constructed, and the pKa value of each metal complex is determined 
from the inflection point of the curve (Figure 5.8 and Figure 5.9, insets). The pKa values 
for [Rh(HDPA)2(chrysi)]
3+
 and [Rh(chrysi)(phen)(DPE)]
2+
 are 7.0 ± 0.5 and 8.7 ± 0.2, 
respectively. This reflects a difference in equilibrium constants of almost 2 orders of 
magnitude, quite possibly due to the negative charge of the DPE ligand as compared to 
HDPA. 
 In order to ascertain the protonation state of [Rh(chrysi)(phen)(DPE)]
2+
 and 
[Rh(HDPA)2(chrysi)]
3+
 upon DNA binding, mismatched DNA was added to both 
compounds in a 1:1 ratio and absorption spectra recorded. As can be seen in Figure 5.10, 
[Rh(chrysi)(phen)(DPE)]
2+
 binds to mismatched DNA with a fully protonated chrysi 
ligand. On the basis of the hypochromicity, it is clear that the chrysi ligand is pi-stacking 
with the DNA bases. In appears that with [Rh(HDPA)2(chrysi)]
3+
, on the other hand, 
there are a mixture of protonation states upon DNA binding. The 400 nm that 
corresponds to the deprotonated species has a much larger hypochromicity than the 445 
nm band. 
All three crystallographically characterized compounds are synthesized as a 
mixture of diasteriomers (See NMR characterization), and only the diasteriomers of 
[Rh(chrysi)(phen)(DPE)]
2+
 were able to be resolved via HPLC. Therefore, this compound 
was chosen for enantiomeric studies. The enantiomers of [Rh(chrysi)(phen)(DPE)]
2+
 
were resolved via HPLC and characterized via circular dichroism spectroscopy (Figure  
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Figure 5.9 pH titration of [Rh(chrysi)(phen)(DPE)]
2+
. Shown are absorption spectra of a 
25 M solution of [Rh(chrysi)(phen)(DPE)]2+as the pH changes from 5.5 (red) to 10.2 
(purple). The black arrows exhibit the direction in which the various bands change as the 
pH increases. (Inset) The absorbance at 440 nm was plotted as a function of pH and fit to 
a sigmoidal curve. The pKa was determined from the inflection point of this curve. 
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Figure 5.10 Absorption spectra of [Rh(chrysi)(phen)(DPE)]
2+
 and 
[Rh(HDPA)2(chrysi)]
3+
 bound to mismatched DNA. Shown in blue are absorption spectra 
of 25 M solutions of [Rh(chrysi)(phen)(DPE)]2+ and [Rh(HDPA)2(chrysi)]
3+
 with 25 
M of the DNA hairpin 5ʹ-GGCAGGCATGGCTTTTTGCCATCCCTGCC-3ʹ (underline 
denotes the CC mismatch). The absorption spectra of the fully protonated species are 
shown in green, those of the fully deprotonated species are in purple, and those of the 
compounds at pH 7.1 with no DNA are shown in red. 
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5.11). HPLC analysis of the purified fractions confirmed >95% ee of the  isomer, and 
~90% ee of the  isomer (data not shown). Furthermore, the enantiomers are stable in 
aqueous solution for up to 1 month; no interconversion of the enantiomers is observed in 
either neutral buffer or buffer with 5 mM glutathione. 
5.3.2 Binding Affinities for Metal Complexes at Single Base Mismatches 
 The new family of compounds promotes no DNA cleavage upon irradiation, and, 
as such, their binding affinities were determined through binding competition titrations 
 ith   μM rac-[Rh(bpy)2(chrysi)]
3+
, which does cleave DNA upon irradiation.
14-16
 A 
synthetic 36-mer oligonucleotide was synthesized with a complement featuring a cytosine 
across from a central cytosine (underlined) to form a mismatched strand of duplex DNA: 
3ʹ - GCG ATG CAG ATA TAC CTA CTA GGA TTC ACT GTC ATG - 5ʹ. A 
representative photocleavage titration can be found in Figure 5.3. The degree of 
photocleavage can be plotted against the log([Rh]) and fit to a sigmoidal curve (Figure 
5.4). On the basis of the binding constant of [Rh(bpy)2(chrysi)]
3+
, the binding constants 
of all subsequent complexes are then determined by solving simultaneous equilibria at the 
inflection point of the photocleavage titration curve. The results are shown in Figure 5.1. 
All racemic mixtures of compounds exhibit binding affinities within a factor of two of 
each other, varying from 2.6 to 5.5 x 10
6
 M
-1
. Most interesting, however, is the 
observation that the two enantiomers of [Rh(chrysi)(phen)(DPE)]
2+
 bind to mismatched 
DNA with the same affinity (6.0 x 10
6
 M
-1
 and 5.7 x 10
6
 M
-1
 for  and , respectively). 
This is in direct contrast to [Rh(bpy)2(chrysi)]
3+ 
, in which only the  isomer binds to 
mismatched DNA.
14
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Figure 5.11 Circular dichroism (CD) spectra of - and - [Rh(chrysi)(phen)(DPE)]2+ in 
water (blue and red, respectively). values for - [Rh(chrysi)(phen)(DPE)]2+: 229 nm 
(77 M
-1
 cm
-1
), 262 nm (46 M
-1
 cm
-1
), 277 nm (-64 M
-1
 cm
-1
), 295 nm (-21 M
-1
 cm
-
1
).values for - [Rh(chrysi)(phen)(DPE)]2+: 229 nm (-82 M-1 cm-1), 262 nm (-53 M-1 
cm
-1
), 277 nm (61 M
-1
 cm
-1
), 295 nm (22 M
-1
 cm
-1
). 
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In order to ascertain if racemization of the two enantiomers occurs upon DNA 
binding, circular dichroism spectra were taken of the two enantiomers before and after 
addition to mismatched DNA. As can be seen in Figure 5.12, the CD spectra of the two 
metalloinsertor-mismatched DNA complexes are distinct from each other, even after 30 
m of incubation (the average time frame of a competition gel titration, wherein both 
enantiomers bind to DNA). This confirms that both enantiomers bind to mismatched 
DNA without racemization. 
 5.3.3 Covalent DNA Binding 
 The ability of [Rh(chrysi)(phen)(PPE)]
2+
 to bind covalently to DNA was assessed 
via UV-Vis spectroscopy. In the event that the Rh-O bond is labile, it is possible for the 
complexes to bind covalently to DNA. In order to determine if covalent binding occurs, 
[Rh(bpy)2(chrysi)]
3+
, [Rh(HDPA)2(chrysi)]
3+
, or [Rh(chrysi)(phen)(PPE)]
2+
 were 
incubated with mismatched DNA under either neutral conditions (phosphate buffer), or a 
reducing environment (5 mM gluthathione in phosphate buffer) for 30 min. The DNA 
was then denatured in order to release any noncovalently attached rhodium complex and 
precipitated out of solution. UV-Vis spectra of the various samples of precipitated DNA 
revealed no covalent DNA binding by any of the three complexes (Figure 5.13) under 
either neutral or reducing conditions; covalent DNA binding would result in a 
characteristic rhodium metalloinsertor MLCT band around 400 nm. Furthermore, the 
absorbance at 260 nm of the various samples confirmed comparable yields of DNA 
precipitation.  
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Figure 5.12 Circular dichroism (CD) spectra of - and - 
[Rh(chrysi)(phen)(DPE)]
2+
  bound to mismatched DNA. Shown are spectra of 25 M 
solutions of - and - [Rh(chrysi)(phen)(DPE)]2+ in 100 mM NaCl, 20 mM NaPi, pH 7.1 
buffer bound to the DNA hairpin 5ʹ-GGCAGGCATGGCTTTTTGCCATCCCTGCC-3ʹ 
(underline denotes the CC mismatch), and the DNA hairpin alone ( in blue,  in red, 
DNA alone in grey). 
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Figure 5.13 Assessment of the ability of [Rh(chrysi)(phen)(PPE)]
2+
 to bind covalently to 
mismatched DNA. A 29-mer hairpin with a CC mismatch was incubated with water, 
[Rh(chrysi)(phen)(PPE)]
2+
, [Rh(bpy)2(chrysi)]
3+
, or [Rh(HDPA)2(chrysi)]
3+
 (latter two 
compounds were included as control compounds that do not covalently bind to DNA). 
Following DNA melting and precipitation, a UV-Vis spectra was taken of the various 
samples. The absence of a band around 400 nm (indicated with red arrow) indicates that 
no Rh complex was still bound (this MLCT band is a characteristic band in all Rh-chrysi 
compounds). 
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5.3.4 Quantitation of Inhibition of Cellular Proliferation using an Enzyme-
Linked Immunosorbent Assay (ELISA) 
 An ELISA for DNA synthesis was used to quantify the effects of the new 
family of metalloinsertors on the proliferation of HCT116N cells (MMR-proficient) and 
HCT116O cells (MMR-deficient). Both cell lines were incubated with the concentrations 
of compounds shown in Figure 5.14. The compound [Rh(HDPA)2(chrysi)]
3+
 was 
included  as a control with which to compare the potencies and cell-selectivities of the 
new compounds. Cisplatin (cis- diamminedichloroplatinum) and MNNG 
(methylnitronitrosoguanidine) were also included as prototypical, FDA-approved 
chemotherapeutic agents that exhibit decreased effectiveness against MMR-deficient 
cancer cells.
17
  Incubations were performed for 24 h, after which time the medium 
containing the chemotherapeutic was replaced with fresh medium, and the cells were 
grown for the remainder of the 72-h period. The extent of cellular proliferation is 
expressed as the ratio of BrdU incorporated by the treated cells as compared to untreated 
controls. Furthermore, we define differential inhibition as the difference in BrdU 
incorporation between the HCT116N and HCT116O cells. The results are shown in 
Figure 5.14. 
Clearly, the new family of compounds has significantly enhanced potency as 
compared to the earlier generation metalloinsertor; concentrations required for optimal 
differential activity are reduced from 10 M for [Rh(HDPA)2(chrysi)]
3+
 (our previously 
most potent compound) to 3 M ([Rh(chrysi)(phen)(DPE)]2+), 1 M 
([Rh(chrysi)(phen)(PPE)]
2+
), and 300 nM ([Rh(chrysi)(phen)(PPO)]
2+
). These 
compounds are also more potent than the FDA-approved chemotherapeutics in these  
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Figure 5.14 Inhibitory effects of rac-[Rh(chrysi)(phen)(DPE)]
2+
, rac-
[Rh(chrysi)(phen)(PPE)]
2+
, rac-[Rh(chrysi)(phen)(PPO)]
2+
, [Rh(HDPA)2(chrysi)]
3+
, 
MNNG, and cisplatin. Shown are plots of BrdU incorporation (a measure of DNA 
synthesis and therefore cellular proliferation) normalized to the BrdU incorporation of 
untreated cells as a function of rhodium concentration. Standard error bars for five trials 
are shown. 
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assay conditions, which require 4 M and 6 M for optimal biological activity of MNNG 
and cisplatin, respectively. In addition, the enhanced cell-selectivity that was observed 
previously with [Rh(chrysi)(phen)(DPE)]
2+
 is conserved across the entire family. At their 
optimal concentrations, their differential inhibition are 55 ± 2%, 53 ± 7%, and 62 ± 2% 
for the DPE, PPE, and PPO derivatives, respectively. These MMR-deficient cell-
selectivities far surpass the MMR-proficient cell-selectivity of cisplatin (25 ± 3%), which 
translates to drug resistance in the clinic, an issue that is currently a major epidemic with 
respect to cancer treatment.
18
 
5.3.5 MTT Cytotoxicity Assay 
The cytotoxic effects of all compounds were determined by MTT assay.
10
 Briefly, 
reduction of the MTT reagent by metabolically active cells leads to the production of 
formazan, which can then be dissolved in acidified SDS to produce a characteristic 
absorbance at 570 nm. This absorbance reflects the percentage of metabolically active 
cells in each sample. HCT116N and HCT116O cells were plated and treated with the 
various rhodium complexes at the concentrations indicated in Figure 5.15 for 72 h. 
Percent viability is defined as the ratio of the amount of formazan in the treated cells to 
that in the untreated cells, and differential cytotoxicity is defined as the difference 
between the percent viabilities of the two cell lines. The results are shown in Figure 5.15. 
All four compounds in this new family display differential cytotoxicity in excess of 50%, 
and three compounds exhibit maximal activity at sub-micromolar concentrations. 
Specifically, the differential cytotoxicities and optimal concentrations of 
[Rh(chrysi)(phen)(DPE)]
2+
, [Rh(chrysi)(phen)(PPE)]
2+
, [Rh(chrysi)(phen)(PPO)]
2+
, and 
[Rh(chrysi)(phen)(PyOctanol)]
2+
 are 76 ± 2% at 6 M, 66 ± 2% at 720 nM, 66 ± 3% at  
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Figure 5.15 Differential cytotoxicities of rac-[Rh(chrysi)(phen)(DPE)]
2+
, rac-
[Rh(chrysi)(phen)(PPE)]
2+
,   rac-[Rh(chrysi)(phen)(PPO)]
2+
, and rac-
[Rh(chrysi)(phen)(PyOctanol)]
2+
.  HCT116N (green) and HCT116O (red) cells were 
plated in 96-well format at densities of 5 x 10
4 
cells/well and treated with the 
concentrations of rhodium metalloinsertors indicated. After 72 hours, the cells were 
labeled with MTT for 4 hours. 
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320 nM, and 55 ± 3% at 480 nM, respectively. This is an increase in cytotoxic potency of 
almost two orders of magnitude as compared to [Rh(HDPA)2(chrysi)]
3+
 (25 M required 
for optimal cytotoxicity). Furthermore, this is the only instance of a metalloinsertor with 
a greasy ancillary ligand retaining the cell-selective activity unique to our compounds. 
The cell-selective cytotoxicities of the two enantiomers of 
[Rh(chrysi)(phen)(DPE)]
2+
 were also assessed, and the results are shown in Figure 5.16. 
Just as both enantiomers bind with equal affinity to DNA mismatches, both enantiomers 
display equal cell-selectivity; their differential cytotoxicities are 78 ± 1% and 75 ± 2% for 
 and , respectively. This is again in direct contrast to [Rh(bpy)2(chrysi)]
3+
, in which 
case only the  isomer displays differential activity.19 
5.3.6 ICP-MS Assay for Whole-Cell Rhodium Levels 
HCT116O and HCT116N cells were treated with each rhodium complex at the 
concentrations indicated for 24 h. Whole cell lysates were analyzed for rhodium levels by 
ICP-MS and normalized to protein content (Figure 5.17). These concentrations roughly 
correspond to the concentrations necessary for optimal biological activity in the 24-h 
ELISA for the four different complexes. Therefore, the intracellular rhodium 
concentrations in this experiment reflect the amount of rhodium required for an optimal 
biological response. It is striking that the new family of compounds require significantly 
less intracellular rhodium to elicit a biological response than the prototypical 
[Rh(HDPA)2(chrysi)]
3+
 compound; specifically, the new compounds exhibit comparable 
biological activity to [Rh(HDPA)2(chrysi)]
3+
 with only 20 ± 2% 
([Rh(chrysi)(phen)(DPE)]
2+
), 15 ± 5% ([Rh(chrysi)(phen)(PPE)]
2+
), or 13 ± 2% 
([Rh(chrysi)(phen)(PPO)]
2+
) of the amount of intracellular rhodium. 
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Figure 5.16 Differential cytotoxicities of -and -[Rh(chrysi)(phen)(DPE)]2+. HCT116N 
(green) and HCT116O (red) cells were plated in 96-well format at densities of 5 x 10
4 
cells/well and treated with the concentrations of rhodium metalloinsertors indicated. 
After 72 hours, the cells were labeled with MTT for 4 hours. 
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Figure 5.17 ICP-MS assay for whole-cell rhodium accumulation. HCT116O and 
HCT116N cells were treated with [Rh(HDPA)2(chrysi)]
3+
, [Rh(chrysi)(phen)(DPE)]
2+
, 
[Rh(chrysi)(phen)(PPE)]
2+
, or [Rh(chrysi)(phen)(PPO)]
2+
 at the concentrations shown for 
24 h. The cells were analyzed for rhodium content by ICP-MS. The rhodium counts were 
normalized to protein content, which was determined by a BCA assay. See Section 
5.2.10. It should be noted that because the rhodium concentrations are normalized to 
protein content, rather than number of cells, the concentrations from the two cell lines 
cannot be directly compared to one another. 
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5.3.7 Mode of cell death 
To characterize the cell death occurring in response to rhodium treatment, a dye-
exclusion flow cytometry assay was employed.
11
 The assay differentiates between live 
cells, dead cells, and cells undergoing apoptosis or necrosis through concurrent staining 
with propidium iodide (a dead-cell-permeable dye) and YO-PRO-1 (an apoptotic-cell-
permeable dye).  By plotting the fluorescence of the YO-PRO-1 channel against the PI 
channel, a pattern emerges.  Healthy cells are seen in the lower lefthand corner of the 
plot.  Apoptotic cells exhibit higher YO-PRO-1 fluorescence, but still exclude propidium 
iodide, placing them in the upper lefthand quadrant of the pattern.  Dead cells admit both 
dyes and are therefore seen in the upper righthand quadrant of the image. Upon flow 
cytometry analysis, cells can be classified as live, apoptotic, necrotic, or dead by defining 
regions in the fluorescence plane corresponding to each category. 
The HCT116N and HCT116O cell lines were incubated with 0 – 0.5 M of 
[Rh(chrysi)(phen)(PPO)]
2+
 for 72 h.  After harvesting the cells and staining with both PI 
and YO-PRO-1, the cells were analyzed by flow cytometry to obtain raw fluorescence 
data.  Representative data for 20 µM rhodium treatment for 72 h are shown in Figure 
5.18. YO-PRO-1 fluorescence is shown on the y-axis, and PI fluorescence is shown on 
the x-axis.  The color scale represents the number of cells, with blue indicating fewer 
cells at a given pair of fluorescence levels, and orange representing a greater number of 
cells at a given pair of fluorescence levels. 
The raw data were analyzed by gating the fluorescence events into one of four 
categories, depending on the fluorescence levels of the two dyes. Figure 5.18 also shows 
histograms of live, apoptotic, necrotic, and dead cells for the HCT116N and HCT116O  
 204 
 
  
Figure 5. 18 Flow cytometry assay of cell death. (Right) HCT116N and HCT116O cells 
were treated with 0.2 µM [Rh(chrysi)(phen)(PPO)]
2+
 for 72 hours. Rhodium treatment 
causes cells to move away from the origin, along the necrotic pathway (lower branch of 
pattern).  The effect is more pronounced in the HCT116O cell line. (Right) HCT116N 
and HCT116O cells were treated with 0.2 µM or 0.5 µM [Rh(chrysi)(phen)(PPO)]
2+
 for  
72 hours.  Rhodium treatment causes a sharp decrease in the live population of the 
HCT116O cell line with a corresponding increase in the necrotic and dead cell 
populations. Less of an effect is seen in the HCT116N cell line. Thus, 
[Rh(chrysi)(phen)(PPO)]
2+
 preferentially induces necrosis in the MMR-deficient 
HCT116O cell line. 
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cell lines based on the flow cytometry. Rhodium treatment was either 0.2, 0.5, or 1 M 
[Rh(chrysi)(phen)(PPO)]
2+
 for 72 h. As with [Rh(HDPA)2chrysi]
3+
,
20
  
[Rh(chrysi)(phen)(PPO)]
2+
 treatment induces necrosis preferentially in the MMR-
deficient HCT116O cell line; the number of necrotic cells increases from 1.2 ± 0.1 % to 
13 ± 2 % after treatment with 0.2 M [Rh(chrysi)(phen)(PPO)]2+. There is no significant 
change in the percentage of cells in the apoptotic region in either cell line following 
metalloinsertor treatment (26 ± 7 % vs. 25 ± 7 % for the HCT116N cell line, and 10 ± 6 
% vs. 17 ± 7 % for the HCT116O cell line). The effect of rhodium treatment is 
significantly more pronounced in the MMR-deficient HCT116O cell line, in which live 
cells drop from 82 ± 7 % to 28 ± 6 % after treatment with 0.2 M 
[Rh(chrysi)(phen)(PPO)]
2+
, versus the MMR-proficient HCT116N cell line, which shows 
no decrease in live cells (57 ± 9 % versus 57 ± 7 %) after treatment with 0.2 M 
[Rh(chrysi)(phen)(PPO)]
2+
. 
5.4 Discussion 
 5.4.1 In Vitro Characterization 
 The DPE ligand was originally designed to coordinate to the Rh center via the two 
pyridine rings, resulting in a tertiary alcohol as a site of conjugation. The solid state 
structure of [Rh(chrysi)(phen)(DPE)]
2+
 was both a surprise and a revelation to us when it 
revealed the true coordination to include an axial Rh-O bond. The driving force of this 
unexpected ligand coordination is believed to be the formation of a 5-membered ring, as 
opposed to the 6-membered ring that would form if the second pyridine ring 
coordinated.
21
 As this compound exhibited enhanced potency and maximal cell-
selectivity,
1
 we sought to investigate this new ligand coordination and determine its role 
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in the biological activity of [Rh(chrysi)(phen)(DPE)]
2+
. In order to assess the generality 
of this ligand coordination, we synthesized the analogous [Rh(chrysi)(phen)(PPE)]
2+
  
compound, which lacks the second pyridine and thus has no possible coordination site 
beyond the oxygen. The resulting compound with a phenyl group dangling off the back 
of the compound was thus made and exhibited a comparable DNA mismatch binding 
affinity. An additional compound with a dangling methyl group was then synthesized in 
order to determine if the steric bulk of the dangling group was responsible for its 
biological activity ([Rh(chrysi)(phen)(PPO)]
2+
), and, finally, we appended a hexyl group 
off the back of the ligand ([Rh(chrysi)(phen)(PyOctanol)]
2+
) to assess the effects of 
lipophilicity on this new family of compounds. All compounds exhibit binding affinities 
within a factor of 2 of each other, indicating that the size of the steric bulk of the dangling 
group has no effect on DNA mismatch binding.  
We hypothesized that perhaps the Rh-O bond is labile, resulting in covalent DNA 
binding following Rh-O cleavage of the inserted complex. The ensuing covalent lesion 
could be more efficiently recognized by the machinery of the cell.
22
 However, even under 
an extremely reducing environment (5 mM glutathione), there is no evidence of covalent 
DNA binding. 
 Spectrophotometric titrations reveal that the acidity of the chrysi immine proton 
of [Rh(chrysi)(phen)(DPE)]
2+
 (pKa of  8.7) varies significantly from that of 
[Rh(bpy)2(chrysi)]
3+
 (pKa of 5.2
13
) and [Rh(HDPA)2(chrysi)]
3+
 (pKa of 7.0). This can 
most likely be explained by the negative charge on the DPE ligand; a more basic 
environment is required to deprotonate the 2+ [Rh(chrysi)(phen)(DPE)]
2+
 species than the 
3+ [Rh(HDPA)2(chrysi)]
3+
 species. Furthermore, in the case of [Rh(bpy)2(chrysi)]
3+
, the 
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chrysi immine proton must be deprotonated in order for the molecule to bind to 
mismatched DNA.
24
 As can be seen in Figure 5.2, when both immine nitrogens are 
protonated, the chrysi ligand is not planar, which, in effect, prevents proper pi-stacking 
with the base pairs adjacent to the mismatched site. Despite this fact, 
[Rh(chrysi)(phen)(DPE)]
2+
 still binds to mismatched DNA with a fully protonated chrysi 
ligand, as can be seen in Figure 5.10. The significant amount of hypochromicity seen 
upon DNA binding confirms that not only does this compound bind to the DNA, but 
there is significant pi-stacking between the DNA and the chrysi ligand. These 
observations suggest a different mechanism of mismatch binding for this new family of 
compounds as compared to [Rh(bpy)2(chrysi)]
3+
. 
 In order to further characterize the compounds, the enantiomers of 
[Rh(chrysi)(phen)(DPE)]
2+
 were separated by HPLC. In the case of a labile Rh-O bond, 
racemization of the enantiomers could occur over time.
23
 However, samples of both 
enantiomers in aqueous solution in light exhibited no racemization over a month, as 
confirmed by chiral HPLC and CD. Furthermore, the two enantiomers do not racemize 
upon DNA binding (Figure 5.12), and, in fact, exhibit distinct CD spectra when bound to 
DNA, providing direct evidence that both enantiomers do indeed bind to mismatches. 
Even more interestingly, both the  and  isomers of [Rh(chrysi)(phen)(DPE)]2+ bind to 
mismatched DNA with equal affinity. In fact, Figure 5.19 compares models of -
[Rh(chrysi)(phen)(DPE)]
2+
, -[Rh(chrysi)(phen)(DPE)]2+,  -[Rh(chrysi)(phen)(PPE)]2+, 
and  -[Rh(chrysi)(phen)(PPO)]2+ bound to a mismatched site in DNA. Preserving the 
DNA conformation from the crystal structure of [Rh(bpy)2(chrysi)]
3+
 bound to an AC 
mismatch,
24
 we simply overlaid the chrysi ligands of the crystal structures of the various  
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Figure 5.19 Modeling of new family of compounds bound to mismatched DNA. Crystal 
structures of -[Rh(chrysi)(phen)(DPE)]2+ (top left, cyan), -[Rh(chrysi)(phen)(DPE)]2+ 
(top right, red),  -[Rh(chrysi)(phen)(PPE)]2+ (bottom left, purple), and  -
[Rh(chrysi)(phen)(PPO)]
2+
 (bottom right, orange) modeled into the crystal structure of 
[Rh(bpy)2(chrysi)]
3+
 bound to an AC mismatch. The metalloinsertors are shown bound to 
the DNA (gray) from the minor groove at the mismatch site with the bases (blue) ejected 
and their chrysi ligands stacked fully with the adjacent base pairs. In all cases, steric 
clashing (shown in green) occurs between the ancillary ligand(s) and the DNA. 
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new compounds with that of -[Rh(bpy)2(chrysi)]
3+
. Figure 5.19 shows that there is the 
potential for significant steric clashing between the dangling group and the DNA 
backbone for the  enantiomers of the DPE and PPE compounds, which is partially 
alleviated for the PPO complex. Even considering free rotation of the aromatic group 
around the quaternary C-aromatic C bond of both ligands, this steric clash cannot be 
diminished. Given the similarity in binding affinities of the various compounds, it is clear 
that this cannot be the same binding conformation for this new family of compounds. In 
addition, there is even more steric clashing between the ancillary ligands of the -
[Rh(chrysi)(phen)(DPE)]
2+
 complex and the DNA backbone, as would be expected given 
the complete lack of DNA binding of - [Rh(bpy)2(chrysi)]
3+
. These models clearly 
imply that the binding mode of this new family of complexes must be structurally distinct 
from that of [Rh(bpy)2(chrysi)]
3+
. 
5.4.2 In Cellulo Characterization 
 We sought to explore the biological effects of the different dangling groups of the 
ancillary ligand. As can be seen from Figure 5.15, all four complexes exhibit the MMR-
deficient cell-selective activity that is unique to rhodium metalloinsertors. Thus, 
appending additional steric bulk off the back of the complexes does not inhibit cellular 
processing of the rhodium-DNA lesion that results from mismatch binding. In addition, 
the fact that [Rh(chrysi)(phen)(PyOctanol)]
2+
 retains its cell-selectivity is very surprising 
given our recent results that the more lipophilic metalloinsertors localize to the 
mitochondria, which in effect abolishes their cell-selectivity.
1
 One explanation is that the 
ancillary PyOctanol ligand falls off either prior to uptake or following cellular uptake. 
The variance in potencies of the four different compounds negates the former, and our 
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result showing the lack of racemization of the [Rh(chrysi)(phen)(DPE)]
2+
 compound over 
a month in a reducing aqueous environment negates the latter. As expected, given its 
mismatch binding affinity, -[Rh(chrysi)(phen)(DPE)]2+ also displayed cell-selective 
activity in the MTT assay. 
Encouraged by the enhanced potencies of the new complexes as compared to our 
earlier generation compounds, we measured their antiproliferative activity alongside two 
FDA-approved chemotherapeutics that display decreased effectiveness against MMR-
deficient cancers in the clinic.
17 
As can clearly be seen in Figure 5.14, the new 
compounds are both more selective and more potent than both classic chemotherapeutics. 
This is very exciting, given that for many years, the focus of numerous laboratories has 
been on the preparation of more potent analogues of cisplatin.
25,26
 However, a new 
strategy based upon selectivity has recently emerged, and focus has shifted towards the 
preparation of chemotherapeutics that are more selective than cisplatin owing to a design 
strategy where the complex interacts with a specific biological target found prominently 
in cancer cells.
27
 This new family of compounds has fulfilled both of these criteria, and 
efforts are currently in motion to test these compounds in vivo. 
In order to further characterize the biological activity of the compounds, we 
assessed cellular uptake of the various compounds and compared them to that of 
[Rh(HDPA)2chrysi]
3+
. Figure 5.17 displays the intracellular rhodium concentrations of 
the various complexes required to produce the same biological effect. It is important to 
note that the new family of compounds require from 7.5- to 5- fold less intracellular 
rhodium as compared to [Rh(HDPA)2chrysi]
3+
 to evoke the same cellular response. This 
may be an indication that the Rh-DNA lesion being formed by the new family of 
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compoun s is mo e  ea i y  ecognize  by the ce  ’s machine y, and thus fewer lesions are 
required for cytotoxicity. Furthermore, the three complexes with Rh-O bonds exhibit 
similar intracellular rhodium concentrations; they vary less than 1.5-fold from each other. 
This is despite a 10-fold difference in the rhodium concentration of the media between 
[Rh(chrysi)(phen)(DPE)]
2+ 
and [Rh(chrysi)(phen)(PPO)]
2+
. This clearly demonstrates that 
the latter compound has more efficient uptake than the DPE parental compound. This 
property is especially valuable in considering these compounds for in vivo work; many 
antitumor agents are limited in their applications due to chronic side effects. In particular, 
doxorubicin is one of the most effect chemotherapies against leukemia and lymphomas,
28
 
yet causes congestive heart failure at a rate that is directly correlated with the total 
amount of drug administered.
29,30
  
Finally, we evaluated the mode of cell death caused by treatment of HCT116 cells 
with the new compound [Rh(chrysi)(phen)(PPO)]
2+
 as a representative member of the 
new family. The admission of the dead-cell stain propidium iodide by the HCT116 cell 
lines upon rhodium treatment reveals that cell death proceeds through a necrotic, rather 
than apoptotic pathway, similar to [Rh(HDPA)2chrysi]
3+
 treatment.
20 
If there is a different 
Rh-DNA lesion being formed by the new family of compounds, then it is not different 
enough to evoke a significantly altered cellular response. The observations that 
significantly less intracellular rhodium is required to elicit the same biological response 
as our previous generation compounds, and the appendage of a greasy hexyl group off the 
ancillary ligand ([Rh(chrysi)(phen)(PyOctanol)]
2+
) does not abolish cell-selectivity
1
 lend 
credence to the theory that this new family of compounds is distinct from our earlier 
generation metalloinsertors. Further evidence to support this hypothesis is the observation 
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that both the  and  enantiomers bind to mismatches in DNA with equal affinity, yet do 
not interconvert with each other. Whatever the reason, the enhanced potency and 
selectivity of these new compounds make them suitable candidates for the next step in 
chemotherapeutic development. 
5.5 Conclusion 
 Here we have described a family of rhodium metalloinsertors with a new ancillary 
ligand coordination. These compounds all contain a Rh-O bond axial to their inserting 
chrysi ligand. This new ligand coordination has been found to be responsible for the 
enhanced potency and selectivity towards MMR-deficient cancer cells that we observe 
with these compounds. Models of the compounds bound to mismatched DNA imply a 
different binding mode than our earlier generation compounds, which may account for 
their biological activity. We are now focusing our studies on structurally characterizing 
their DNA-bound conformation. Furthermore, this new ligand scaffold is very amenable 
to conjugation, and thus effort will be made to further enhance their potency and 
selectivity by conjugating these new types of compounds to cell-penetrating peptides and 
antibodies.  
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Chapter 6: Conclusion 
 The motivation behind the work in this thesis is the biological consequences of 
lesions in DNA. If they are left uncorrected, they will ultimately lead to mutations in our 
DNA, which leads to mutations in the corresponding proteins. About 80-90% of protein 
mutations that are responsible for human disease are caused by the substitution, deletion, 
or insertion of only a single nucleotide. Clearly, the design and study of drugs that can 
recognize such lesions is incredibly important for the future development of cures and 
treatments for these diseases.  
My work focused on DNA mismatches in particular, which are recognized and 
fixed in vivo by the mismatch repair (MMR) pathway. However, inactivation of this 
pathway leads to a large increase in the number of mismatches in a given cell, resulting in 
an increased rate of mutagenesis and predisposition to cancer. Cancers that display MMR 
deficiencies are notoriously difficult to treat; the current standard-of-care treatment is 
adjuvant chemotherapy with 5-fluorouracil (5-FU), despite multiple studies showing its 
ineffectiveness against these cancers.  
The observation in 1999 that rhodium metalloinsertors can bind selectively and 
with high affinity to DNA mismatch opened up an entire new avenue of research in the 
Barton laboratory. Their mismatch binding characteristics were studied extensively in the 
test tube until 2006, when the first cell work on rhodium metalloinsertors showed that 
after treatment for 72 h with 0 - 25 M, these compounds can selectively inhibit growth 
in MMR-deficient cells for isogenic MMR-proficient cells. My thesis has focused on 
enhancing the biological activity of these compounds, so that one day (hopefully soon), 
they can be tested in the clinic. 
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My work with Russell Ernst showing that later-generation compounds can 
actively kill cancer cells rather than just inhibit growth was the start of this journey. I 
have since shown that localization to the nucleus, the site of mismatches in genomic 
DNA, is required for their unique activity. Through our collaboration with Amgen I have 
also been able to further validate these compounds by showing that their unique cell-
selective targeting is observed across multiple experiments and cell lines. Most recently, I 
have been able to increase their activity from inhibition of growth at 0 - 25 M 
metalloinsertor to cytotoxicity at 0 - 500 nM metalloinsertor, potency that surpasses even 
FDA-approved chemotherapeutics. 
It has been especially gratifying to witness the first in vivo work done with these 
compounds. Amgen has run some pharmacokinetic studies on both 
[Rh(chrysi)(phen)(PPO)]
2+
 and [Rh(HDPA)2(chrysi)]
3+
, both of which look very 
promising. It will be an incredibly rewarding experience if these compounds make it to 
clinical trials, and we are well on our way there. 
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Appendix: Crystallographic Data 
A.1 [Rh(HDPA)2(chrysi)]Cl2 
 
Table A.1 Crystal data and structure refinement for [Rh(HDPA)2(chrysi)]Cl2. 
Identification code  ack002 
Empirical formula  C42 H43 Cl2 N8 O3 Rh 
Formula weight  881.65 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/n 
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Unit cell dimensions a = 9.4383(4) Å = 90°. 
 b = 25.4636(10) Å = 96.746(2)°. 
 c = 16.6094(6) Å  = 90°. 
Volume 3964.1(3) Å3 
Z 4 
Density (calculated) 1.477 Mg/m3 
Absorption coefficient 0.617 mm-1 
F(000) 1816 
Crystal size 0.500 x 0.400 x 0.150 mm3 
Theta range for data collection 2.315 to 30.547°. 
Index ranges -13<=h<=13, -35<=k<=36, -23<=l<=23 
Reflections collected 178000 
Independent reflections 12143 [R(int) = 0.0639] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7461 and 0.6942 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12143 / 13 / 538 
Goodness-of-fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0284, wR2 = 0.0641 
R indices (all data) R1 = 0.0371, wR2 = 0.0677 
Largest diff. peak and hole 0.745 and -0.767 e.Å-3 
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Table A.2 Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for [Rh(HDPA)2(chrysi)]Cl2. U(eq) is defined as one-third of the trace of the  
orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
Cl(1) 3083(1) 9952(1) 8823(1) 16(1) 
Cl(2) 4096(1) 6979(1) 5314(1) 23(1) 
Cl(2A) 4496(15) 7220(7) 5078(7) 48(5) 
Rh(1) 5622(1) 8722(1) 7938(1) 9(1) 
N(1) 5365(1) 9494(1) 7748(1) 11(1) 
C(1) 5762(2) 9663(1) 7073(1) 11(1) 
C(2) 5582(2) 10197(1) 6763(1) 13(1) 
C(3) 4825(2) 10572(1) 7160(1) 16(1) 
C(4) 4618(2) 11072(1) 6843(1) 18(1) 
C(5) 5158(2) 11197(1) 6123(1) 18(1) 
C(6) 5915(2) 10830(1) 5732(1) 17(1) 
C(7) 6159(2) 10320(1) 6042(1) 13(1) 
C(8) 6939(2) 9921(1) 5612(1) 15(1) 
C(9) 7586(2) 10077(1) 4918(1) 22(1) 
C(10) 8224(2) 9723(1) 4465(1) 23(1) 
C(11) 8229(2) 9181(1) 4653(1) 16(1) 
C(12) 8777(2) 8811(1) 4131(1) 20(1) 
C(13) 8702(2) 8283(1) 4274(1) 20(1) 
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C(14) 8093(2) 8108(1) 4959(1) 21(1) 
C(15) 7580(2) 8457(1) 5486(1) 18(1) 
C(16) 7623(2) 9008(1) 5352(1) 14(1) 
C(17) 7017(2) 9394(1) 5852(1) 12(1) 
C(18) 6444(2) 9249(1) 6616(1) 11(1) 
N(2) 6542(1) 8786(1) 6935(1) 12(1) 
N(3) 3767(1) 8591(1) 7202(1) 11(1) 
C(21) 2678(2) 8942(1) 7190(1) 13(1) 
C(22) 1535(2) 8943(1) 6598(1) 17(1) 
C(23) 1505(2) 8571(1) 5973(1) 17(1) 
C(24) 2573(2) 8203(1) 5991(1) 15(1) 
C(25) 3693(2) 8212(1) 6636(1) 12(1) 
N(4) 4704(1) 7825(1) 6657(1) 13(1) 
C(26) 5552(2) 7626(1) 7324(1) 12(1) 
C(27) 5961(2) 7097(1) 7296(1) 17(1) 
C(28) 6778(2) 6880(1) 7954(1) 19(1) 
C(29) 7187(2) 7192(1) 8631(1) 17(1) 
C(30) 6766(2) 7708(1) 8618(1) 14(1) 
N(5) 5979(1) 7929(1) 7969(1) 11(1) 
N(6) 7498(1) 8894(1) 8628(1) 11(1) 
C(31) 8749(2) 8799(1) 8323(1) 14(1) 
C(32) 10030(2) 8987(1) 8676(1) 16(1) 
C(33) 10063(2) 9284(1) 9387(1) 16(1) 
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C(34) 8817(2) 9371(1) 9713(1) 14(1) 
C(35) 7532(2) 9164(1) 9323(1) 11(1) 
N(7) 6303(1) 9259(1) 9674(1) 15(1) 
C(36) 5109(2) 8944(1) 9671(1) 13(1) 
C(37) 4382(2) 8946(1) 10363(1) 20(1) 
C(38) 3191(2) 8638(1) 10370(1) 21(1) 
C(39) 2740(2) 8322(1) 9700(1) 17(1) 
C(40) 3511(2) 8335(1) 9049(1) 14(1) 
N(8) 4666(1) 8650(1) 9022(1) 11(1) 
O(1S) 948(2) 10540(1) 7590(1) 38(1) 
C(1S) -486(2) 10348(1) 7535(1) 32(1) 
C(2S) -1230(2) 10528(1) 8232(1) 28(1) 
O(1T) 2272(2) 7456(1) 7645(1) 29(1) 
C(1T) 820(2) 7533(1) 7760(2) 36(1) 
C(2T) -190(3) 7445(1) 7002(2) 56(1) 
O(1W) 2631(2) 6513(1) 6806(1) 40(1) 
 
Table A.3 Selected bond lengths [Å] and angles [°] for [Rh(HDPA)2(chrysi)]Cl2. 
_____________________________________________________  
Rh(1)-N(2)  1.9738(12) 
Rh(1)-N(1)  2.0019(13) 
Rh(1)-N(6)  2.0408(12) 
Rh(1)-N(3)  2.0417(12) 
Rh(1)-N(5)  2.0450(13) 
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Rh(1)-N(8)  2.1135(12) 
N(2)-Rh(1)-N(1) 80.93(5) 
N(2)-Rh(1)-N(6) 90.99(5) 
N(1)-Rh(1)-N(6) 87.59(5) 
N(2)-Rh(1)-N(3) 86.52(5) 
N(1)-Rh(1)-N(3) 89.19(5) 
N(6)-Rh(1)-N(3) 176.21(5) 
N(2)-Rh(1)-N(5) 90.91(5) 
N(1)-Rh(1)-N(5) 171.73(5) 
N(6)-Rh(1)-N(5) 93.90(5) 
N(3)-Rh(1)-N(5) 89.00(5) 
N(2)-Rh(1)-N(8) 179.15(5) 
N(1)-Rh(1)-N(8) 99.35(5) 
N(6)-Rh(1)-N(8) 88.22(5) 
N(3)-Rh(1)-N(8) 94.28(5) 
N(5)-Rh(1)-N(8) 88.83(5) 
 
Table A.4 Anisotropic displacement parameters (Å2x 103) for [Rh(HDPA)2(chrysi)]Cl2. 
The anisotropic displacement factor exponent takes the form: -22[ h2 a*2U11 + ...  + 2  
h k a* b* U12 ]. 
________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________ 
Cl(1) 15(1)  18(1) 15(1)  -5(1) 4(1)  0(1) 
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Cl(2) 28(1)  22(1) 15(1)  -8(1) -5(1)  6(1) 
Cl(2A) 44(6)  64(9) 31(5)  -22(6) -17(4)  37(6) 
Rh(1) 9(1)  10(1) 8(1)  -1(1) 2(1)  -1(1) 
N(1) 11(1)  12(1) 11(1)  -3(1) 3(1)  0(1) 
C(1) 9(1)  12(1) 12(1)  -1(1) 1(1)  -1(1) 
C(2) 13(1)  12(1) 14(1)  -1(1) 1(1)  -1(1) 
C(3) 16(1)  15(1) 18(1)  -2(1) 4(1)  0(1) 
C(4) 17(1)  14(1) 24(1)  -3(1) 2(1)  2(1) 
C(5) 18(1)  13(1) 24(1)  2(1) -1(1)  0(1) 
C(6) 18(1)  16(1) 18(1)  3(1) 2(1)  -2(1) 
C(7) 12(1)  15(1) 14(1)  0(1) 1(1)  -1(1) 
C(8) 15(1)  16(1) 13(1)  1(1) 3(1)  0(1) 
C(9) 29(1)  19(1) 19(1)  6(1) 10(1)  1(1) 
C(10) 29(1)  26(1) 17(1)  4(1) 12(1)  2(1) 
C(11) 16(1)  22(1) 12(1)  0(1) 4(1)  1(1) 
C(12) 19(1)  30(1) 12(1)  -2(1) 5(1)  3(1) 
C(13) 19(1)  28(1) 14(1)  -8(1) 3(1)  3(1) 
C(14) 25(1)  19(1) 19(1)  -6(1) 6(1)  0(1) 
C(15) 22(1)  17(1) 15(1)  -3(1) 6(1)  -1(1) 
C(16) 13(1)  18(1) 10(1)  -2(1) 2(1)  0(1) 
C(17) 12(1)  15(1) 10(1)  0(1) 2(1)  -1(1) 
C(18) 11(1)  14(1) 10(1)  -2(1) 2(1)  -2(1) 
N(2) 12(1)  14(1) 10(1)  -2(1) 2(1)  -1(1) 
 225 
 
N(3) 10(1)  12(1) 10(1)  0(1) 2(1)  -1(1) 
C(21) 13(1)  13(1) 15(1)  -1(1) 3(1)  -1(1) 
C(22) 14(1)  16(1) 19(1)  1(1) 1(1)  2(1) 
C(23) 16(1)  20(1) 15(1)  1(1) -3(1)  -1(1) 
C(24) 18(1)  17(1) 11(1)  -1(1) -2(1)  -1(1) 
C(25) 12(1)  14(1) 10(1)  1(1) 1(1)  -1(1) 
N(4) 15(1)  14(1) 10(1)  -4(1) -1(1)  1(1) 
C(26) 11(1)  14(1) 12(1)  -1(1) 2(1)  -1(1) 
C(27) 18(1)  15(1) 17(1)  -5(1) -1(1)  1(1) 
C(28) 21(1)  14(1) 22(1)  -1(1) 0(1)  4(1) 
C(29) 19(1)  16(1) 15(1)  2(1) -1(1)  2(1) 
C(30) 14(1)  16(1) 11(1)  0(1) 2(1)  -1(1) 
N(5) 11(1)  11(1) 10(1)  -1(1) 2(1)  -1(1) 
N(6) 10(1)  13(1) 11(1)  -1(1) 2(1)  -1(1) 
C(31) 13(1)  16(1) 12(1)  0(1) 3(1)  2(1) 
C(32) 12(1)  20(1) 16(1)  1(1) 3(1)  1(1) 
C(33) 12(1)  16(1) 19(1)  0(1) -1(1)  -2(1) 
C(34) 14(1)  14(1) 15(1)  -2(1) 0(1)  -2(1) 
C(35) 12(1)  11(1) 11(1)  0(1) 2(1)  0(1) 
N(7) 12(1)  20(1) 14(1)  -8(1) 4(1)  -3(1) 
C(36) 12(1)  15(1) 13(1)  -1(1) 3(1)  1(1) 
C(37) 19(1)  26(1) 15(1)  -4(1) 6(1)  -2(1) 
C(38) 20(1)  26(1) 19(1)  1(1) 11(1)  1(1) 
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C(39) 16(1)  17(1) 21(1)  5(1) 6(1)  -1(1) 
C(40) 12(1)  13(1) 17(1)  1(1) 2(1)  -1(1) 
N(8) 11(1)  13(1) 11(1)  0(1) 3(1)  0(1) 
O(1S) 27(1)  55(1) 33(1)  20(1) 3(1)  4(1) 
C(1S) 31(1)  41(1) 25(1)  -2(1) 1(1)  3(1) 
C(2S) 26(1)  33(1) 24(1)  1(1) 2(1)  0(1) 
O(1T) 25(1)  29(1) 31(1)  1(1) 2(1)  -3(1) 
C(1T) 30(1)  23(1) 56(1)  -4(1) 10(1)  -3(1) 
C(2T) 27(1)  74(2) 66(2)  39(2) -6(1)  -18(1) 
O(1W) 37(1)  39(1) 46(1)  -3(1) 14(1)  -1(1) 
________________________________________________________________________  
 
Table A.5 Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x  
103) for [Rh(HDPA)2(chrysi)]Cl2. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
H(1N) 4920(20) 9708(7) 8041(11) 13 
H(3) 4453 10482 7649 19 
H(4) 4112 11327 7114 22 
H(5) 5005 11538 5897 22 
H(6) 6279 10925 5243 21 
H(9) 7573 10437 4768 26 
H(10) 8673 9841 4015 28 
H(12) 9204 8932 3675 24 
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H(13) 9057 8038 3915 24 
H(14) 8036 7742 5059 25 
H(15) 7188 8328 5949 21 
H(21) 2711 9197 7610 16 
H(22) 782 9189 6611 20 
H(23) 751 8574 5540 21 
H(24) 2559 7946 5576 18 
H(4N) 4550(20) 7606(7) 6262(10) 16 
H(27) 5676 6890 6828 20 
H(28) 7060 6522 7946 23 
H(29) 7746 7049 9093 20 
H(30) 7036 7919 9083 17 
H(31) 8731 8594 7844 16 
H(32) 10883 8916 8444 19 
H(33) 10937 9424 9639 19 
H(34) 8820 9568 10199 17 
H(7N) 6440(20) 9477(7) 10082(10) 18 
H(37) 4711 9157 10818 23 
H(38) 2674 8640 10827 25 
H(39) 1923 8104 9696 21 
H(40) 3224 8115 8598 17 
H(1S) 1470(30) 10344(11) 7944(15) 58 
H(1S1) -474 9959 7522 39 
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H(1S2) -1021 10472 7022 39 
H(2S1) -781 10366 8733 42 
H(2S2) -2236 10425 8141 42 
H(2S3) -1162 10911 8278 42 
H(1T) 2210(30) 7153(8) 7361(15) 43 
H(1T1) 696 7895 7955 43 
H(1T2) 570 7288 8185 43 
H(2T1) 53 7684 6576 85 
H(2T2) -1169 7514 7114 85 
H(2T3) -112 7081 6821 85 
H(1W) 3140(30) 6221(9) 6876(19) 60 
H(2W) 2920(30) 6588(12) 6350(13) 60 
________________________________________________________________________ 
 
Table A.6 Hydrogen bonds for [Rh(HDPA)2(chrysi)]Cl2  [Å and °]. 
________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
________________________________________________________________________ 
 N(1)-H(1N)...Cl(1) 0.869(14) 2.371(16) 3.1773(13) 154.4(17) 
 C(21)-H(21)...Cl(1) 0.95 2.78 3.7250(15) 174.5 
 C(24)-H(24)...Cl(2) 0.95 2.92 3.6648(17) 136.5 
 C(24)-H(24)...Cl(2A) 0.95 2.79 3.537(8) 135.8 
 N(4)-H(4N)...Cl(2) 0.861(15) 2.248(15) 3.1068(13) 174.9(19) 
 N(4)-H(4N)...Cl(2A) 0.861(15) 2.194(17) 3.029(8) 163(2) 
 C(27)-H(27)...Cl(2) 0.95 2.78 3.5588(16) 139.9 
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 C(29)-H(29)...Cl(2A)#1 0.95 2.87 3.397(11) 116.2 
 C(30)-H(30)...Cl(2)#1 0.95 2.66 3.4562(16) 141.3 
 C(30)-H(30)...Cl(2A)#1 0.95 2.71 3.329(8) 123.4 
 C(34)-H(34)...Cl(1)#2 0.95 2.84 3.6221(16) 140.8 
 N(7)-H(7N)...Cl(1)#2 0.874(15) 2.329(15) 3.2023(13) 177.3(19) 
 C(39)-H(39)...Cl(2)#3 0.95 2.98 3.7786(17) 143.0 
 C(39)-H(39)...Cl(2A)#3 0.95 2.58 3.482(10) 158.0 
 C(40)-H(40)...O(1T) 0.95 2.41 3.343(2) 168.7 
 O(1S)-H(1S)...Cl(1) 0.879(17) 2.216(18) 3.0853(15) 170(3) 
 O(1T)-H(1T)...O(1W) 0.904(16) 1.936(18) 2.816(2) 164(3) 
 O(1W)-H(1W)...O(1S)#40.884(17) 2.09(2) 2.938(3) 161(3) 
 O(1W)-H(2W)...Cl(2) 0.855(17) 2.375(19) 3.2044(19) 164(3) 
________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1/2,-y+3/2,z+1/2    #2 -x+1,-y+2,-z+2    #3 x-1/2,-y+3/2,z+1/2      #4 -x+1/2,y-1/2,-
z+3/2.      
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A.2 [Rh(chrysi)(phen)(DPE)]Cl2 
 
Table A.7 Crystal data and structure refinement for [Rh(chrysi)(phen)(DPE)]Cl2. 
Identification code  ack007 
Empirical formula  C46 H47 Cl2 N6 O5 Rh 
Formula weight  937.70 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 9.6145(8) Å = 64.434(4)°. 
 b = 15.7645(13) Å = 85.049(4)°. 
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 c = 16.8583(14) Å  = 73.491(4)°. 
Volume 2208.0(3) Å3 
Z 2 
Density (calculated) 1.410 Mg/m3 
Absorption coefficient 0.560 mm-1 
F(000) 968 
Crystal size 0.450 x 0.300 x 0.200 mm3 
Theta range for data collection 2.211 to 30.586°. 
Index ranges -13<=h<=13, -22<=k<=22, -24<=l<=24 
Reflections collected 153083 
Independent reflections 13536 [R(int) = 0.0310] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7461 and 0.6678 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 13536 / 299 / 674 
Goodness-of-fit on F2 1.120 
Final R indices [I>2sigma(I)] R1 = 0.0418, wR2 = 0.1050 
R indices (all data) R1 = 0.0468, wR2 = 0.1110 
Extinction coefficient n/a 
Largest diff. peak and hole 2.425 and -0.777 e.Å-3 
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Table A.8 Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for [Rh(chrysi)(phen)(DPE)]Cl2.  U(eq) is defined as one-third of  the trace of  
the orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
O(1W) 3806(2) 6958(1) 6716(1) 21(1) 
O(2W) 1928(2) 6067(1) 7957(1) 26(1) 
Cl(1) 4995(1) 6766(1) 4985(1) 21(1) 
Cl(2) 3958(1) 3897(1) 8810(1) 36(1) 
Rh(1) 1864(1) 3770(1) 2999(1) 12(1) 
N(1) 2672(2) 2748(1) 4196(1) 14(1) 
C(1) 2487(2) 1890(1) 4438(1) 16(1) 
C(2) 3154(2) 1016(2) 5218(1) 20(1) 
C(3) 3945(3) 1066(2) 5850(2) 25(1) 
C(4) 4699(3) 214(2) 6542(2) 31(1) 
C(5) 4655(3) -683(2) 6603(2) 33(1) 
C(6) 3848(3) -739(2) 5998(2) 29(1) 
C(7) 3078(3) 109(2) 5287(2) 22(1) 
C(8) 2199(3) 55(2) 4643(2) 22(1) 
C(9) 2241(3) -877(2) 4702(2) 35(1) 
C(10) 1470(3) -959(2) 4110(2) 38(1) 
C(11) 497(3) -139(2) 3473(2) 27(1) 
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C(12) -375(3) -241(2) 2905(2) 36(1) 
C(13) -1376(3) 545(2) 2327(2) 36(1) 
C(14) -1574(3) 1469(2) 2317(2) 36(1) 
C(15) -727(3) 1593(2) 2850(2) 27(1) 
C(16) 374(2) 804(2) 3421(2) 21(1) 
C(17) 1348(2) 890(2) 3967(1) 18(1) 
C(18) 1598(2) 1823(1) 3796(1) 15(1) 
N(2) 1244(2) 2636(1) 3081(1) 15(1) 
N(3) 38(2) 4327(1) 3530(1) 13(1) 
C(21) -1165(2) 4036(2) 3738(1) 18(1) 
C(22) -2362(2) 4516(2) 4068(2) 22(1) 
C(23) -2307(2) 5306(2) 4200(2) 22(1) 
C(24) -1037(2) 5619(2) 4003(1) 19(1) 
C(25) -839(3) 6413(2) 4138(2) 24(1) 
C(26) 423(3) 6668(2) 3948(2) 25(1) 
C(27) 1606(2) 6163(2) 3591(1) 19(1) 
C(28) 2944(3) 6396(2) 3370(2) 23(1) 
C(29) 3961(3) 5895(2) 2990(2) 23(1) 
C(30) 3682(2) 5151(2) 2839(1) 18(1) 
N(4) 2455(2) 4893(1) 3070(1) 13(1) 
C(31) 1420(2) 5396(1) 3437(1) 14(1) 
C(32) 109(2) 5110(1) 3663(1) 14(1) 
N(5) 1233(2) 4665(1) 1719(1) 13(1) 
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C(41) 24(2) 5421(1) 1428(1) 17(1) 
C(42) -265(2) 6036(2) 542(1) 19(1) 
C(43) 725(2) 5867(2) -60(1) 20(1) 
C(44) 1961(2) 5081(2) 241(1) 18(1) 
C(45) 2196(2) 4489(1) 1139(1) 14(1) 
C(46) 3549(2) 3637(1) 1521(1) 15(1) 
O(1) 3685(2) 3334(1) 2448(1) 14(1) 
C(53) 4889(2) 3981(2) 1112(1) 21(1) 
C(47) 3442(2) 2778(2) 1345(1) 19(1) 
C(48) 4627(3) 2232(2) 1074(2) 32(1) 
C(49) 4493(4) 1429(2) 973(2) 45(1) 
C(50) 3191(4) 1205(2) 1126(2) 41(1) 
C(51) 2058(3) 1790(2) 1375(2) 30(1) 
N(6) 2165(2) 2562(1) 1489(1) 22(1) 
O(1E) 2690(7) 2953(4) 7910(3) 64(2) 
C(11E) 2806(12) 1985(5) 8484(6) 63(2) 
C(12E) 2220(13) 1525(6) 8029(7) 77(3) 
O(2E) 5257(12) 2014(8) 7005(6) 54(2) 
C(21E) 4513(15) 1903(10) 7648(9) 50(3) 
C(22E) 3204(14) 2115(10) 7999(8) 46(2) 
O(3E) 4777(12) 1536(10) 8491(10) 65(3) 
C(31E) 3670(20) 1336(11) 8984(11) 68(3) 
C(32E) 2480(14) 2362(11) 8657(10) 46(2) 
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O(1F) 8115(9) 2310(8) 9372(7) 95(2) 
C(11F) 7652(13) 1845(10) 9038(8) 91(2) 
C(12F) 8717(14) 1205(10) 8760(8) 91(3) 
O(2F) 9572(18) 1499(13) 9924(11) 102(4) 
C(21F) 8750(20) 1178(16) 9578(11) 75(3) 
C(22F) 7963(15) 552(10) 10165(8) 51(3) 
O(3F) 6833(12) 2132(11) 9774(8) 111(5) 
C(31F) 8163(19) 2140(20) 9803(13) 96(4) 
C(32F) 9128(15) 1970(17) 9142(12) 87(4) 
 
Table A.9 Selected bond lengths [Å] and angles [°] for [Rh(chrysi)(phen)(DPE)]Cl2. 
_____________________________________________________  
Rh(1)-N(2)  1.9870(16) 
Rh(1)-O(1)  1.9964(14) 
Rh(1)-N(1)  2.0064(17) 
Rh(1)-N(5)  2.0315(17) 
Rh(1)-N(3)  2.0462(16) 
Rh(1)-N(4)  2.0592(16) 
N(2)-Rh(1)-O(1) 89.62(6) 
N(2)-Rh(1)-N(1) 78.02(7) 
O(1)-Rh(1)-N(1) 91.01(6) 
N(2)-Rh(1)-N(5) 97.68(7) 
O(1)-Rh(1)-N(5) 81.68(6) 
N(1)-Rh(1)-N(5) 171.58(7) 
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N(2)-Rh(1)-N(3) 95.10(7) 
O(1)-Rh(1)-N(3) 175.15(6) 
N(1)-Rh(1)-N(3) 91.05(7) 
N(5)-Rh(1)-N(3) 96.57(7) 
N(2)-Rh(1)-N(4) 173.15(7) 
O(1)-Rh(1)-N(4) 94.69(6) 
N(1)-Rh(1)-N(4) 96.56(6) 
N(5)-Rh(1)-N(4) 88.22(6) 
N(3)-Rh(1)-N(4) 80.72(6) 
_____________________________________________________________  
 
Table A.10 Anisotropic displacement parameters  (Å2x 103) for 
[Rh(chrysi)(phen)(DPE)]Cl2.  The anisotropic displacement factor exponent takes the  
form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]. 
________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________ 
O(1W) 18(1)  23(1) 24(1)  -13(1) 2(1)  -5(1) 
O(2W) 24(1)  29(1) 25(1)  -11(1) 4(1)  -10(1) 
Cl(1) 20(1)  23(1) 28(1)  -15(1) 5(1)  -10(1) 
Cl(2) 39(1)  36(1) 37(1)  -18(1) 17(1)  -13(1) 
Rh(1) 13(1)  11(1) 14(1)  -7(1) 2(1)  -5(1) 
N(1) 16(1)  13(1) 14(1)  -6(1) 1(1)  -6(1) 
C(1) 18(1)  15(1) 15(1)  -6(1) 4(1)  -7(1) 
C(2) 26(1)  16(1) 16(1)  -4(1) 3(1)  -9(1) 
C(3) 36(1)  22(1) 17(1)  -4(1) -1(1)  -14(1) 
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C(4) 42(1)  29(1) 18(1)  -3(1) -4(1)  -14(1) 
C(5) 42(1)  25(1) 21(1)  1(1) -2(1)  -11(1) 
C(6) 37(1)  18(1) 26(1)  -3(1) 1(1)  -10(1) 
C(7) 29(1)  16(1) 21(1)  -5(1) 4(1)  -10(1) 
C(8) 26(1)  15(1) 26(1)  -7(1) 3(1)  -10(1) 
C(9) 45(2)  15(1) 43(1)  -6(1) -8(1)  -13(1) 
C(10) 46(2)  18(1) 56(2)  -16(1) -10(1)  -12(1) 
C(11) 27(1)  20(1) 42(1)  -17(1) -1(1)  -10(1) 
C(12) 36(1)  26(1) 56(2)  -25(1) -6(1)  -10(1) 
C(13) 29(1)  35(1) 57(2)  -28(1) -8(1)  -10(1) 
C(14) 25(1)  30(1) 60(2)  -25(1) -11(1)  -3(1) 
C(15) 20(1)  22(1) 47(1)  -20(1) -4(1)  -4(1) 
C(16) 18(1)  19(1) 32(1)  -15(1) 4(1)  -9(1) 
C(17) 18(1)  15(1) 24(1)  -10(1) 5(1)  -9(1) 
C(18) 15(1)  16(1) 19(1)  -9(1) 5(1)  -7(1) 
N(2) 16(1)  13(1) 19(1)  -9(1) 1(1)  -6(1) 
N(3) 13(1)  14(1) 15(1)  -7(1) 2(1)  -5(1) 
C(21) 17(1)  21(1) 20(1)  -10(1) 4(1)  -9(1) 
C(22) 16(1)  28(1) 24(1)  -12(1) 6(1)  -9(1) 
C(23) 17(1)  26(1) 23(1)  -13(1) 6(1)  -4(1) 
C(24) 19(1)  18(1) 19(1)  -9(1) 4(1)  -4(1) 
C(25) 28(1)  20(1) 25(1)  -15(1) 8(1)  -5(1) 
C(26) 34(1)  18(1) 28(1)  -16(1) 7(1)  -8(1) 
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C(27) 26(1)  16(1) 21(1)  -10(1) 4(1)  -9(1) 
C(28) 31(1)  21(1) 26(1)  -14(1) 6(1)  -16(1) 
C(29) 24(1)  22(1) 29(1)  -13(1) 6(1)  -14(1) 
C(30) 17(1)  17(1) 20(1)  -9(1) 4(1)  -7(1) 
N(4) 14(1)  11(1) 14(1)  -6(1) 2(1)  -5(1) 
C(31) 19(1)  13(1) 14(1)  -6(1) 1(1)  -6(1) 
C(32) 16(1)  14(1) 15(1)  -7(1) 3(1)  -5(1) 
N(5) 13(1)  13(1) 16(1)  -6(1) 1(1)  -5(1) 
C(41) 15(1)  16(1) 20(1)  -9(1) 1(1)  -3(1) 
C(42) 18(1)  18(1) 20(1)  -8(1) -2(1)  -2(1) 
C(43) 22(1)  21(1) 16(1)  -6(1) 0(1)  -6(1) 
C(44) 18(1)  20(1) 17(1)  -9(1) 2(1)  -6(1) 
C(45) 14(1)  14(1) 17(1)  -8(1) 1(1)  -4(1) 
C(46) 14(1)  17(1) 16(1)  -9(1) 1(1)  -3(1) 
O(1) 12(1)  16(1) 14(1)  -7(1) 1(1)  -3(1) 
C(53) 15(1)  29(1) 20(1)  -10(1) 4(1)  -7(1) 
C(47) 21(1)  16(1) 18(1)  -9(1) -4(1)  1(1) 
C(48) 25(1)  34(1) 43(1)  -28(1) -6(1)  5(1) 
C(49) 42(2)  39(2) 63(2)  -41(2) -12(1)  11(1) 
C(50) 58(2)  24(1) 47(2)  -24(1) -14(1)  0(1) 
C(51) 44(1)  23(1) 29(1)  -14(1) -1(1)  -13(1) 
N(6) 29(1)  19(1) 21(1)  -10(1) 1(1)  -9(1) 
O(1E) 97(4)  75(3) 35(2)  -17(2) -12(2)  -48(3) 
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C(11E) 94(5)  42(3) 63(4)  -37(2) -19(4)  -2(3) 
C(12E) 107(7)  59(4) 70(5)  -23(4) -39(5)  -26(5) 
O(2E) 74(6)  60(6) 42(4)  -24(4) 14(4)  -39(5) 
C(21E) 78(6)  39(5) 48(5)  -29(5) 18(5)  -25(5) 
C(22E) 78(5)  46(5) 29(4)  -32(4) 6(4)  -15(5) 
O(3E) 53(5)  60(6) 89(7)  -46(5) -20(4)  2(4) 
C(31E) 113(7)  54(5) 51(6)  -33(5) 2(5)  -26(5) 
C(32E) 52(5)  64(6) 52(6)  -42(5) 19(5)  -35(4) 
O(1F) 53(4)  119(6) 94(5)  -40(5) -10(4)  2(4) 
C(11F) 66(5)  107(6) 68(5)  -5(4) -5(4)  -29(4) 
C(12F) 85(6)  117(8) 71(6)  -32(5) -24(5)  -31(5) 
O(2F) 86(7)  124(8) 81(7)  -18(7) -16(6)  -42(6) 
C(21F) 52(5)  102(6) 55(5)  -18(5) 7(4)  -22(5) 
C(22F) 48(7)  60(7) 34(6)  -22(5) 11(5)  3(5) 
O(3F) 54(4)  112(8) 73(6)  5(6) 22(4)  36(5) 
C(31F) 90(5)  103(7) 62(6)  -15(6) 12(5)  -14(5) 
C(32F) 44(5)  118(8) 76(7)  -21(6) 13(5)  -24(6) 
________________________________________________________________________ 
Table A.11 Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x  
103)for [Rh(chrysi)(phen)(DPE)]Cl2. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
H(11W) 4540(30) 6920(30) 6970(20) 32 
H(12W) 4060(40) 6890(30) 6257(16) 32 
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H(21W) 2380(40) 5472(15) 8160(20) 39 
H(22W) 2620(30) 6240(30) 7650(20) 39 
H(1N) 3270(30) 2800(20) 4528(17) 17 
H(3) 3964 1684 5805 30 
H(4) 5240 247 6969 37 
H(5) 5188 -1267 7068 39 
H(6) 3812 -1361 6063 34 
H(9) 2813 -1451 5159 42 
H(10) 1591 -1586 4128 46 
H(12) -261 -869 2927 43 
H(13) -1935 470 1936 44 
H(14) -2304 2014 1935 43 
H(15) -886 2223 2835 33 
H(2N) 920(30) 2630(20) 2619(15) 18 
H(21) -1216 3483 3660 22 
H(22) -3212 4295 4200 26 
H(23) -3115 5636 4422 27 
H(25) -1605 6767 4366 28 
H(26) 529 7193 4053 30 
H(28) 3136 6893 3484 28 
H(29) 4858 6054 2828 27 
H(30) 4391 4822 2564 21 
H(41) -647 5535 1843 20 
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H(42) -1125 6563 350 23 
H(43) 558 6284 -670 24 
H(44) 2640 4950 -164 22 
H(53A) 4859 4578 1170 32 
H(53B) 4894 4115 488 32 
H(53C) 5769 3469 1417 32 
H(48) 5516 2406 960 39 
H(49) 5296 1040 801 55 
H(50) 3072 659 1061 50 
H(51) 1151 1639 1471 36 
H(1E) 3033 3215 8159 96 
H(11A) 2253 1952 9015 76 
H(11B) 3837 1629 8671 76 
H(12A) 2269 847 8436 115 
H(12B) 2798 1536 7518 115 
H(12C) 1208 1890 7834 115 
H(2E) 6028 1556 7143 80 
H(21A) 5111 2047 7999 60 
H(21B) 4742 1180 7926 60 
H(22A) 3294 1742 8640 69 
H(22B) 2491 1940 7759 69 
H(22C) 2882 2816 7850 69 
H(3E) 4987 1999 8530 97 
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H(31A) 3931 1077 9616 82 
H(31B) 3312 854 8888 82 
H(32A) 1620 2293 9010 69 
H(32B) 2209 2590 8037 69 
H(32C) 2878 2836 8723 69 
H(1F) 8414 2756 8971 143 
H(11C) 6996 2330 8525 109 
H(11D) 7062 1457 9479 109 
H(12D) 8234 919 8489 137 
H(12E) 9325 682 9269 137 
H(12F) 9324 1573 8329 137 
H(2F) 10366 1493 9673 153 
H(21C) 9392 830 9256 90 
H(21D) 8056 1754 9140 90 
H(22D) 7283 457 9831 77 
H(22E) 7422 845 10547 77 
H(22F) 8635 -81 10526 77 
H(3F) 6805 1593 9799 166 
H(31C) 8596 1633 10387 115 
H(31D) 8159 2778 9775 115 
H(32D) 10127 1892 9303 131 
H(32E) 8839 2531 8569 131 
H(32F) 9070 1377 9107 131 
________________________________________________________________________ 
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Table A.12 Hydrogen bonds for [Rh(chrysi)(phen)(DPE)]Cl2 [Å and °]. 
________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
________________________________________________________________________ 
 O(1W)-H(11W)...O(1)#10.837(18) 1.891(19) 2.723(2) 172(3) 
 O(1W)-H(12W)...Cl(1) 0.831(18) 2.319(18) 3.1463(17) 174(3) 
 O(2W)-H(21W)...Cl(2) 0.838(18) 2.34(2) 3.166(2) 170(4) 
 O(2W)-H(22W)...O(1W)0.836(18) 1.99(2) 2.804(2) 164(4) 
 N(1)-H(1N)...Cl(1)#1 0.876(17) 2.305(18) 3.1547(17) 163(3) 
 N(2)-H(2N)...N(6) 0.870(17) 2.19(3) 2.793(3) 126(2) 
 C(21)-H(21)...O(2W)#2 0.95 2.60 3.092(3) 112.3 
 C(21)-H(21)...N(2) 0.95 2.69 3.197(3) 113.7 
 C(22)-H(22)...Cl(1)#2 0.95 2.62 3.531(2) 160.9 
 C(29)-H(29)...Cl(2)#1 0.95 2.87 3.433(2) 118.8 
 C(30)-H(30)...O(1W)#1 0.95 2.65 3.323(3) 128.6 
 C(41)-H(41)...N(3) 0.95 2.66 3.202(3) 116.6 
 C(44)-H(44)...Cl(2)#3 0.95 2.87 3.747(2) 153.3 
 C(53)-H(53A)...Cl(2)#1 0.98 2.95 3.867(2) 156.1 
 C(48)-H(48)...O(3F)#3 0.95 2.41 2.939(11) 115.2 
 O(1E)-H(1E)...Cl(2) 0.84 2.21 3.050(5) 179.5 
 C(32E)-H(32C)...Cl(2) 0.98 2.26 3.240(14) 175.2 
________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+1,-z+1    #2 -x,-y+1,-z+1    #3 x,y,z-1.    
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A.3 [Rh(chrysi)(phen)(PPE)]Cl2 
 
 
Table A.13 Crystal data and structure refinement for [Rh(chrysi)(phen)(PPE)]Cl2. 
Identification code  ack010 
Empirical formula  C47 H48 Cl2 N5 O5 Rh 
Formula weight  936.71 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 10.7782(6) Å = 72.345(3)°. 
 b = 12.1739(6) Å = 89.877(3)°. 
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 c = 17.5944(10) Å  = 80.812(3)°. 
Volume 2169.0(2) Å3 
Z 2 
Density (calculated) 1.434 Mg/m3 
Absorption coefficient 0.570 mm-1 
F(000) 968 
Crystal size 0.250 x 0.150 x 0.150 mm3 
Theta range for data collection 1.216 to 30.663°. 
Index ranges -15<=h<=15, -17<=k<=17, -25<=l<=25 
Reflections collected 115348 
Independent reflections 13351 [R(int) = 0.0555] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7461 and 0.6896 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 13351 / 160 / 625 
Goodness-of-fit on F2 1.055 
Final R indices [I>2sigma(I)] R1 = 0.0372, wR2 = 0.0859 
R indices (all data) R1 = 0.0499, wR2 = 0.0919 
Extinction coefficient n/a 
Largest diff. peak and hole 0.965 and -0.864 e.Å-3 
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Table A.14 Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for [Rh(chrysi)(phen)(PPE)]Cl2. U(eq) is defined as one-third of   
the trace of the orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
Rh(1) 2693(1) 3315(1) 2995(1) 16(1) 
N(1) 2433(2) 5037(1) 2474(1) 18(1) 
C(1) 2575(2) 5401(2) 1716(1) 18(1) 
C(2) 2212(2) 6597(2) 1198(1) 21(1) 
C(3) 1757(2) 7499(2) 1518(1) 28(1) 
C(4) 1358(2) 8622(2) 1013(2) 34(1) 
C(5) 1412(2) 8840(2) 196(2) 33(1) 
C(6) 1850(2) 7957(2) -124(1) 30(1) 
C(7) 2272(2) 6807(2) 371(1) 23(1) 
C(8) 2780(2) 5861(2) 37(1) 22(1) 
C(9) 2712(2) 6084(2) -804(1) 29(1) 
C(10) 3143(2) 5243(2) -1139(1) 32(1) 
C(11) 3772(2) 4137(2) -680(1) 28(1) 
C(12) 4262(2) 3278(2) -1044(2) 35(1) 
C(13) 4901(2) 2221(3) -606(2) 39(1) 
C(14) 5140(2) 1998(2) 217(2) 33(1) 
C(15) 4686(2) 2814(2) 588(1) 25(1) 
C(16) 3930(2) 3886(2) 164(1) 23(1) 
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C(17) 3326(2) 4746(2) 521(1) 20(1) 
C(18) 3126(2) 4461(2) 1372(1) 17(1) 
N(2) 3292(2) 3438(1) 1904(1) 19(1) 
N(3) 4367(2) 3371(1) 3525(1) 19(1) 
C(21) 5499(2) 3385(2) 3225(1) 26(1) 
C(22) 6544(2) 3470(2) 3660(2) 31(1) 
C(23) 6424(2) 3521(2) 4425(1) 29(1) 
C(24) 5241(2) 3499(2) 4762(1) 24(1) 
C(25) 5001(2) 3571(2) 5548(1) 29(1) 
C(26) 3827(2) 3588(2) 5823(1) 31(1) 
C(27) 2786(2) 3532(2) 5344(1) 27(1) 
C(28) 1536(2) 3570(2) 5581(1) 35(1) 
C(29) 614(2) 3515(2) 5073(1) 36(1) 
C(30) 912(2) 3422(2) 4318(1) 28(1) 
N(4) 2080(2) 3381(1) 4079(1) 20(1) 
C(31) 3002(2) 3442(2) 4578(1) 21(1) 
C(32) 4237(2) 3433(2) 4284(1) 19(1) 
N(5) 2786(2) 1550(1) 3368(1) 23(1) 
C(41) 3670(2) 769(2) 3870(1) 32(1) 
C(42) 3624(3) -413(2) 4113(2) 44(1) 
C(43) 2631(3) -793(2) 3833(2) 45(1) 
C(44) 1720(3) 8(2) 3319(2) 37(1) 
C(45) 1811(2) 1188(2) 3085(1) 27(1) 
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C(46) 879(2) 2151(2) 2510(1) 25(1) 
O(1) 972(1) 3230(1) 2646(1) 23(1) 
C(47) -475(2) 1933(2) 2678(2) 35(1) 
C(51) 1137(2) 2232(2) 1637(1) 25(1) 
C(52) 558(2) 3233(2) 1044(1) 29(1) 
C(53) 720(2) 3345(2) 242(1) 31(1) 
C(54) 1468(2) 2465(2) 20(1) 32(1) 
C(55) 2052(2) 1483(2) 600(1) 33(1) 
C(56) 1887(2) 1360(2) 1408(1) 30(1) 
Cl(1) 1877(1) 6439(1) 3680(1) 25(1) 
Cl(2) 5971(1) 1151(1) 2442(1) 77(1) 
O(1M) -1157(2) 4705(2) 2678(1) 37(1) 
C(1M) -962(2) 5850(2) 2320(2) 37(1) 
O(2M) 6712(3) 9455(3) 4209(2) 88(1) 
C(2M) 7926(4) 9647(4) 4304(2) 67(1) 
C(2MA) 6880(20) 10615(12) 4027(11) 58(4) 
O(3M) 4512(3) 9503(2) 1827(2) 60(1) 
C(3M) 4789(7) 8480(4) 2460(3) 67(2) 
O(3MA) 5573(17) 8317(16) 2301(9) 90(4) 
C(3MA) 4330(18) 8100(20) 2399(13) 75(5) 
O(4M) 8468(4) 9977(3) 1948(2) 60(1) 
C(4M) 8242(8) 8851(6) 2028(6) 78(2) 
O(4MA) 9825(9) 8629(7) 2836(6) 56(3) 
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C(4MA) 8748(13) 8761(15) 2358(9) 48(3) 
O(4MB) 7647(15) 9150(16) 1585(7) 65(4) 
C(4MB) 7459(13) 8662(12) 2398(7) 24(2) 
 
Table A.15 Selected bond lengths [Å] and angles [°] for [Rh(chrysi)(phen)(PPE)]Cl2. 
_____________________________________________________  
Rh(1)-O(1)  1.9827(14) 
Rh(1)-N(1)  1.9905(15) 
Rh(1)-N(2)  1.9934(16) 
Rh(1)-N(5)  2.0339(16) 
Rh(1)-N(4)  2.0373(16) 
Rh(1)-N(3)  2.0530(17) 
O(1)-Rh(1)-N(1) 91.59(6) 
O(1)-Rh(1)-N(2) 90.74(6) 
N(1)-Rh(1)-N(2) 77.79(6) 
O(1)-Rh(1)-N(5) 80.78(7) 
N(1)-Rh(1)-N(5) 170.43(7) 
N(2)-Rh(1)-N(5) 96.43(7) 
O(1)-Rh(1)-N(4) 90.69(6) 
N(1)-Rh(1)-N(4) 96.09(6) 
N(2)-Rh(1)-N(4) 173.75(6) 
N(5)-Rh(1)-N(4) 89.81(6) 
O(1)-Rh(1)-N(3) 171.30(6) 
N(1)-Rh(1)-N(3) 90.66(6) 
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N(2)-Rh(1)-N(3) 97.95(7) 
N(5)-Rh(1)-N(3) 97.74(7) 
N(4)-Rh(1)-N(3) 80.72(7) 
_____________________________________________________________  
Table A.16 Anisotropic displacement parameters  (Å2x 103) for 
[Rh(chrysi)(phen)(PPE)]Cl2. The anisotropic displacement factor exponent takes the  
form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]. 
________________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________ 
Rh(1) 18(1)  13(1) 17(1)  -4(1) 4(1)  -3(1) 
N(1) 19(1)  15(1) 19(1)  -5(1) 4(1)  -4(1) 
C(1) 16(1)  17(1) 20(1)  -5(1) 2(1)  -6(1) 
C(2) 20(1)  19(1) 22(1)  -3(1) 2(1)  -6(1) 
C(3) 33(1)  19(1) 28(1)  -3(1) 4(1)  -4(1) 
C(4) 40(1)  18(1) 40(1)  -3(1) 3(1)  -3(1) 
C(5) 30(1)  22(1) 38(1)  6(1) -2(1)  -5(1) 
C(6) 28(1)  30(1) 25(1)  3(1) -2(1)  -10(1) 
C(7) 21(1)  25(1) 21(1)  -1(1) -1(1)  -8(1) 
C(8) 19(1)  30(1) 19(1)  -5(1) 2(1)  -12(1) 
C(9) 25(1)  42(1) 19(1)  -4(1) 0(1)  -13(1) 
C(10) 26(1)  55(1) 19(1)  -12(1) 4(1)  -19(1) 
C(11) 20(1)  47(1) 25(1)  -17(1) 7(1)  -15(1) 
C(12) 27(1)  61(2) 28(1)  -27(1) 9(1)  -14(1) 
C(13) 30(1)  58(2) 43(1)  -35(1) 13(1)  -12(1) 
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C(14) 23(1)  43(1) 40(1)  -24(1) 11(1)  -8(1) 
C(15) 19(1)  36(1) 26(1)  -15(1) 9(1)  -10(1) 
C(16) 17(1)  36(1) 23(1)  -15(1) 7(1)  -12(1) 
C(17) 17(1)  28(1) 18(1)  -8(1) 4(1)  -10(1) 
C(18) 14(1)  21(1) 19(1)  -7(1) 3(1)  -7(1) 
N(2) 20(1)  18(1) 21(1)  -9(1) 5(1)  -5(1) 
N(3) 20(1)  17(1) 21(1)  -6(1) 3(1)  -2(1) 
C(21) 24(1)  27(1) 27(1)  -10(1) 6(1)  -5(1) 
C(22) 22(1)  34(1) 39(1)  -12(1) 5(1)  -5(1) 
C(23) 27(1)  24(1) 35(1)  -8(1) -5(1)  -4(1) 
C(24) 30(1)  14(1) 25(1)  -4(1) -2(1)  -2(1) 
C(25) 42(1)  21(1) 23(1)  -5(1) -5(1)  -4(1) 
C(26) 48(1)  27(1) 18(1)  -6(1) 1(1)  -6(1) 
C(27) 39(1)  22(1) 18(1)  -3(1) 7(1)  -4(1) 
C(28) 44(1)  38(1) 20(1)  -7(1) 14(1)  -3(1) 
C(29) 31(1)  43(1) 29(1)  -7(1) 14(1)  -3(1) 
C(30) 25(1)  31(1) 26(1)  -4(1) 8(1)  -4(1) 
N(4) 22(1)  17(1) 18(1)  -3(1) 6(1)  -3(1) 
C(31) 28(1)  14(1) 18(1)  -2(1) 4(1)  -1(1) 
C(32) 25(1)  12(1) 19(1)  -3(1) 2(1)  -2(1) 
N(5) 32(1)  16(1) 21(1)  -5(1) 3(1)  -5(1) 
C(41) 48(1)  18(1) 26(1)  -5(1) -4(1)  -2(1) 
C(42) 78(2)  18(1) 31(1)  -2(1) -10(1)  0(1) 
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C(43) 84(2)  18(1) 34(1)  -3(1) -1(1)  -14(1) 
C(44) 60(2)  25(1) 31(1)  -8(1) 5(1)  -22(1) 
C(45) 38(1)  21(1) 24(1)  -7(1) 6(1)  -12(1) 
C(46) 27(1)  25(1) 26(1)  -6(1) 3(1)  -12(1) 
O(1) 21(1)  22(1) 27(1)  -8(1) 2(1)  -5(1) 
C(47) 33(1)  44(1) 33(1)  -10(1) 9(1)  -22(1) 
C(51) 26(1)  27(1) 25(1)  -8(1) 4(1)  -15(1) 
C(52) 24(1)  33(1) 30(1)  -8(1) 2(1)  -11(1) 
C(53) 27(1)  38(1) 28(1)  -4(1) -2(1)  -14(1) 
C(54) 30(1)  48(1) 26(1)  -14(1) 5(1)  -22(1) 
C(55) 36(1)  36(1) 34(1)  -17(1) 8(1)  -15(1) 
C(56) 34(1)  28(1) 30(1)  -9(1) 3(1)  -12(1) 
Cl(1) 31(1)  26(1) 24(1)  -13(1) 8(1)  -10(1) 
Cl(2) 120(1)  50(1) 48(1)  -22(1) -22(1)  37(1) 
O(1M) 23(1)  40(1) 42(1)  -7(1) 5(1)  -4(1) 
C(1M) 35(1)  39(1) 38(1)  -13(1) 2(1)  -4(1) 
O(2M) 115(2)  78(2) 61(2)  -2(2) -14(2)  -21(2) 
C(2M) 78(2)  52(2) 48(2)  13(2) 20(2)  1(2) 
C(2MA) 75(10)  61(5) 31(8)  -17(7) -4(7)  14(7) 
O(3M) 89(2)  36(1) 44(2)  -6(1) 0(1)  6(1) 
C(3M) 128(5)  36(2) 32(2)  -14(1) 11(3)  9(3) 
O(3MA) 130(9)  95(8) 54(7)  -17(6) -9(7)  -52(8) 
C(3MA) 115(9)  76(10) 33(7)  -11(8) 6(8)  -24(9) 
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O(4M) 91(3)  36(2) 59(2)  -14(2) 38(2)  -28(2) 
C(4M) 90(6)  47(3) 109(6)  -35(4) 41(4)  -24(4) 
O(4MA) 65(6)  27(4) 72(6)  -16(4) -20(4)  9(4) 
C(4MA) 49(6)  51(6) 50(6)  -26(5) 8(4)  -8(5) 
O(4MB) 50(7)  83(8) 29(5)  20(6) 4(5)  8(6) 
C(4MB) 25(6)  26(6) 26(5)  -11(4) 11(5)  -11(5) 
_____________________________________________________________________________ 
Table A.17 Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x  
103) for [Rh(chrysi)(phen)(PPE)]Cl2. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
H(1N) 2160(20) 5526(18) 2733(13) 21 
H(3) 1722 7341 2080 33 
H(4) 1051 9238 1226 41 
H(5) 1143 9611 -151 40 
H(6A) 1867 8127 -687 36 
H(9) 2355 6841 -1138 35 
H(10) 3019 5403 -1699 38 
H(12) 4140 3445 -1605 42 
H(13) 5185 1639 -853 47 
H(14) 5622 1274 520 39 
H(15) 4884 2654 1141 30 
H(2N) 3540(20) 2872(17) 1735(14) 22 
H(21) 5601 3336 2699 31 
 254 
 
H(22) 7338 3493 3425 37 
H(23) 7134 3571 4724 35 
H(25) 5676 3607 5882 35 
H(26) 3693 3639 6346 37 
H(28) 1336 3635 6093 42 
H(29) -230 3539 5231 43 
H(30) 260 3388 3968 34 
H(41) 4349 1037 4063 38 
H(42) 4263 -953 4466 53 
H(43) 2576 -1602 3994 54 
H(44) 1032 -246 3124 45 
H(47A) -619 1819 3245 53 
H(47B) -600 1232 2545 53 
H(47C) -1068 2607 2353 53 
H(52) 49 3842 1190 34 
H(53) 318 4027 -156 38 
H(54) 1575 2540 -529 39 
H(55) 2573 883 451 40 
H(56) 2290 675 1804 36 
H(1O) -500(20) 4270(30) 2630(20) 55 
H(1M1) -1763 6386 2260 56 
H(1M2) -623 5920 1793 56 
H(1M3) -363 6049 2655 56 
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H(2M) 6437 9805 3737 133 
H(2MA) 6311 9367 3828 133 
H(2M1) 7909 10472 4259 101 
H(2M2) 8441 9451 3889 101 
H(2M3) 8287 9155 4831 101 
H(2M4) 6210 11042 4260 86 
H(2M5) 6833 10972 3446 86 
H(2M6) 7697 10650 4247 86 
H(3M) 4920 10002 1895 90 
H(3M1) 4985 8669 2945 100 
H(3M2) 5516 7975 2340 100 
H(3M3) 4062 8073 2543 100 
H(3MA) 6060 7687 2343 136 
H(3M4) 3978 8365 2840 113 
H(3M5) 4325 7263 2519 113 
H(3M6) 3821 8529 1906 113 
H(4M) 7782 10417 1947 90 
H(4M1) 9028 8357 1975 117 
H(4M2) 7623 8884 1610 117 
H(4M3) 7914 8522 2554 117 
H(4MA) 9622 8582 3305 84 
H(4M4) 8178 8251 2656 72 
H(4M5) 8984 8548 1877 72 
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H(4M6) 8324 9576 2205 72 
H(4MB) 7877 9801 1509 97 
H(4M7) 8266 8259 2679 37 
H(4M8) 6877 8102 2463 37 
H(4M9) 7104 9283 2621 37 
 
Table A.18 Hydrogen bonds for [Rh(chrysi)(phen)(PPE)]Cl2 [Å and °]. 
________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
________________________________________________________________________ 
 N(1)-H(1N)...Cl(1) 0.870(16) 2.263(17) 3.1054(17) 163(2) 
 C(21)-H(21)...Cl(2) 0.95 2.80 3.374(2) 119.9 
 C(22)-H(22)...O(1M)#1 0.95 2.47 3.314(3) 147.5 
 C(29)-H(29)...Cl(1)#2 0.95 2.61 3.468(2) 150.1 
 C(30)-H(30)...O(1) 0.95 2.50 3.021(3) 114.5 
 C(44)-H(44)...O(4MA)#3 0.95 2.19 3.111(9) 161.8 
 C(47)-H(47B)...O(4M)#3 0.98 2.43 3.369(4) 159.9 
 O(1M)-H(1O)...O(1) 0.834(18) 1.860(18) 2.691(2) 173(3) 
 O(2M)-H(2M)...Cl(2)#4 0.84 2.37 3.187(3) 165.3 
 C(2MA)-H(2M5)...Cl(2)#40.98 1.93 2.804(19) 146.4 
 O(3M)-H(3M)...Cl(2)#4 0.84 2.34 3.162(3) 164.8 
 O(4M)-H(4M)...Cl(2)#4 0.84 2.30 3.091(4) 157.7 
 C(4MB)-H(4M9)...Cl(2)#4 0.98 2.33 3.217(14) 149.8 
___________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z    #2 -x,-y+1,-z+1    #3 x-1,y-1,z    #4 x,y+1,z.      
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A.4 [Rh(chrysi)(phen)(PPO)]Cl2 
 
Table A.19 Crystal data and structure refinement for [Rh(chrysi)(phen)(PPO)]Cl2. 
Identification code  ack013 
Empirical formula  C45 H48 Cl2 N5 O3 Rh 
Formula weight  880.69 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 9.1633(11) Å = 110.881(2)°. 
 b = 15.4046(19) Å = 94.610(2)°. 
 c = 16.791(2) Å  = 105.705(2)°. 
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Volume 2090.2(4) Å3 
Z 2 
Density (calculated) 1.399 Mg/m3 
Absorption coefficient 0.583 mm-1 
F(000) 912 
Crystal size 0.500 x 0.500 x 0.400 mm3 
Theta range for data collection 1.324 to 30.043°. 
Index ranges -12<=h<=12, -21<=k<=21, -23<=l<=22 
Reflections collected 61440 
Independent reflections 11087 [R(int) = 0.0277] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7460 and 0.6697 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 11087 / 3 / 521 
Goodness-of-fit on F2 1.112 
Final R indices [I>2sigma(I)] R1 = 0.0308, wR2 = 0.0703 
R indices (all data) R1 = 0.0387, wR2 = 0.0750 
Extinction coefficient n/a 
Largest diff. peak and hole 1.020 and -0.486 e.Å-3 
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Table A.20 Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for [Rh(chrysi)(phen)(PPO)]Cl2. U(eq) is defined as one-third of   
the trace of the orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
Cl(1) 1297(1) 4156(1) 7867(1) 19(1) 
Cl(2) 2592(1) 2117(1) 5123(1) 21(1) 
Rh(1) 3196(1) 6463(1) 2924(1) 10(1) 
N(1) 3955(2) 6414(1) 4040(1) 12(1) 
C(1) 3105(2) 5737(1) 4242(1) 12(1) 
C(2) 3470(2) 5578(1) 5027(1) 14(1) 
C(3) 4863(2) 6154(1) 5623(1) 17(1) 
C(4) 5158(2) 6015(1) 6384(1) 19(1) 
C(5) 4080(2) 5306(2) 6548(1) 20(1) 
C(6) 2716(2) 4730(1) 5956(1) 18(1) 
C(7) 2369(2) 4846(1) 5178(1) 14(1) 
C(8) 924(2) 4221(1) 4531(1) 14(1) 
C(9) -98(2) 3464(1) 4707(1) 19(1) 
C(10) -1470(2) 2876(1) 4163(1) 20(1) 
C(11) -1890(2) 2935(1) 3359(1) 18(1) 
C(12) -3269(2) 2258(1) 2776(1) 23(1) 
C(13) -3648(2) 2259(2) 1972(1) 24(1) 
C(14) -2646(2) 2944(1) 1731(1) 22(1) 
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C(15) -1322(2) 3625(1) 2293(1) 19(1) 
C(16) -878(2) 3662(1) 3136(1) 15(1) 
C(17) 514(2) 4348(1) 3766(1) 13(1) 
C(18) 1569(2) 5169(1) 3636(1) 12(1) 
N(2) 1350(2) 5524(1) 3058(1) 11(1) 
N(3) 5185(2) 7459(1) 2927(1) 13(1) 
C(21) 6442(2) 7286(1) 2670(1) 17(1) 
C(22) 7742(2) 8050(2) 2712(1) 21(1) 
C(23) 7738(2) 8998(2) 3027(1) 22(1) 
C(24) 6421(2) 9202(1) 3326(1) 19(1) 
C(25) 6278(2) 10162(1) 3674(1) 25(1) 
C(26) 4990(2) 10308(1) 3962(1) 25(1) 
C(27) 3707(2) 9503(1) 3933(1) 20(1) 
C(28) 2346(2) 9596(1) 4237(1) 24(1) 
C(29) 1203(2) 8772(1) 4177(1) 21(1) 
C(30) 1395(2) 7848(1) 3808(1) 16(1) 
N(4) 2670(2) 7735(1) 3524(1) 13(1) 
C(31) 3825(2) 8554(1) 3586(1) 15(1) 
C(32) 5174(2) 8405(1) 3272(1) 15(1) 
N(5) 2416(2) 6281(1) 1683(1) 13(1) 
C(41) 1803(2) 6876(1) 1450(1) 17(1) 
C(42) 1410(2) 6728(2) 588(1) 21(1) 
C(43) 1617(2) 5929(2) -49(1) 21(1) 
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C(44) 2223(2) 5308(1) 192(1) 18(1) 
C(45) 2642(2) 5505(1) 1069(1) 14(1) 
C(46) 3341(2) 4877(1) 1398(1) 14(1) 
C(47) 2102(2) 3886(1) 1193(1) 23(1) 
C(48) 4698(2) 4699(2) 961(1) 23(1) 
O(1) 3933(1) 5361(1) 2304(1) 14(1) 
O(1S) 5474(3) 1234(2) 9592(1) 57(1) 
C(1S) 4384(4) 1360(2) 9035(2) 55(1) 
C(2S) 3435(6) 1899(3) 9575(3) 95(2) 
C(3S) 6343(4) 670(2) 9131(2) 52(1) 
C(4S) 7480(5) 583(3) 9769(2) 78(1) 
O(1T) 177(2) 1093(1) 3360(1) 32(1) 
C(1T) 904(2) 1483(2) 2785(1) 27(1) 
C(2T) -245(3) 1054(2) 1938(2) 48(1) 
C(3T) 2393(3) 1257(2) 2671(2) 42(1) 
________________________________________________________________________ 
Table A.21 Selected bond lengths [Å] and angles [°] for [Rh(chrysi)(phen)(PPO)]Cl2. 
_____________________________________________________  
Rh(1)-O(1)  1.9725(12) 
Rh(1)-N(1)  1.9803(14) 
Rh(1)-N(2)  1.9936(14) 
Rh(1)-N(3)  2.0385(14) 
Rh(1)-N(5)  2.0407(14) 
Rh(1)-N(4)  2.0667(15) 
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O(1)-Rh(1)-N(1) 89.38(5) 
O(1)-Rh(1)-N(2) 89.84(6) 
N(1)-Rh(1)-N(2) 78.17(6) 
O(1)-Rh(1)-N(3) 91.41(6) 
N(1)-Rh(1)-N(3) 95.51(6) 
N(2)-Rh(1)-N(3) 173.55(6) 
O(1)-Rh(1)-N(5) 81.86(5) 
N(1)-Rh(1)-N(5) 170.60(6) 
N(2)-Rh(1)-N(5) 98.30(6) 
N(3)-Rh(1)-N(5) 88.14(6) 
O(1)-Rh(1)-N(4) 172.06(6) 
N(1)-Rh(1)-N(4) 93.31(6) 
N(2)-Rh(1)-N(4) 98.02(6) 
N(3)-Rh(1)-N(4) 80.90(6) 
N(5)-Rh(1)-N(4) 95.83(6) 
_____________________________________________________________  
 
Table A.22 Anisotropic displacement parameters  (Å2x 103) for 
[Rh(chrysi)(phen)(PPO)]Cl2. The anisotropic displacement factor exponent takes the  
form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]. 
________________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________ 
Cl(1) 15(1)  24(1) 20(1)  8(1) 1(1)  10(1) 
Cl(2) 21(1)  15(1) 21(1)  6(1) -2(1)  2(1) 
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Rh(1) 10(1)  11(1) 12(1)  6(1) 1(1)  3(1) 
N(1) 11(1)  12(1) 12(1)  5(1) 1(1)  4(1) 
C(1) 14(1)  11(1) 12(1)  4(1) 2(1)  6(1) 
C(2) 18(1)  15(1) 13(1)  7(1) 4(1)  9(1) 
C(3) 18(1)  18(1) 16(1)  7(1) 2(1)  8(1) 
C(4) 22(1)  23(1) 15(1)  7(1) 0(1)  12(1) 
C(5) 27(1)  27(1) 15(1)  11(1) 6(1)  18(1) 
C(6) 23(1)  22(1) 18(1)  13(1) 9(1)  13(1) 
C(7) 18(1)  15(1) 14(1)  7(1) 6(1)  11(1) 
C(8) 18(1)  12(1) 16(1)  6(1) 7(1)  8(1) 
C(9) 25(1)  17(1) 20(1)  11(1) 8(1)  9(1) 
C(10) 23(1)  14(1) 26(1)  11(1) 10(1)  6(1) 
C(11) 18(1)  13(1) 23(1)  7(1) 7(1)  6(1) 
C(12) 21(1)  17(1) 30(1)  11(1) 6(1)  3(1) 
C(13) 19(1)  18(1) 28(1)  7(1) 1(1)  0(1) 
C(14) 22(1)  20(1) 20(1)  7(1) 1(1)  2(1) 
C(15) 20(1)  17(1) 19(1)  7(1) 4(1)  2(1) 
C(16) 16(1)  12(1) 16(1)  5(1) 5(1)  5(1) 
C(17) 15(1)  13(1) 14(1)  6(1) 6(1)  6(1) 
C(18) 13(1)  12(1) 12(1)  5(1) 4(1)  5(1) 
N(2) 10(1)  12(1) 12(1)  6(1) 1(1)  3(1) 
N(3) 12(1)  14(1) 15(1)  9(1) 1(1)  3(1) 
C(21) 13(1)  19(1) 20(1)  11(1) 1(1)  5(1) 
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C(22) 12(1)  27(1) 26(1)  15(1) 3(1)  4(1) 
C(23) 15(1)  23(1) 27(1)  16(1) -1(1)  -1(1) 
C(24) 18(1)  16(1) 22(1)  11(1) -3(1)  1(1) 
C(25) 25(1)  14(1) 30(1)  11(1) -4(1)  -2(1) 
C(26) 30(1)  13(1) 28(1)  6(1) -3(1)  4(1) 
C(27) 23(1)  14(1) 19(1)  5(1) -2(1)  6(1) 
C(28) 29(1)  18(1) 22(1)  4(1) 0(1)  12(1) 
C(29) 22(1)  23(1) 18(1)  6(1) 2(1)  12(1) 
C(30) 17(1)  18(1) 14(1)  7(1) 2(1)  6(1) 
N(4) 16(1)  13(1) 12(1)  6(1) 1(1)  5(1) 
C(31) 16(1)  13(1) 14(1)  7(1) -2(1)  3(1) 
C(32) 16(1)  15(1) 15(1)  9(1) -2(1)  3(1) 
N(5) 10(1)  17(1) 14(1)  10(1) 1(1)  3(1) 
C(41) 15(1)  17(1) 19(1)  10(1) 1(1)  4(1) 
C(42) 19(1)  24(1) 24(1)  16(1) -2(1)  4(1) 
C(43) 18(1)  30(1) 15(1)  14(1) 0(1)  2(1) 
C(44) 14(1)  25(1) 16(1)  8(1) 2(1)  5(1) 
C(45) 9(1)  19(1) 16(1)  8(1) 2(1)  3(1) 
C(46) 14(1)  17(1) 13(1)  5(1) 2(1)  6(1) 
C(47) 22(1)  18(1) 25(1)  7(1) -1(1)  4(1) 
C(48) 19(1)  35(1) 17(1)  6(1) 5(1)  15(1) 
O(1) 16(1)  15(1) 11(1)  5(1) 1(1)  8(1) 
O(1S) 97(2)  43(1) 31(1)  8(1) -2(1)  34(1) 
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C(1S) 74(2)  43(2) 37(1)  14(1) -8(1)  12(2) 
C(2S) 150(4)  80(3) 56(2)  6(2) -10(2)  77(3) 
C(3S) 76(2)  33(1) 38(1)  9(1) 7(1)  14(1) 
C(4S) 118(4)  80(3) 59(2)  28(2) 20(2)  63(3) 
O(1T) 26(1)  30(1) 30(1)  10(1) 0(1)  -5(1) 
C(1T) 24(1)  25(1) 30(1)  10(1) 5(1)  7(1) 
C(2T) 43(2)  67(2) 36(1)  16(1) 2(1)  26(1) 
C(3T) 30(1)  48(2) 39(1)  5(1) 6(1)  12(1) 
 
Table A.23 Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x  
103) for [Rh(chrysi)(phen)(PPO)]Cl2. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
H(1N) 4861(19) 6777(14) 4365(13) 14 
H(3) 5601 6636 5505 21 
H(4) 6096 6405 6793 23 
H(5) 4280 5215 7072 24 
H(6) 1996 4243 6079 22 
H(9) 186 3367 5218 23 
H(10) -2163 2416 4326 24 
H(12) -3941 1797 2946 27 
H(13) -4575 1802 1584 29 
H(14) -2888 2938 1167 27 
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H(15) -681 4088 2112 23 
H(2N) 461(19) 5372(15) 2753(13) 14 
H(21) 6468 6632 2454 20 
H(22) 8628 7905 2519 25 
H(23) 8608 9513 3045 26 
H(25) 7104 10709 3704 30 
H(26) 4930 10955 4188 30 
H(28) 2220 10224 4482 28 
H(29) 285 8829 4384 25 
H(30) 586 7283 3760 20 
H(41) 1635 7412 1889 20 
H(42) 1005 7167 436 26 
H(43) 1346 5809 -646 25 
H(44) 2351 4750 -240 22 
H(47A) 2544 3487 1419 34 
H(47B) 1743 3541 562 34 
H(47C) 1228 3998 1468 34 
H(48A) 5465 5331 1064 35 
H(48B) 4321 4325 334 35 
H(48C) 5176 4328 1205 35 
H(1S1) 3707 713 8605 65 
H(1S2) 4924 1739 8716 65 
H(2S1) 2915 1523 9893 142 
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H(2S2) 2660 1982 9196 142 
H(2S3) 4110 2545 9989 142 
H(3S1) 6898 989 8775 62 
H(3S2) 5648 10 8736 62 
H(4S1) 8133 1240 10173 117 
H(4S2) 8128 222 9456 117 
H(4S3) 6921 232 10094 117 
H(1TO) 800(30) 1330(20) 3854(14) 49 
H(1T) 1139 2211 3038 33 
H(2T1) -506 338 1692 72 
H(2T2) 209 1317 1530 72 
H(2T3) -1184 1229 2044 72 
H(3T1) 3117 1577 3232 63 
H(3T2) 2847 1503 2253 63 
H(3T3) 2184 546 2456 63 
 
Table A.24 Hydrogen bonds for [Rh(chrysi)(phen)(PPO)]Cl2 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________  
 N(1)-H(1N)...Cl(2)#1 0.871(15) 2.360(16) 3.2012(15) 162.6(19) 
 N(2)-H(2N)...Cl(1)#2 0.852(15) 2.261(17) 3.0219(15) 148.7(19) 
 C(21)-H(21)...Cl(1)#1 0.95 2.65 3.3762(19) 133.9 
 C(21)-H(21)...O(1) 0.95 2.53 3.039(2) 114.0 
 C(29)-H(29)...Cl(2)#2 0.95 2.98 3.819(2) 147.7 
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 C(30)-H(30)...Cl(1)#2 0.95 2.87 3.4777(19) 123.2 
 C(41)-H(41)...N(4) 0.95 2.65 3.195(2) 116.8 
 C(44)-H(44)...Cl(1)#3 0.95 2.97 3.5805(19) 123.1 
 O(1T)-H(1TO)...Cl(2) 0.861(17) 2.286(18) 3.1420(17) 173(3) 
________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+1,-z+1    #2 -x,-y+1,-z+1    #3 x,y,z-1. 
